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In this thesis, I aimed to demonstrate the capability and versatility of Magnetic Resonance 
Imaging (MRI) to perform diagnostic imaging at different physical scales, from physiological 
to cellular and finally at the molecular level. Chapter 2 illustrates the ability of ‘Dynamic 
Contrast Enhanced Magnetic Resonance Imaging’ or ‘DCE-MRI’ to measure an important 
physiological parameter that is a biomarker of nutrient delivery, which is hemodynamic 
perfusion. The use of a T1-reducing contrast agent in facilitating DCE-MRI in the mouse 
pancreas is described. A mathematical approach to quantify tracer pharmacokinetics in order 
to estimate blood flow is also illustrated. The competency of DCE-MRI to distinguish 
between normal and angiogenesis-impaired pancreas in a STAT3 knock-out mouse model is 
also be presented. 
 
Chapter 3 ventured higher up the magnification scale into the cellular regime, whereby 
cellular tracking of exogenous cells transplanted for tissue repair was visualized with positive 
contrast. Superparamagnetic iron-oxide particles (SPIO) were the selected passive probes that 
acted as beacons of delivered cells. The superior detection sensitivity offered by a Multiple-
Echo Ultrashort Echo Time (MUTE) MRI technique was demonstrated. In addition, I 
proposed a novel method that provides robust positive contrast with high temporal efficiency 
to advance cellular tracking technology. The physical principles of positive contrast sensing 
and factors affecting detection sensitivity are discussed.  
 
Finally, molecular imaging is demonstrated in Chapter 4 via the use of an avant-garde 
technique that permits real-time dynamic monitoring of carbohydrate metabolism, this is 
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‘Dynamic Nuclear Polarized 13C Magnetic Resonance Spectroscopy (DNP-MRS)’. Here, the 
biomarkers of interest were also the molecular probes themselves. They are the downstream 











acetyl-carnitine. In addition, the generation and utilization of these substrates were dependent 
on underlying enzyme activity such as pyruvate dehydrogenase (PDH), carbonic anhydrase 
(CA) and carnitine acetyltransferase (CAT). By measuring the MR signal amplitude of these 
reporting probes, I was able to quantify critical biological parameters such as intracellular pH, 
and track its changes at the onset of ischaemia. I also demonstrated the utilization of this 
technique to study the dynamic energy storage mechanism of the heart. The potential of [1,4-
13
C] fumarate as a biomarker of necrosis in the heart was also investigated. Finally, 2-
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1.1 Emergence of Cellular and Molecular Imaging 
 
The development of life is a proficiently orchestrated process of a myriad of distinctive 
molecules. From DNA to cells to tissues and organs, biomolecules are the building blocks of 
all life. The ability to probe molecular and cellular processes during mammalian development 
facilitates the understanding of how aberrant events can lead to disease pathogenesis (1-3). 
The acme of interventional medicine is the application of ameliorative actions as soon as a 
molecular aberration occurs or even before the event (4).  It is optimistic that by taking such 
preemptive measures, disease progression could be arrested and physiological injury could be 
limited, sparing patients of unnecessary duress (5-7). Possible preventive or interventional 
treatments include gene therapy whereby beneficial genes are transfected for transcription of 
therapeutic proteins (e.g. SERCA2a gene therapy in heart failure to improve contractility) (8), 
pharmacological inhibition of specific proteins to block deleterious signaling pathways (e.g. 
inhibiting matrix metallo-proteinases MMPs to reduce left myocardium wall thinning in heart 
failure) (9), or tissue repair with exogenous cell therapy (e.g. stem-cell transplantation in 
infarcted myocardium) (10). With the advances in high throughput screening technology, 
combinatorial drug chemistry, recombinant protein developments and availability of 
transgenic models, many more therapeutic targets are being discovered at a rapid pace. 
Molecular medicine is thus propelling a paradigm shift not only in the way drugs are being 
developed and customized (11-14), but also the translational relationship between basic 




The pursuit of molecular medicine encompasses multiple levels of research which begins 
from basic research at the bench to validation in animal models and finally translation into 
the clinic. The translational researcher who carries out this arduous task is one who needs to 
characterize the molecular mechanism underlying the pathology in the laboratory, devise a 
method to measure that in-situ in the human disease state and develop a beneficial 
intervention in the clinic (17). He or she would demand a series of imaging modalities to 
visualize specific molecular and cellular interactions as well as detect physiological response 
at various experimental stages (3). These imaging paradigms can be broadly categorized into 
molecular, cellular and physiological imaging (3,18). Cellular imaging has in fact been 
present since the invention of the optical microscope in the 17
th
 century, when Robert Hooke 
first described cells in a cork (19). Modern microscopes with much higher magnification and 
advanced optics now enable detailed visualization of constituents in a cell as well as cellular 
activity at the microscopic level. Molecular imaging on the other hand, is a contemporary 
concept involving the detection of molecular events and mechanisms below the microscopic 
level, encompassing processes such as metabolic activity, reporter gene expression and 
enzymatic action (20). It is to be noted that visualization of a single biological process can 
fall into both cellular and molecular imaging regimes. For example apoptosis or programmed 
cell death can be characterized by morphological changes including plasma membrane 
blebbing, cell shrinkage, chromatin condensation and formation of apoptotic bodies (21). The 
visualization of such structural demise is categorized under cellular imaging. But these 
permutations are initially triggered by a series of biochemical events including activation of 
initiator caspases and mitochondrial release of ‘apoptogens’, which can be detected using 
different fluorescent platforms (22). The apoptotic stage can be assessed by measuring 
Annexin-V binding to phosphatidylserine (23,24), a protein that gets enhanced exposure on 
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the external cell membrane during early apoptosis. Visualization of such intracellular and 
extracellular proteins unique to apoptosis is an application of molecular imaging. 
 
Progress in cellular and molecular imaging is driven primarily by the following demands in 
molecular medicine research (3): [1] to develop non-invasive in-vivo imaging methods that 
reflect specific cellular and molecular processes, for example gene expression or more 
complex molecular interactions such as protein–protein interactions; [2] to monitor multiple 
molecular events about-simultaneously; [3] to follow cell trafficking; [4] to optimize drug 
and gene therapy; [5] to assess pathological progression at a molecular level; and [6] to 
achieve all of the above goals in a rapid, reproducible, and quantitative manner. The 
emergence of modern molecular and cellular imaging strategies can be attributed to recent 
unprecedented advances in molecular biology techniques such as polymerase chain reaction 
(PCR) technology (25), development of transgenic (26-28) and experimental animal models 
(29,30) as well as successful implementation of small-animal instrumentation (31,32). In 
addition, the nascent biomedical nanotechnology sector heralds a new paradigm in targeted 
molecular imaging and therapy by increasing the availability of novel imaging probes and 
drugs that are highly specific (33-36). For example engineered antibodies attached with 
radio-nuclides now empower the oncologist to locate specific tumor markers in-vivo and 
quantify concentration and uptake levels, boosting diagnostic precision (37,38). The 
operating mode can then be switched from radiology to therapy by increasing the radioactive 





1.2 Cellular and Molecular Imaging Modalities 
 
The foray into molecular medicine is a seemingly daunting task judging from the sheer 
amount of biological information that has to be extracted and interpreted. As new molecular 
pathways in pathology are being discovered, more specific and accurate methods of imaging 
would be demanded, in order to identify potential targets for therapeutic intervention (1). 
Developments in molecular and cellular imaging can be basically grouped into three 
categories (41): [1] the physics and engineering of imaging techniques and instruments, [2] 
the chemical and materials science needs for designing imaging probes and contrast agents, 
and [3] the biological questions to be answered. It is thus appropriate here to identify the 
roles of biomarkers, imaging probes and their sensing modalities.  
 
1.2.1 Biomarkers 
A biomarker is a biological characteristic that is objectively measured and evaluated as an 
indicator of normal or pathogenic processes, as well as pharmacological responses to a 
therapeutic intervention. Typical biomarkers are molecular in nature such as intracellular 
proteins (e.g. STAT proteins) (42), surface receptors (e.g. Her2 tyrosine kinase receptor in 
breast cancers) (43), metabolites (e.g. lactate) (44), mRNA expression profiles (e.g. in 
Huntington’s disease) (45) or antibodies (e.g. human immune deficiency). Depending on 
application, a biomarker might also be cellular morphology change or even behavioral 
symptom. For example, Parkinson’s disease (PD) is characterized by a loss of dopamine 
producing neurons in the substantia nigra pars compacta (46,47). Molecular biomarkers of 
this particular neurodegenerative disease include elevated striatal dopamine D1 and D2 
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receptors (48), increased levels of cytokines such as interleukin-1 (49) and increased iron 
deposits (50). Cellular biomarkers include decreased number of dopaminergic neurons and 
presence of Lewy bodies (51). Cognitive and motor impairments such as dementia (52,53), 
tremor, rigidity and akinesia are some of its physiological biomarkers. Thus a combination of 
biomarkers at different scales is necessary to confirm diagnosis, monitor disease progression 
and assess therapeutic efficacy (54). Because a disease might have a plethora of biomarkers 
which weigh differently in the diagnostic process, the National Institute of Health conjured a 
classification system to optimize the use of biomarkers in the development and evaluation of 
novel therapies (55). Since biomarkers are usually the intermittent or end products of a 
pathological signaling pathway, they are often pharmaceutical targets as well (e.g. protein 
kinases in cancer therapy) (56).  Biomarkers in general play important roles in management 
and treatment of pathology. 
 
1.2.2 Molecular Imaging Probes 
Molecular imaging probes, on the other hand, are molecular compounds that can be sensed by 
an imaging modality. They include small molecules such as receptor ligands or enzyme 
substrates, large molecular-weight affinity ligands such as monoclonal antibodies or 
recombinant proteins. Molecular probes provide the imaging signal or contrast in the imaging 
assays. They are usually introduced into the biological sample (serum, blood, cells, biopsies 
etc) or delivered into the subject to visualize specific biological or molecular events. A 











There are many categories of molecular probes including but not limited to:  
[1] Activatable or passive. Activatable probes are smart sensors that emit a signal (as in PET, 
fluorescence or bioluminescence) or induce proton relaxation changes (as in MRI) when they 
interact with their targets, else they remain inactive. An example of an activatable MR probe 
is the 5-hydroxytryptamide (MPO-Gd) molecule. The biomarker myeloperoxidase is 
produced during inflammatory phase in the infarcted heart, and this molecule activates the 
molecular probe which then binds to matrix proteins and becomes trapped in the vicinity, 
leading to localized enhancement on T1-weighted MRI (57). Other examples include 
magnetic nanosensors that can interact with DNA or RNA sequences (58) and activatable 
paramagnetic chelators (59).  
[2] Direct/in-direct imaging. A direct reporting probe is one that emits a signal when the 
target is reached, or when the biological event of interest occurs (e.g. location of signal voids 
in MRI are direct indicators of iron-oxide labeled cells). An example of in-direct imaging is 
‘reporter gene expression’, whereby a reporter gene such as GFP is inserted in the same loci 
as the gene of interest and its expression implies that the targeted gene is expressed as well.  
[3] Specific/Non-specific Imaging. In order to be useful as a beacon for a specific molecular 
process, a probe has to be linked to the biomarker for that particular event. Therefore it 
usually has a modular design composing of a high affinity ligand that binds to the biomarker 
and a signaling component for imaging. Specific probes have a distinct set of targets while 
non-specific ones do not. Specificity is increasingly important as molecular biologists dig 
deeper into the root causes of pathological diseases, and discover potential pharmaceutical 
targets along the signalling pathway. Molecular imaging probes with high specificity and 
targeting potential can be made by attachment of the signalling probe to antibodies, ligands, 
or substrates that interact only with their respective targets, e.g. magnetic nanocrystals 
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conjugated to antibody Herceptin specific for Her2/neu surface receptors in breast cancer 
cells (60). Non-specific probes do not lock-in to certain biological targets but constantly emit 
detection signals instead, e.g. cell labelling with superparamagnetic iron-oxide nanoparticles 
for in-vivo tracking (61,62). 
 
Molecular probes consist of a myriad of compounds including radio-labeled ligands in 
positron emission tomography (PET) (34,63) and single photon emission computed 




) (65,66) or superparamagnetic (iron-
oxides) (61,67) contrast agents for magnetic resonance imaging detection, and fluorescent 
dyes for optical detection (68,69). Recent advances in probe development explored the 
potential in multi-modality detection of a molecular event as well as report the location of the 
event. For example, Josephson et al synthesized a biocompatible, dextran-coated 
superparamagnetic nanoparticle conjugated to a Tat-peptide with a fluorescent tag (CLIO-
TAT-FITC) and demonstrated its affinity to cell membrane receptors which resulted in a high 
labeling efficiency and enhanced detection sensitivity (70). Its bifunctionality allows it to be 
detected with MRI and fluorescent microscopy, facilitating in-vivo detection with 
histological confirmation. Regardless of the type of probe used to visualize the occurrence of 
the molecular event or cell of interest, it should ideally possess these properties for optimal 
detection and precision in reporting of biological processes:  
[1] High specificity towards the desired ligand or protein biomarker targets 
[2] Appropriate amplification strategies exist for heightened sensitivity 
[3] Quantifiable relationship between biomarker concentration and frequency or 
magnitude of event such as pathological severity or therapeutic efficacy  
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[4] Biocompatiblity and negligible toxicity  
[5] Cost-effective and provide  robust signals 
[6] Imaging modality used for its detection must be sensitive, possesses low background 
noise and produces images of high spatial and temporal resolution. 
 
As we learn more about the biological mechanisms of major killers such as cancer, heart 
failure and diabetes and their mutual interactions and effects on one another, the demands for 
molecular probes are expected to exceed these requirements. We envision the future of 
reporter probes that not only emit different signals for distinct molecular events in-vivo, but 
adapt to the detected pathological process and implement immediate corrective actions, e.g. 
drug release upon identification of a target. Multi-functional molecular probes that integrate 
imaging, detection, and therapy are a harbinger of this foreseeable future (71). 
 
 1.2.3 Molecular Imaging Modalities 
The pace of translation from in-vitro to in-vivo experimental models has quickened in recent 
years resulting in demand for high performance molecular imaging. The technology 
employed to probe the myriad of biochemical processes from molecular to cellular and 
physiological scales should ideally incorporate the following characteristics: [1] high 
sensitivity, [2] excellent spatial/temporal resolution, [3] high signal-to-noise/contrast, [4] 
wide field-of-view and large penetration depth, [5] minimal radioactivity, [6] minimal 
invasiveness, [7] speed and [8] cost effectiveness. A wide range of technologies is currently 
available for in-vitro, ex-vivo and in-vivo molecular imaging. Apart from their reporting 
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mechanism (i.e. the detection of resonant magnetic frequencies, radio-nuclides, emitted light 
or ultrasound), these techniques vary in many other aspects, from their invasiveness to cost-
effectiveness. The choice of technique depends not only on the molecules or cells one wishes 
to detect in living subjects, but also be influenced by the number of repeat assessments 
required and the resulting risks involved (72). Key instruments used in clinical and animal 
research are positron emission tomography (PET), single-photon emission computed 
tomography (SPECT), bioluminescence imaging (BLI), optical fluorescence imaging, 
magnetic resonance imaging (MRI), computed tomography (CT) and ultrasound (US). The 
preferred imaging modality depends on the translation stage. Optical imaging provides very 
high spatial and temporal resolution for genomic and proteomic studies, PET and SPECT 
enables functional imaging while MRI and US contribute the horsepower for in-vivo 
physiological imaging. Massoud and Gambhir have elegantly summarized the characteristics 
of these imaging modalities, including spatial resolution, sensitivity, molecular probe, 
temporal resolution, cost and quantitative degree (3).  
 
Since this thesis primarily utilized MRI as the imaging modality in physiological perfusion 
measurement, exogenous cell tracking and monitoring real-time metabolic processes, I shall 







1.3 Physical Principles of Magnetic Resonance Imaging (MRI)  
 
1.3.1 Origin of MRI Signal 
Magnetic resonance imaging is based on the interaction of nuclear spins with an external 
field         . The dominant nucleus in MRI is the proton in hydrogen and its interaction with the 
external field results in precession of the proton spin about the field direction (see Fig. 1.1a) 
with a fixed frequency (known as Larmor Frequency) given by 
                     (1.1)  
    
 
  
            
(1.2)  
where  is a constant called the gyromagnetic ratio and    is the magnetic dipole moment 
vector. 
 
Figure 1.1: A) A spinning nucleus precessing about B0 at Larmor frequency. B) Thermal 




The bulk magnetization is prevented from relaxing fully to an alignment along the external 
magnetic field           because of thermal energy associated with the absolute temperature T. At 
human body temperatures the average thermal energy T, where  is the Boltzmann constant 
(1.38 x 10
-23 
J/K), is millions of times higher than the quantum energy difference between 
parallel alignment (lower energy, spin-up ↑) and anti-parallel alignment (higher-energy, spin-
down ↓). The quantum energy difference ΔE between the two energy states in a spin ½-
system is proportional to the Larmor frequency, where h is the Planck quantum constant. 
         (1.3)  
The Boltzmann’s probability for the two spin- ½ states (magnetic number m =  ½) is  
 
    
     
            
     




In other words, P is the probability of a nuclear spin with energy     
   
 
 and parallel / 
anti-parallel alignment, respectively. The number of spins parallel to the magnetic field N(↑) 
exceeding the number anti-parallel to that field N(↓), or the ‘spin excess’, is defined as 
               
                 
                                  
  
 
              
(1.5)  
Thus the proton spin excess at a magnetic field strength of 1.5 T is only 5 out of a million 
spins while it is 32 ppm at 9.4T. Taking into consideration electronic noise and hardware 
limitations, the number of detectable spins would be even lower. This minuscule spin 
inequality (also known as polarization) is the reason for the low detection sensitivity of MRI 
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(typically in order of mM) and the technological push for higher magnetic field strength 
(73,74). Even though the paucity of spin excess might appear disheartening, the detectable 
NMR signal is actually quite decent because there are Avogadro numbers of protons in a few 
grams of tissue. We shall explore the intrinsic properties in MRI that affects detection 
sensitivity. Consider the average magnetic dipole density, or ‘longitudinal equilibrium 
magnetization’    (that is the longitudinal component of the sample magnetization      ) with 
a magnitude given by 
 
    
   
   
   
   (1.6)  
where 0 is the number of protons per unit volume or ‘spin density’. Although M0 is limited 
by the small spin excess, there exists measurable NMR signal (75,76) because of the large 
spin density. We also observe that M0 is proportional to the square of the gyromagnetic ratio , 
and since hydrogen has the largest value among the spin- ½ nuclei (42.58 MHz/T), it is the 
most prevalent nucleus measured with MRS and MRI. In order to generate an MR signal, the 
magnetization vector        has to be tipped away from the external field direction         in order to 
set it into precession. This is accomplished by using a transmit coil to apply a short 
radiofrequency pulse (tens of s to a few ms duration) at the Larmor frequency 0. This is the 
resonance condition in MR. As illustrated in Figure 1.1B, when a RF pulse is applied along x’ 
with magnitude field B1, the equilibrium magnetization is rotated at a rate corresponding to 
the frequency  





The angle upon which     is rotated depends on both B1 amplitude and RF duration rf: 
          
   
 
 (1.8)  
The transverse magnetization Mxy induces a voltage on the receiver coil which is sampled and 
stored. That is the magnetic resonance or free-induction decay signal that we shall refer to for 
remainder of the thesis.  
 
1.3.2 Proton Relaxation and Signal Attenuation 
In MRI, we are primarily concerned with proton imaging, with the exception of Chemical 
Shift Imaging in Chapter 4. An image is made up of a matrix of voxels. Each voxel is a 
volume of proton spins with the same phase (‘spin isochromat’). The magnetization of each 
voxel is thus a summation of magnetic moment of all individual spins as defined in eqn. (1.9) 
below, assuming a uniform B0 field across the voxel. When a magnetic moment is immersed 
in a magnetic field, it will tend to line up parallel to the field in order to reach its minimum 
energy state. Since each spin is in thermal contact with the lattice of nearby protons, it can 
exchange energy with the lattice. After spins are excited by a RF pulse, this interaction 
enables them to relax energetically and gradually re-align to the main magnetic field. The rate 
of change in longitudinal magnetization Mz, as defined in eqn. (1.10) as a consequent of this 
relaxation mechanism is characterized by the ‘spin-lattice relaxation time’ T1. This 
characteristic time is a very important parameter in understanding the re-growth of 
longitudinal magnetization after an excitation, and is crucial in pulse sequence design.  
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 (1.9)  
 





        (1.10)  
The transverse magnetization Mxy is affected not only by the amount of longitudinal 
magnetization present before excitation Mz (t = 0), but also the physical interaction between 
spins (77). Spins experience the main magnetic field as well as the local fields of their 
neighbors. When local field variations are present, the effective magnetic field experienced 
by a spin will be              , leading to different local precessional frequencies.  As 
displayed in Figure 1.2, the excited spins will then tend to fan out in time (this process is also 
known as dephasing). Thus the vector sum of the individual magnetic moments within a 
voxel would be reduced, decreasing the net transverse magnetization and ultimately the MR 






















Mxy (t = 0) = M0
Mxy (t = T2) = 0.37 M0
90 excitation






Figure 1.2: The effect of dephasing is illustrated here in the laboratory frame. When a set of 
spin isochromats is tipped into the x-y plane by a 90° RF excitation pulse, each individual 
spin will precess at a slightly different frequency due to the local field variation induced by 
spin-spin interactions. The transverse magnetization Mxy in the voxel thus attenuates with 
time.  
 
There is another important component that further attenuates sensitivity in MRI, and that is 
the spatially dependent external field inhomogeneity      . When a sample or patient is 
loaded into the magnet, its dielectric inhomogeneity distorts the main magnetic field, causing 
localized variation in Larmor frequency     . This results in additional dephasing of the 
transverse magnetization which further suppresses the MR signal. Incorporating this decay 
time T2
’
 yields the effective transverse relaxation time constant T2
*










  (1.11)  
The overall rate of change in transverse magnetization can thus be included in the equation of 
precessional motion for interacting spins to become 
 
         
  
                
 
  
       (1.12)  
If we combine the longitudinal and transverse relaxation effects into a single vector equation, 
we yield the total rate of change in the magnetization vector in eqn. (1.13).   
 
     
  
                
 
  
          
 
  




In order to ameliorate the detrimental effect of magnetic field inhomogeneities, a mandatory 
procedure in MRI is gradient shimming. This exercise is extremely important in maintaining 
a homogenous magnetic field in the desired volume-of-interest and its incompetency 
adversely impacts the spectral resolution in spectroscopy (78-80) and image quality in 
imaging (81-83). Sophisticated shimming gradient coils are integrated into the spatial 
encoding coils with implementation of extensive algorithms to correct field inhomogeneities 
(84-92). Together with intricate gradient shimming methods (93-97), spin-echo acquisition 
sequences are also frequently utilized to reverse the signal loss caused by field 
inhomogeneities (98,99). Note that if T2
’
 << T2, then T2
*
 is substituted by T2. This occurs 
when the magnetic field is homogenous after shimming or spin-echoes are acquired. 
 
The effects of relaxation on the magnetization of the system can perhaps be effectively 
conveyed with the Bloch equation (100), whereby influences of spatial and time varying 
gradients                       
     
     
     




 , together with 
the physical effect of the applied         field on the magnetization are summarized. This matrix 
relation is the fundamental physical basis of MRI and its solution could be numerically 
obtained to optimize either pulse sequences (101-103) or RF pulse designs (104,105). An 
extremely useful application of the Bloch equation is to measure chemical reaction rates in 







   











          
       
 
  
     
            
 






   
   
  





  (1.14)  
 
In summary, the transverse magnetization decays at a time-constant of T2 while the 
longitudinal component recovers at a T1-dependent rate upon excitation. Since biological 
tissues vary in their molecular composition, cellular phenotypes and vasculature, their T1 and 
T2 relaxation time constants are different. Therefore their Mz recovery and Mxy signal decay 
will be dissimilar. This aspect has traditionally been the source of contrast in MR imaging 
and is the reason for its superiority in in-vivo visualization of soft tissue (109-111). In 
molecular and cellular imaging, the use of MR contrast agents exploits this feature by 
increasing either longitudinal or transverse relaxation of targeted molecules or cells to 
differentiate them from the background. This methodology extends the sensitivity limit of 
MRI and enables applications beyond routine anatomical imaging. With respect to MR 
contrast agents, Chapter 2 investigates the use of gadolinium compounds to increase blood 
vessel signals and facilitate blood flow measurements. Augmenting detection sensitivity of 
exogenous cells via labeling with T2
*
 contrast agents is demonstrated in Chapter 3. Chapter 4 
adopts a unique 
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Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) is an established 
technique used for characterization of microvasculature in oncology. Its sensitivity to 
physiological biomarkers such as blood flow, transendothelial permeability and volume of 
extracellular space enables differentiation between pathological states and assists in 
therapeutic assessment. In this chapter, we exploit the strengths of DCE-MRI to probe the 
microvasculature in the mouse pancreas, which is a critical organ maintaining glucose 
homeostasis via insulin secretion. Semi-quantitative analysis comparing the pancreatic 
hemodynamics between STAT3-deficient and healthy mice is first presented, in order to 
demonstrate its potential as a biomarker to probe angiogenesis impairment.  Subsequently, 
quantitative pancreatic blood flow is deduced via pharmacokinetic modeling and rapid 
imaging techniques in order to achieve a biomarker with direct physiological relevance. Such 
an endeavor has not yet been attempted by the scientific community because of intricate 
challenges.      
  
2.2 Why image blood flow in the pancreas?  
Insulin secretions by beta-cells in the pancreatic islets of Langerhans are critical in 
maintaining blood glucose homeostasis. A rise in blood glucose level (e.g. after a meal) under 
normal physiological condition triggers insulin secretion, which in turn signals for increased 
glucose uptake in tissues. Defects in the insulin secretion mechanism create a metabolic 
disorder of multiple etiologies characterized by chronic hyperglycemia with disturbances of 
carbohydrate, fat and protein metabolism (1). This pathological condition that affects more 
than 220 million people worldwide is known as diabetes mellitus (2). All forms of diabetes 
have very serious effects on health. There are a number of long-term complications 
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associated with the disease. These include cardiovascular, peripheral vascular, ocular, 
neurologic and renal abnormalities, which are responsible for morbidity, disability and 
premature death in young adults (3-5). Furthermore, the disease is associated with 
reproductive complications causing problems for both mothers and their children (6). The 
American Diabetes Association estimates that the mortality rate doubles in diabetics. Cost to 
the American health care system is estimated to be $174 billion in 2007, of which $116 
billion was for direct care of diabetes, $58 billion for treatment of diabetes complications and 
the rest due to increased incidence of other diseases such as heart failure (7). Although 
improved glycemic control may decrease the risk of developing these complications, diabetes 
remains a very significant cause of social, psychological and financial burdens in populations 
worldwide (8,9).  
 
There are two major types of diabetes, Type 1 and 2. Type-1 diabetes, previously known as 
insulin-dependent diabetes mellitus or IDDM, is characterized by the specific autoimmune 
recognition and destruction of insulin-generating beta-cells (10,11), leading to absolute 
insulin deficiency. The mechanism is hypothesized to be the triggering of an inflammation 
response by T-lymphocytes in the islets, provoking destruction of the -cells by leukocytes, a 
condition known as insulitis (12). Figure 2.1 illustrates this hypothetical inflammation 




Figure 2.1: Proposed scheme for the 
initiation of type 1 diabetes (12). Antigen 
presenting cells trigger the influx of T-
lymphocytes, provoking a destructive 
autoimmune process against -cells. 
The majority of diabetic patients though suffer from Type-2 diabetes (also known as non-
insulin dependent diabetes mellitus NIDDM), which is a chronic metabolic disorder arising 
from defects in insulin secretion and insulin action (13,14). They create multiple disturbances 
in glucose homeostasis, including: (1) impaired insulin secretion; (2) insulin resistance in 
muscle, liver, and adipocytes; and (3) abnormalities in splanchnic glucose uptake (15). Type-
2 diabetes is also associated with several other metabolic abnormalities such as central 
obesity, hypertension, and dyslipidemia, contributing to the very high rate of cardiovascular 
morbidity and mortality (16). The onset of diabetes mellitus is thus attributed to a 
convolution of factors ranging from genetic predisposition (17,18) to the environment (19,20). 
It is obvious that diabetes is an intricate collection of diseases, originating from various 
causes with different progression paths. Since these pathologies appear to converge and 
develop into hyperglycemia, insulin production by -cells is therefore a very important 
biological process in the development of the disease.   
 
The central role of -cells in the pathogenesis of diabetes has attracted great interest in the 
use of molecular and cellular imaging techniques for in-vivo detection of their function and 
physiology. A host of molecular probes are being developed to sense the occurrence of 
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important processes that seek to destroy -cells or seriously disrupt their function. Tracking 
the homing of lymphocytes labeled with anionic magnetic nanoparticles for instance, offers a 
real-time monitor of the auto-immune destruction of  -cells in the diabetic pancreas (21). 
Specific targeting of the auto-reactive lymphocytes via a molecular probe of high affinity (e.g. 
NRP-V7 peptide conjugated to a cross-linked superparamagnetic iron-oxide nanoparticle) 
enables identification of an explicit lymphocyte population that triggers the auto-immune 
destruction of -cells (CD8+ T-cells in this example) (22). Although cellular tracking allows 
a probe into the inflammatory response in the pancreatic islets, it is at the end-point and 
affected -cells will still be eliminated subsequently. It is perhaps more useful to study the 
processes that precede the islet destruction and implement preventive actions. Accumulating 
evidence suggests that vascular endothelium is of crucial importance for the development of 
inflammatory reactions (23). The roles of endothelial and leukocyte surface receptors in the 
homing of inflammatory cells to the pancreatic islets are becoming more evident, shedding 
light on their participation in the origin of insulitis and IDDM (24-26). Furthermore, changes 
in vascular permeability of islet blood vessels during the development of IDDM have been 
described in diabetic rodent models (27,28). Notwithstanding its role in facilitating 
autoimmune destruction of -cells, the microvascular network in the islets is also a key 
infrastructure in transmission of information pertaining to the blood glucose level, which 
regulates insulin production, and in transportation of the secreted hormone (29). This 
information highway is extremely crucial in glucose sensing and maintaining homeostasis 
(30,31).  It is thus not surprising that the microvasculature of the pancreatic islets is an 
intricate network of arterioles and capillaries (32), which receive a significant 10-20% of the 
total pancreatic arteriolar blood flow (33), despite their relatively minute composition (1.7% 
mass) in the whole pancreas. It is thus intuitive that in-vivo detection of blood flow, blood 
volume and vessel permeability of the pancreas could serve as biomarkers of islet viability 
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and function (34). Obtaining real-time macroscopic information pertaining to the 
hemodynamic properties of the pancreas would then herald pathogenesis and perturbations in 
the glucose balancing mechanism.  
 
2.3 Pancreatic Perfusion Quantification Methods  
2.3.1 Pancreas Morphology 
Accomplishing this goal of measuring pancreatic perfusion quantitatively with DCE-MRI is a 
tremendous challenge owing to the unique cellular composition and structure of the pancreas. 
The pancreas consists of the endocrine and exocrine glands, consisting of the islets of 
Langerhans and the pancreatic acini, respectively. Pancreatic islets are small organ-like 
entities dispersed throughout the pancreas at a low density and account for only 1.7% of the 
pancreatic volume (35). It is a complex structure comprising four types of secretory 
endocrine cells, namely the insulin-containing -cells, the glucagon-containing -cells, the 
somatostatin-containing -cells and the pancreatic polypeptide-producing (PP) cells (36). In 
humans, the cellular composition appears to depend on the region in the pancreas; with -
cells contributing between 48% and 59% of total cell population, -cells between 33% and 
46%, and -cells between 8% and 12% (37). Islet cellular composition also varies widely in 
healthy and diabetic patients (38), further convoluting the microcirculation morphology. Thus 
subject variability is expected to be substantial in the quantified pharmacokinetic parameters. 
Nonetheless, the advantages offered by DCE-MRI to probe pancreatic microcirculation 
propel us to develop a protocol for non-invasive blood flow measurements in a very 




2.3.2 Microsphere Technique for Blood Flow Measurement  
Pancreatic blood flow in small animals has traditionally been measured with the invasive 
method of polystyrene microspheres injection into a carotid cannula with simultaneous blood 
withdrawal for quantification reference. The rate of blood flow per sphere is then assumed to 
equal the rate of withdrawal divided by the number of spheres in the withdrawn blood 
volume. By dissecting the pancreatic tissue and counting the number of spheres in the 
microvasculature, the blood flow (ml min
-1




) can be deduced 
(35,39). Distribution of islet blood flow can subsequently be mapped out according to islet 
size. In a rodent, the distribution of islet blood flow ranges from 3% to 64% of total islet 
blood flow, depending on islet diameter (25 – 300m) (40). Although this method permits 
quantification of blood flow down to the tens of m in spatial resolution, it is a terminal 
procedure and does not allow longitudinal assessment of hemodynamics in the pancreas.  
 
2.3.3 Appeal of DCE-MRI in Perfusion Studies 
A more appealing method for in-vivo perfusion measurement is the non-invasive dynamic 
contrast enhanced magnetic resonance imaging technique, whereby either a T1 or T2 reducing 
agent is infused into the blood stream to create signal enhancement or depletion in perfused 
tissues, respectively (41,42). If a low molecular weight contrast agent is used, its molecules 
are transiently confined within blood vessels during first passage and then rapidly diffused 
through the fenestrated capillaries into the extravascular extracellular space (EES). The rate 
of extravasation depends upon the endothelial permeability, surface area, tracer’s particle size 
and blood flow. The flux of the contrast agent back into the microcirculation will occur 
subsequently at a rate dependent on the endothelial permeability. By measuring the temporal 
changes in tissue signal intensity, the concentration of the exogenous contrast agent in the 
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tissue can be derived, divulging its diffusion kinetics into the tissue extracellular space. The 
tracer’s bio-distribution provides information on perfusion and microvessel characteristics, 
such as endothelial permeability, volume of the plasma space and interstitial volume (41,43-
45). These parameters have proven valuable in the assessment of tumor vasculature and 
function (46,47), as well as in the analysis of tumor response to therapeutic drugs such as 
anti-angiogenesis inhibitors (48-50). A clinical example would be the comparison of 
pharmacokinetic parametric maps between treated and untreated tumors, such as K
trans
 
(volume transfer constant), in order to determine the arrest efficiency of the therapeutic agent 
(51,52).  
 
2.4 Probing of Pancreatic Microvasculature with DCE-MRI  
2.4.1 Novelty in Mouse Pancreas DCE-MRI 
Very little literature exists on the quantitative perfusion of the mouse pancreas. In fact we 
found only one in PubMed that measures T1 in the pancreas and not perfusion per se (i.e. 
semi-quantitative only) (53). There are a couple of reasons for such scarcity. First is the 
complex structure of the mouse pancreas, which is a thin film of tissue (~1 mm) that stretches 
across the abdomen in an irregular fashion in-between gastrointestinal structures. Therefore, 
dedicated small animal MRI system is necessary to achieve the required resolution and 
precision. Second, it is extremely difficult to obtain the arterial input function (AIF) in mice 
because of its rapid cardiac cycle. Yet the AIF is fundamental for quantitative blood flow 
deduction. High temporal resolution is thus essential and that stresses the gradient 
performance of the system. To appreciate the technical challenges faced and limitations in the 
physiological interpretation of quantities obtained with DCE-MRI, we will have to 
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understand the quantification process including the difficulties encountered in magnetic 
resonance imaging of the mouse pancreas.  
 
2.4.2 Roadmap to Mouse Pancreatic Perfusion Quantification 
We begin this journey by comparing DCE-MRI techniques that could measure MR signal 
changes dynamically. Identification of the different T1-reducing exogenous contrast agents 
available and a description of their distinct pharmacokinetics in tissue perfusion are then 
presented. A systematic approach for consistent mouse pancreas MR imaging then follows. 
Semi-quantitative T1 DCE-MRI analysis is performed on a STAT3 knockout model to search 
for abnormalities in pancreatic microvessel development. As we progress to quantitative 
perfusion measurements, an introduction of contrast agent mass transport kinetics and the 
relevant physiological parameters affecting their pharmacokinetic properties will be made, 
using a two-compartment model (54). We shall seek to derive tissue perfusion information by 
fitting dynamic concentration curves into this model. Finally, a quantitative treatment of the 
dynamic signal enhancement with the two-compartment model, upon infusion of a low 
molecular weight T1-reducing contrast agent, is performed to extract blood flow and volume 
percentage of extracellular space in the mouse pancreas.   
 
2.4.3 Pharmacokinetic Modeling with DCE-MRI 
Types of DCE-MRI 
DCE-MRI has proven its potential to distinguish the vasculatures of normal and pathological 
tissues in oncology. Semi-quantitative and quantitative analysis further makes it appealing as 
a potent biomarker for non-invasive grading of tumor (55-57). The pharmacokinetic 
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properties that can be derived in a DCE-MRI experiment depend on the applied methodology. 
DCE-MRI sequences can be designed to be sensitive to the vascular phase of contrast 
medium delivery (so-called dynamic susceptibility contrast which reflects on tissue perfusion 
and blood volume). In this technique, a rapid injection of high-concentration contrast agent is 
infused (a ‘bolus’), giving rise to magnetic field inhomogeneities that decrease the MRI 
signal (58). This effect is most pronounced during the first passage through the tissue, after 
which signal quickly recovers to its equilibrium value. The real-time changes in tissue signal 
intensity has to be tracked rapidly using a fast imaging sequence, with a typical temporal 
resolution of 1-2 seconds over a period of 60 seconds post-injection. Generally, a gradient-
echo or spin-echo sequence is used, with the latter providing greater sensitivity to 
microvessels (59). To increase sensitivity to blood flow and reduce dependency on tracer 
molecule diffusion into the tissue extracellular space, a blood-pool agent is preferred. Semi-
quantitative analysis of the signal changes may be performed to obtain parameters indirectly 
related to physiology (60) . Alternatively, if contrast agent concentration is known together 





), tissue blood volume tBV (ml g
-1
) and mean transit time MTT (the average time 
taken for the tracer to pass through the vascular bed within the voxel; units are in minutes) 
can be generated from the time-course of the MRI signal changes by applying kinetic analysis 
(61,62). Since its initial maximum peak enhancement (‘first pass’) usually occurs within 10 
seconds upon infusion in mice and is substantially completed in half that time (63), some 
technical requirements must therefore be fulfilled to ensure accuracy in bolus tracking 
experiments. High spatial resolution for accurate derivation of the arterial input function, 
together with a high temporal resolution to capture the peak enhancement during the bolus 
phase (64) are essential conditions. A typical mouse has a blood volume of about 2 mL and a 
cardiac output of 11 mL min
-1
 (65), and thus its circulation period is only about 11 seconds. 
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A healthy human being on the other hand has approximately 5 liters of blood and an output of 
5.5 L min
-1
, resulting in a period of 55 seconds. Thus if the first pass in the mouse is to be 
captured with sufficient temporal resolution, ultra-fast imaging techniques must be adopted 
without sacrificing accuracy in quantification. 
 
Alternatively, T1-weighted sequences can be employed to create signal enhancement. If a low 
molecular weight tracer is used in conjunction, these techniques become sensitive to the 
presence of contrast medium in the EES, which reflect microvessel perfusion, endothelium 
permeability and extracellular leakage volume. T1-weighted DCE-MRI is what we have 
adopted in this work because of the interest in studying the microvascular characteristics in 
the pancreas and thus its utilization will be further discussed in subsequent sections. A brief 
overview comparing T2
*













*-weighted imaging T1-weighted imaging 
Tissue signal intensity 
change 
Darkening Enhancement 
Temporal resolution 1 – 2s 2 – 25s 
Duration on imaging 60 – 90s 5 – 10min 
Magnitude of effect Small Larger 
Type of contrast agent 
Blood-pool agents (molecular 
weight MW > 70kDa preferred) 
Low to moderate MW agents 
that diffuse into the EES 
Optimal contrast medium 
dose 
> 0.2 mmol/kg body weight 0.1 - 0.2 mmol/kg b.w. 
Quantification method 
used 
Relative more than absolute relative and absolute 
Physiological property 
measured 
Perfusion / blood volume 
Trans-endothelial permeability, 




Blood volume and flow, transit 
time 
Transfer and rate constants, 
leakage space 
Pathological correlates 
Tumor grade and microvessel 
density 
microvessel density 
Clinical MR applications 
Lesion characterization - breast, 
liver and brain 
Vascular endothelial growth 
factor (VEGF) inhibition 
Directing brain tumor grading 
Lesion detection and 
characterization 
Directing brain autopsy 
Improving accuracy of tumor 
staging 
Determining brain tumor 
prognosis 
Predicting response to treatment 
Monitoring treatment, e.g. 
radiotherapy 
Monitoring response to 
treatment 
 
Novel therapies including anti-
angiogenic drugs 
 Detecting tumor relapse 
Special technical 
requirements for small 
animal imaging 
Ultra-fast sequence to capture 
first-passage of contrast medium 
in the tissue 
Good slice profile for very thin 
slices of  ~ 0.50 mm 
 
Very short echo-time to 
minimize T2
*-effect at high 
magnetic field 
Table 2.1: Comparison of T2
*
- and T1- weighted dynamic contrast enhanced MRI techniques. 
Requirements unique to small animal DCE-MRI at high magnetic field are also included. 
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2.4.4 Contrast Agents for T1-weighted DCE-MRI 
There are essentially two types of exogenous contrast agents for T1-weighted DCE-MRI, 
namely low molecular weight (< 1000 Da) and moderate molecular weight contrast media (> 
10000 Da). The appropriate tracer to use depends on the desired application. Low molecular 
weight (or extravascular) contrast agents allow probing of microvascular properties such as 
transendothelial permeability P, capillary surface area S, transfer and rate constants K
trans
, 
micro-vessel density, fractional volume of extracellular extravascular space ve, and plasma 
space vp (68). These microvascular characteristics directly impact tracer uptake and clearance 
in the tissue and alter the MRI signal in the tissue. These properties are dependent on the 
current physiological state, and thus tracking their changes could benefit pathodiagnosis and 
disease staging. Numerous clinical studies have demonstrated their utility in measuring or 
assessing therapeutic response of tumors in the bladder, breast, brain, cervix and bone in 
patients (69-73). However, there are instances in which only the blood flow and volume are 
desired. Then the contrast medium preferably remains in the blood circulation with minimal 
loss into the tissue interstitial space and low molecular weight contrast agents will not be 
suitable for this task. This requirement can be met by attaching low molecular weight contrast 
media to macromolecules such as peptides. The resulting macromolecular contrast agents 
possess limited ability to diffuse through the capillary endothelium, enabling diminished 
tissue uptake and slower clearance from the blood pool. This category of tracers is clinically 
termed intravascular contrast agents, because of their prolonged plasma lifetimes. Their 
excretion is also retarded, yielding flatter arterial input functions. The slower kinetics allows 
for higher dynamic range in quantification of vascular leakage and acquisition of much 
higher-resolution images (74). To achieve intravascular retention, several paramagnetic 
chelates have been proposed and tested. These included Gd-DTPA-albumin (75), Gd-DTPA-
dextran (76) and Gd-DTPA-polylysine (77), with molecular weights ranging from 48 to 
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150kDa. Molecular size is a critical factor determining the retention of these compounds in 
the intravascular compartment as well as its relaxivity. Although they are most commonly 
used in bolus tracking experiments with T2
*
-weighted MRI, I adapted their utilization in 
prolonged perfusion imaging with T1-weighted DCE-MRI by gradual infusion at low 
concentration. By doing so, I could perform semi-quantitative analysis on the resulting signal 
enhancement curve (see section 2.6). The availability of low molecular and macromolecular 
weight contrast agents thus facilitates the investigation of microvascular dynamics as well as 
offers a probe into the endothelial membrane integrity. 
 
2.4.5 Definition of Semi-Quantitative DCE-MRI Parameters  
When a contrast agent is delivered into the systemic circulation, it is carried in the blood 
plasma and delivered throughout the body. A portion is initially absorbed into the tissue 
extracellular extravascular space (EES) via diffusion through the capillary endothelium. 
There is also back-diffusion from the EES into the plasma space before equilibrium is 
established. Subsequently as more tracer molecules are excreted, contrast agent concentration 
in the blood plasma will diminish. The concentration gradient changes polarity and the tracer 
begins to wash-out from the tissue EES. The whole process from infusion to absorption and 
finally clearance describes the pharmacokinetics of the contrast agent and indirectly reports 
on the pathophysiological status of the targeted tissue. The blood circulation at the capillary 
level, or microcirculation, is driven by the metabolic activity of the tissue. In pathological 
processes, such as tumorigenesis, this microcirculation becomes altered and leads to an 
increase in microvascular density resulting from the growth of new capillary networks as well 
as vasodilation of existing vessels (78). To describe the impact of these physiological 
metamorphoses on the MR signal, a series of terminology has been proposed including the 
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initial area under the Gadolinium curve (IAUGC), maximum enhancement gradient and 
enhancement (79). Such semi-quantitative DCE-MRI has benefitted disease prognosis and 
been particularly useful in the investigation of tumor angiogenesis (80). It enables the study 
of microcirculation in a number of diseases including breast metastases in which a highly 
vascularized carcinoma is characterized by a rapid upslope, high signal enhancement and 
clear washout phase (81), in bone sarcoma where necrotic, semi-necrotic, proliferating and 
viable regions of the bone displayed distinct tracer pharmacokinetics (69), and in the 
evaluation of the use of an inhibitor of VEGF receptor  tyrosine kinase to retard angiogenesis 
in metastatic liver lesions (82). Rate of tracer uptake and clearance have also been employed 
as biomarkers to gauge blood-brain barrier breakdown in neurodegenerative diseases such as 
multiple sclerosis (83,84), which indirectly report the rate of axon demyelination. Regardless 
of the contrast agent’s principal relaxation mechanism (T1- or T2- shortening), the induced 
signal changes can be chronologically measured with dynamic MRI. Before pioneering 
quantification work from Tofts (45), Brix (85) and Parker (86), semi-quantitative DCE-MRI 
provided the pragmatic information to distinguish between necrotic and viable tissues (87-89), 
merely from the comparison of their signal enhancement curves. This is a valuable diagnostic 
tool in MRI that has been extensively used in the past two decades and remains so. To exploit 
its advantages, I defined the parameters that are commonly used in the clinic to describe the 
dynamic signal enhancement data. Furthermore, to showcase an application of this semi-
quantitative methodology in the investigation of pancreatic vasculature, I measured these 
parameters in a study comparing the signal enhancement curves between a wild-type and a 
STAT3 knock-out mouse, and attempted to interpret the physiological relationship between 





A starting point in semi-quantitative analysis is to look at a typical T1-weighted dynamic 
contrast enhancement signal intensity curve illustrated in Figure 2.2. There are normally three 
distinct phases in the signal enhancement time evolution; the upslope, maximum 
enhancement and washout (66). It is generally recognized that the upslope is highly 
dependent on tissue perfusion and permeability, with perfusion dominating principally due to 
high blood volume and high first pass extraction. Maximum enhancement is related to the 
total uptake concentration of the contrast medium in the interstitial space and washout rate is 
associated with a decrease in the concentration of the tissue contrast agent. The latter two 
phases are strongly coupled to vascular permeability. Semi-quantitative analysis of signal 
intensity changes with respect to these three phases and provides insight into the 
pharmacokinetics of the contrast agent, which is influenced by the underlying physiology. 
Thus it offers a fast and convenient method to aid in diagnosis. Parameters for description of 
tracer kinetics include the following and are shown in Figure 2.2 (86):  
1. Onset time: defined as the time period between the midpoint of the tracer injection 
and the point on the enhancement curve at which signal is 10% of its maximum. 
2. Maximum signal intensity: defined as the peak level of relative signal intensity within 
the tissue of interest, within the dynamic measurement method. 
3. Initial gradient: defined as the rate of change in relative signal intensity at the 10% 
point on the uptake curve. 
4. Mean gradient: defined as the average rate of change in relative signal intensity 
between the 10% point and the 90% point on the enhancement curve. 
5. Washout gradient: defined as the average rate of change in signal intensity between 
the point of maximum enhancement and the end of the dynamic scanning period, if a 
maximum is reached during the time.     
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6. Initial area under the gadolinium curve (IAUGC): Integral area under the signal 
enhancement curve from tracer delivery till after the first pass. Commonly used as an 
endpoint in assessment of blood flow, vascular permeability and interstitial space (90). 
 
Figure 2.2: Relative signal intensity of wild-type mouse in a T1-weighted DCE-MRI 
experiment after an intravenous injection of 0.2 mmol kg
-1
 Vasovist® (intravascular contrast 
agent) at time t = 0 s. Relative signal intensity is defined as 
           
               
, where S(t) is the 
absolute signal at time t, S(0) is the baseline signal and max[S(t)] is the maximum signal 
intensity.  
 
2.4.6 Pharmacokinetics of Low Molecular Weight Extracellular Contrast Agents 
Low molecular contrast media available in the clinic, such as gadopentetate dimeglumine 
(Gd-DTPA) with a molecular weight of 590 Da, diffuse from the blood plasma pool into the 
EES of the pancreas at a rate determined by the blood flow into the tissue F, the permeability 
90% of Max. Enhancement
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of the capillaries P and the surface area of the perfusing vessels S. The contrast agent 
molecules do not cross cell membranes and hence its volume distribution is effectively the 
extracellular extravascular space, as shown in Figure 2.3. On T1-weighted images, the 
shortened T1-relaxation times of the blood pool and extracellular water, induced by the tracer 
in the plasma and interstitial spaces, respectively, result in positive enhancement. The early 
phase in contrast enhancement, which is equivalent to the first-pass in a bolus injection, 
involves the arrival of the contrast medium in the pancreas via the arterial supply, and lasts 
several cardiac cycles. The contrast agent subsequently diffuses back into the vasculature and 
is excreted via the reticuloendothelial system (RES). When these influx and outflux processes 
are limited in poorly perfused regions, it is reflected in the lower volume transfer parameter 
K
trans
 (91). This discrepancy in tracer uptake and clearance between normal and pathological 
tissues could be used as biomarkers in treatment diagnosis and disease staging (92). In order 
to obtain accurate quantitative information from DCE-MRI for sensible correlation to 
physiology, we will need to model the in-vivo pharmacokinetics of the contrast agent.  
 
The rate of accumulation and wash-out of a contrast agent into the interstitial space, assuming 
it is homogenous in the vascular plasma space p and well-mixed in the EES, can be 
described by the steady-state mass transfer equation from Kety (93): 
   
      
  
                     (2.1)  
where e is the volume of the EES per unit volume of tissue, Ce (mM) is the concentration of 
the agent in e, p is the blood plasma volume per unit volume of tissue, Cp (mM) is the 
concentration of agent inp, and K
trans
 is the volume transfer constant between p and e (41) 
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(see Figure 2.3). The transfer constant depends on the equilibrium between capillary 
permeability and blood flow in the tissue of interest. In a highly-permeable membrane, the 
flux across the endothelium is flow-limited and K
trans
 is equal to the blood plasma flow per 
unit volume of tissue according to Eqn. (2.2). F is the perfusion of whole blood per unit mass 




),  is tissue density (g ml-1), Hct is the hematocrit, P is the total 
permeability of the capillary wall (cm min
-1






                                                    (2.2)  
In the reversed scenario of low permeability limiting tracer flux, the transfer constant is equal 
to the permeability surface area product between blood plasma and EES per unit volume of 
tissue, i.e. 
                                                      (2.3)  
In the general mixed perfusion- and permeability-limited regime, K
trans
 becomes equal to 
EF (1-Hct), where E is the extraction fraction of the tracer (i.e. the fraction of tracer that is 
extracted from p into e in a single capillary transit). Thus E = 1 in a flow-limited situation 
while E = PS / [F(1-Hct)] in a permeability-limited regime. 




Figure 2.3: Major compartments involved in the distribution of a contrast agent tracer 
 
Ct is the tracer concentration in the tissue that is indirectly measured in DCE-MRI. If we 
ignore the contribution of intravascular tracer to the tissue concentration, then it is defined as 
(41) 
               (2.5)  
Substituting this into Eqn. (2.1), the resulting 1
st
 order differential equation to solve would be 
 
      
  
                        (2.6)  
The problem with this Tofts-Kermode (TK) model is the assumption that the observed 
contrast agent concentration changes in a voxel is entirely caused by the leakage of tracer 
molecules into the EES. In reality signal enhancement, upon induced T1-relaxation with 
Ktrans






membrane with permeability 




contrast media, occurs in both capillary vascular plasma space p and the EES e (assuming 
no cellular uptake). The flawed assumption leads to erroneously high K
trans
 values caused by 
intravascular contrast agent and inflates vascular permeability estimates (94,95). This artifact 
has therefore been referred to as “pseudo-permeability’ (54). To rectify the modeling error, 
the total contrast agent concentration in the tissue voxel should reflect the component of 
intravascular tracer and thus eqn. (2.5) is modified to become eqn. (2.7). Putting this into eqn. 
(2.1), we obtain the total tissue concentration per voxel according to eqn. (2.8). 
                       (2.7)  
                
          
       





    (2.8)  
Ct(t) may also be expressed in the form presented in eqn. (2.9), where H(t) is the impulse 
function given by eqn. (2.10) and  denotes the convolution operation. This is known as the 
modified TK model. 
                          (2.9)  
                
        
  
  (2.10)  
Tracer concentration in the blood plasma changes with regard to the pharmacokinetics of the 
contrast agent in the pancreas, hemodynamics of the animal and excretion. Its effect on T1-
enhancement is mixed with that in the EES and is not easily extracted from the measured MR 
signal. Tofts and Kermode approximated this arterial input function (AIF) by a bi-exponential 
function that was scaled according to the administered dose of contrast agent D (mmol kg
-1
 
body weight) , with the constants a1, a2, m1, m2 and A (41,96): 
                                    (2.11)  
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Determination of the AIF is a critical component in the quantitative process. The easiest way 
to introduce an AIF to a DCE-MRI kinetic modeling experiment is to assume one derived 
from the time course of the mean vascular concentration measured in blood samples from 
healthy subjects (97). Although this simple method is convenient, it does not consider the 
actual AIF of the subject and would most likely introduce parametric errors in the model. To 
avoid such detrimental consequences, we prefer to measure the AIF for each subject, using an 
MRI procedure if possible. In this thesis, we used the abdominal aorta as the source of arterial 
input function to fit into eqn. (2.11) and estimate Cp(t). Together with the measured tracer 
concentration in the pancreas, Ct(t), the modified TK model is fitted to the dynamic MR 
concentration data using nonlinear least squares estimation to obtain values for K
trans
, ve and 
vp in eqn. (2.9). Pancreatic blood flow is then extracted from K
trans
 according to eqn. (2.2), 
assuming a pancreatic tissue density of =1.05 g ml-1 and a haematocrit of 0.49.  
 
2.4.7  Dynamic T1 Quantification  
It is apparent that the contrast agent concentration in the tissue Ct and plasma Cp are key 
parameters in the determination of tissue uptake rate, capillary permeability and blood flow. 
The determination of Ct and Cp is perhaps the most challenging step in the quantitative 
characterization of tracer pharmacokinetics. Since MRI does not measure concentration per 
se, it will have to be extracted from the MR signal. A straightforward approach is to assume 
that the change in signal intensity is directly proportional to tracer concentration according to 
eqn. (2.12). T10 is the baseline tissue longitudinal relaxation time before infusion of contrast 
agent (i.e. at t = 0) while T1(t) are the dynamic values upon tracer delivery. Tracer relaxivity 
r1 depends on the field strength, the chemical nature of the contrast agent and the 
physicochemical properties of the tissue. T1 depends on the inherent tissue properties such as 
47 
 
proton density content and the microenvironment of the various proton pools. When contrast 
agent particles enter the circulation, some will diffuse into the extracellular extravascular 
space of the pancreas while others remain in the blood plasma or are excreted via the kidneys. 
These Gd-complexes hasten relaxation of juxtaposed proton pools in the blood plasma as 
well as in the EES, resulting in the voxel signal becoming an ensemble of relaxation effects 
from different compartments. This weighted signal inclines towards either the EES or 
vascular space compartment as spatial resolution improves. It is intuitive from eqn. (2.12) 
that if we measure T1 variation with time, an estimate of contrast agent concentration in tissue 
could be obtained (96).  
 
      
 
 
     
 
 





Measurement of T1 in DCE-MRI requires accuracy and sufficient signal-to-noise ratio over a 
wide range of values (i.e. good dynamic range). This is because the T1 of the mouse pancreas 
can vary from about 650 ms pre-contrast to 194 ms upon infusion at 9.4T field strength (53). 
Therefore the measurement method must be rigorously validated over a wide range of T1 
values. In order to obtain a sufficient in-plane spatial resolution (~150  150 m2) within a 
reasonable time, and to minimize the transverse relaxation effect of the contrast agent, the 
most common approach to dynamic T1 measurements is to employ a rapid gradient echo-
based sequence such as Snap-Shot Flash (98). This technique possesses a number of 
advantages including speed and ease of T1 estimation. The MR signal S from a spoiled-
gradient echo image with echo time, TE is  
   
          
       
             
       
 
 (2.13)  
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where TR is the repetition time,  is the RF flip angle used, and S0 is the relaxed signal for a 
90° pulse when TR >> T1 and TE << T2
*
 (i.e. the proton-density signal). By making multiple 
acquisitions with different repetition times and/or different flip angles, it is possible to 
estimate the T1 of the tissue. For quantitative DCE-MRI, a straightforward protocol involves 
a single heavily proton density-weighted acquisition, prior to contrast agent administration, 
followed by numerous T1-weighted acquisitions over time (see Figure 2.4) (86,99,100). This 
could be achieved by choosing a low PDW for PD-weighted acquisition and a higher T1W for 
dynamic T1-weighted acquisitions. If their respective flip angles sum up to 90°, i.e.  
             
  (2.14)  
then the expected ratio of the T1-weighted signal,   , to the proton density weighted signal, 




     
                
                
                    
                     
 (2.15)  
where        , TRA is the repetition time of the T1-weighted sequence and TRB is that for 
the proton density weighted sequence. As the proton density – weighted image is only 
recorded once, the temporal resolution of the T1 measurement in the dynamic study is the 




Figure 2.4: Schematic of a typical DCE-MRI acquisition protocol. T1 maps at each time-point 
are calculated by relating the signal intensity in the dynamic T1-weighted series to the 
baseline PD-weighted data set, which is acquired prior to infusion of contrast agent.  
 
2.5 Rapid Localization of the Mouse Pancreas with MRI 
The delineation of the mouse pancreas is not a trivial task because it is a very thin piece of 
tissue (~1 mm) that is spread out between the spleen, stomach and kidney. There is no single 
oblique slice that could capture the whole pancreas in an MR image because of its dispersed 
distribution across the abdomen. After some trial and error attempts, I established an imaging 
protocol for quick localization of the mouse pancreas and identification of an optimal slice 
for quantification.  Initially, multiple coronal slices (using rapid T1W- gradient echo imaging) 
are taken along the abdomen to locate the stomach and spleen, which act as landmarks. The 
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tail of the pancreas is closely adjacent to the spleen and stomach. The spleen appears as a 
triangular shape structure in coronal view, as shown in Figure 2.5a; the stomach is an oval 
structure with a low signal lumen, continuing to the right into the duodenum and lying 
adjacent to the right lobe of the liver. The pancreas tail is usually situated distal to the 
stomach, medial to and partly covering the spleen and also the upper pole of the left kidney, 
filling a triangular-shaped space between the stomach, kidney and spleen. Following the tail 
of the pancreas to the right allows easy delineation of the pancreas body, which lies 
immediately adjacent to the duodenum. In order to identify the pancreatic structures it is 
crucial to obtain thin adjacent slices of 1 mm or less in thickness without any gap between 
them, in order to allow the differentiation of the pancreatic tissue from adjacent gut structures 
(101). The next step is to acquire oblique slices that cover a major area of the pancreas with 
T2-weighted MRI as shown in Figure 2.5b. The pancreas (bordered in red) can then be 
distinguished from other abdominal structures. The stringent requirement of thin slices 
demands high gradient strengths, which are usually available only in preclinical MRI 
scanners. Fortunately the scanner in our facility is a 9.4 T small animal system with a 
gradient strength of 40 gauss cm
-1
 at a rise time of 130 s and has the capability to perform a 





Figure 2.5: A quick method to locate the pancreas in less than 2 minutes: (a) Fast gradient-
echo images in the coronal direction with 5 averages and no respiratory gating. (b) A T2-
weighted oblique slice below the stomach and across the spleen provides a lucid view of the 
pancreas. This slice orientation is subsequently applied in T1-weighted dynamic MRI. Both 
images are thin 0.5mm slices with an in-plane spatial resolution of approximately 
150x150m2 and 75 x 75m2 respectively.  
 
2.6  Semi-Qualitative DCE-MRI Perfusion Study in a STAT3 Knockout Mouse with a 
Blood Pool Contrast Agent (MS-325) 
2.6.1 Signal transducers and activators of transcription (STAT3) Knockout Mouse 
Signal transducers and activators of transcription (STAT) proteins are a family of latent 
cytoplasmic transcription factors that are produced in many cell types and that are activated 
by tyrosine phosphorylation and dimerization in response to a wide variety of extracellular 
ligands, such as cytokines and growth factors (102). STAT3 in particular is a ubiquitous 
transcription factor that is indispensible during early embryogenesis and is one of the 









hepatocyte growth factor, betacellulin and heparin-blinding EGF-like growth factor. STAT3 
plays an important role in -cell insulin secretion, maintaining normal islet morphology and 
glucose tolerance (103).  When the STAT3 gene is disrupted in mice -cells, islet architecture 
is impaired together with a 45% reduction of vascular endothelial growth factor (VEGF) 
expression (104). One in particular is VEGF-A, which induces capillary networks in the 
pancreatic islet that are essential for optimized blood glucose regulation (105,106). Originally 
discovered as a vascular permeability factor (107), VEGF-A induces vessel fenestration that 
increases vascular permeability and regulates the transport of solutes across to the 
extracellular space (108). Its importance becomes apparent when we consider the formation 
of the pancreatic islet, which occurs in two sequential steps: the first step involves the 
signaling from blood vessel endothelium to induce islet formation adjacent to the vessels. In 
the second step, the newly formed islets reciprocally signal to the adjacent endothelial cells, 
via VEGF-A, to induce formation of a dense network of fenestrated capillaries (109). Mice 
with disrupted VEGF-A gene specifically in beta cells has been shown to possess reduced 
islet vascular density with impaired formation of endothelial fenestration. With regard to -
cells function, their insulin release mechanism is impaired, resulting in glucose intolerance 
(110). Thus STAT3 regulation of VEGF-A is crucial in the development of 
microvascularization in the pancreatic islets and ultimately their glucose sensing ability. 
Furthermore, the observation that MRI kinetic parameters can detect suppression of vascular 
permeability after anti-VEGF antibody (111) and after the administration of inhibitors of 
VEGF signaling (112) lends weight to the important role of VEGF in determining MRI 
enhancement. We therefore expect to detect differences in signal enhancement between the 




2.6.2 Materials and Methods 
Intravascular Contrast Agent for Semi-quantitative DCE-MRI 
In this section, I used a blood pool agent MS-325 (gadofosveset trisodium, Vasovist®), 
which is the first gadolinium-based blood pool MR agent to be approved by the FDA for 
clinical use, to probe the microenvironment of the pancreas. When intravenously injected into 
the blood circulation, the low molecular weight contrast agent binds strongly but reversibly 
with serum albumin in the plasma to result in a 90 kDa macromolecule. Protein binding 
reduces extravasation of the chelates from the vasculature, leading to an increased plasma 
half-life of 2-3h (113). In addition, Vasovist® is a negatively charged hydrophilic compound 
which makes it unlikely to diffuse across the lipid bilayer of cell membranes. Thus even if it 
diffuses across the epithelium, it would most likely remain in the extracellular space. The 
reduced tumbling rate of albumin-bound MS-325 also enables large r1 relaxivity, providing 
superior positive contrast in MR angiography studies (114-117). 
 
DCE-MRI of STAT3 Knockout and Wild-type Mice 
Wild-type and STAT3 knockout phenotype mice were anaesthetized with 1.5% isoflurane 
and ventilated with 1 L min
-1
 of air/oxygen mixture, in accordance with local IACUC. MRI 
with respiratory monitoring was conducted in a 9.4T preclinical Varian scanner. Localization 
of the pancreas was accomplished by multi-slice gradient echo imaging to locate the spleen, 
and then followed by a T2-weighted fast-spin-echo sequence to identify the pancreas, a 
procedure mentioned in section 2.5. Once a suitable slice of the pancreas is found, a dynamic 
T1-weighted fast spin-echo pulse (FSE) sequence is applied in the semi-quantitative 
investigation of contrast agent pharmacokinetics. Echo-train length was 8, giving a temporal 
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resolution of 12 seconds per image. Critical MR parameters were: TR = 0.81 s, TE = 11.8 ms, 
Matrix = 128 x 128, FOV = 23 x 16 mm, slice thickness = 0.5 mm, spatial resolution = 180 x 
125 m2. A 10 ul (0.1 mmol kg-1) bolus volume of Vasovist® was injected intravenously 
within 10 s, via a catheter inserted into the tail vein, after 3 mins of baseline scan.  
 
2.6.3 Results and Discussion 
Figure 2.6 displays the baseline image at time t = 0, defined as the instant of tracer delivery, 
and the dynamic image at t = 30 min in the wild-type mouse. Notice the considerable signal 
reduction in the kidney. Its signal intensity curve, which is derived from the mean intensity at 
the drawn region-of-interest (ROI), illustrates the excretion of MS-325 upon infusion. 
Because MS-325 is only 80% reversibly bound to albumin in rodents compared to 95% in 
humans (118), a significant unbound portion (with molecular weight of only 957 Da) is 
present in the blood plasma and that is rapidly cleared by the renal system. Signal attenuation 
with time is seen instead of enhancement due to the high concentration of unbound MS-325 








Figure 2.6: T1-weighted DCE-MRI images at time t = 0 min (beginning of MS-325 
intravenous injection) and at t = 30 min. Hypointensed kidney is caused by the clearance of 
unbound tracer molecules. Excretion in the kidney serves as an indicator of successful 
infusion via the mouse tail-vein.  
 
Figure 2.7 illustrates the relative signal enhancement at the pancreas in the wild-type and 
STAT3 knockout mice. Their semi-quantitative parameters are summarized in Table 2.2. The 
onset time occurs 6 times earlier in the STAT3-deficient mouse which might be attributed to 
lower capillary blood flow, a less developed capillary network, or reduced endothelial 
membrane permeability. The uptake and wash-out gradients are also much reduced, 
corroborating the hypothesis on impaired capillary fenestration. The maximum enhancement 
phase is significantly longer, which we attribute to the saturation of the EES with tracer 
























Kidney Signal Enhancement in DCE-MRI
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phenotypes, which indicates unchanged interstitial volume. This is consistent with the finding 
that -cell mass is comparable between mutant and control mice (104). 
 
Figure 2.7: Signal intensity curve comparing tracer uptake between control and STAT3 
knock-out mice. 
 
Semi-quantitative parameter Wild-type Stat3 knockout 
Onset  time (mins) 0.8 4.7 
Time-to-maximum intensity (mins) 15 30 
Max. signal intensity 0.0018 0.002 
Duration of max. enhancement phase (mins) 13 35 
Initial gradient 5.88E-05 2.05E-05 
Mean gradient 3.40E-05 2.12E-05 
Washout gradient -4.05E-06 -1.35E-06 
IAUGC 0.0259 0.058 
Table 2.2: Semi-quantitative parameters used in the comparison of MS-325 pharmacokinetics 
between wild-type mouse and the conditional STAT3-knockout phenotype 
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Although semi-quantitative analysis offers a convenient and often reliable gauge in 
pathodiagnosis, the biological relevance behind the parameters is not clearly defined. 
Absolute or relative changes in the semi-quantitative parameters can neither be directly 
translated into physiological properties nor interpreted as occurrence of specific biological 
events. For example, it has been initially suggested that IAUGC is related to blood flow, 
vascular permeability and the fraction of interstitial space, but there was no qualification of 
that relationship (99). Subsequently Walker et al. showed, via pharmacokinetic simulations, 
that IAUGC is actually a mixed parameter that is correlated with K
trans
, vp and ve and it has an 
intractable relationship with all three (119). Therefore, quantification of these 
pharmacokinetic parameters is necessary to truly characterize the underlying pathological 
mechanism as well as isolate noise caused by intra- and inter-subject variability.   
 
2.6.4 Conclusion 
The slow uptake, prolonged enhancement and retarded tracer washout could perhaps serve as 
a biomarker of arrested microvessel development in the pancreatic islets, and measure the 
degree of debilitation in microvascular perfusion. Semi-quantitative DCE-MRI permits an 








2.7 Quantitative Pancreatic Blood Flow Measurement with DCE-MRI 
Using the modified Tofts-Kermode model illustrated in section 2.4.6, we aim to quantify the 
blood flow in a mouse pancreas with a clinical low molecular weight contrast agent 




 at 9.4 T).  
 
2.7.1 Materials and Methods 
Animal Preparation 
The wild-type mice (n = 2) were anaesthetized with 1.5% Isoflurane and ventilated with a 
mixture of medical air and oxygen at a flow rate of 1 L min
-1
. A proton-density weighted 
baseline image was first acquired with the following settings with a normal spoiled gradient-
echo sequence: TR = 500 ms, TE = 1.9ms, Matrix = 192 x 192, FOV = 30 x 30mm
2
, slice 
thickness = 0.5 mm, in-plane resolution = 156  156 m2, number of averages = 3, PDW = 20° 
and no respiratory gating was applied.  
 
DCE-MRI 
At the beginning of the dynamic T1-weighted scan with the Snapshot FLASH sequence, 
approximately 3 min of baseline scan was acquired followed by a 10 l (0.1 mmol kg-1) 
intravenous injection of Gadovist® into the tail-vein in under a minute. Successful infusion is 
immediately known from the almost instantaneous signal decay in the kidney. Scan 
parameters for the dynamic T1-weighted MRI were: TR = 10 ms, TE = 1.9 ms, Matrix = 192 
 192, FOV = 30 x 30 mm2, slice thickness = 0.5 mm, in-plane resolution = 156 x 156 m2, 
number of averages = 3, T1W = 70°, temporal resolution = 9 s, number of dynamic scans = 
59 
 
300 and no respiratory gating was applied. The mean intensities of the respective ROIs at the 
abdominal aorta and pancreas were used in the model fit.  
 
Pharmacokinetics Modeling 
The pharmacokinetics quantification process began with the estimation of dynamic T1 values 
in the pancreas and aorta using eqn. (2.15). Then the concentrations of the contrast agent in 
these respective compartments are derived from the T1 values using eqn. (2.12). Step three 
involves the estimation of the arterial input function according to a bi-exponential model 
similar to eqn. (2.11). Inputs into the AIF model consist of ROI mean intensity of the aorta, 
dosage D (0.1mmol/kg) and acquisition time t. The calculated AIF is then fitted into the TK 
model to yield K
trans
, vp and ve. Assuming the perfusion situation is flow-limited, i.e. PS >> F, 
pancreatic blood flow can be extracted according to eqn. (2.2).  
 
2.7.2 Results and Discussion 
Figure 2.8 displays the PD-weighted image and a dynamic T1-weighted image with the 
pancreas and abdominal aorta delineated for region-of-interest (ROI) analysis. The fitted 
arterial input function Cp(t) is displayed in Figure 2.9a. Our quantitative treatment results in a 
pancreatic blood flow of approximately 0.465ml/min/g, which is almost equivalent to the 
value of 0.54ml/min/g obtained by Carlsson et al., who used the microspheres injection 
technique (35). Unfortunately, we cannot verify the authenticity of vp and ve because of the 
absence of literature regarding quantitative MRI perfusion studies in the mouse pancreas. 
Although Hathout et al. evaluated the in-vivo dynamic contrast enhancement time-course of 
transplanted islets in mice and claimed they could quantify changes in vascularization; their 
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study was in fact only semi-quantitative and they merely used IAUGC and tissue 
concentration Ct as biomarkers of angiogenesis (120), without further pharmacokinetics 
quantification. Nonetheless, the pharmacokinetic values measured in the pancreas of other 
mammals could serve as a guide. Yu et al. assessed the pancreatic microcirculation in type-2 
diabetic patients and healthy controls with DCE-MRI and observed a significant difference 
between their fractional interstitial space ve (0.141 vs 0.103) (121); the latter being similar to 
our measured value of 0.101 in the mice. In addition, Bolender carried out a detailed 
morphological analysis of the guinea pig pancreas and found the fractional volume of the 
EES (which he called extra-exocrinocytic spaces) to be 0.0838 (122), again quite similar to 
our value. It is to be noted though that DCE-MRI measures total tracer concentration 
including that in the islets, acinar tissue and blood vessels. Thus the blood flow obtained in 
the pharmacokinetic modeling is a wholesome perfusion measurement of the pancreas. 
Although the pancreatic islets form only 1-2% of pancreatic mass, they receive 10-20% of 
total pancreatic blood supply; therefore we believe that abnormalities in microvascular 
development of the pancreatic islets should be sufficiently captured in such quantitative 
perfusion measurement. The ability to characterize microcirculation in the mouse pancreas is 
an invaluable asset that could be exploited to investigate alterations in microvasculature in 
the endocrine (e.g. insulitis) or in the exocrine systems (e.g. pancreatitis). An application 
could be the investigation of angiogenesis induced by pancreatic islet transplantation. An 
adequate revascularization is crucial for islet survival and function after transplantation which 
implicates islet graft metabolism and insulin secretion (123). It has been suggested that 
vascular density is dramatically reduced in grafted islets in mice and the reduced blood flow 
could potentially undermine the transplantation success (124). DCE-MRI possesses the 
capability to probe this physiological property in-vivo and in real-time, and might enable 
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longitudinal monitoring of vascular development, improve islet delivery strategies and 
optimize the transplantation procedure.     
 
Figure 2.8: Baseline proton-density weighted and dynamic T1-weighted MRI images acquired 








Figure 2.9: (a) Dynamic contrast agent concentration in the blood plasma (arterial input 
function), fitted into a bi-exponential model according to eqn. (3.11). (b) Quantified 
pharmacokinetic parameters, blood flow F, vp and ve in the mouse pancreas.  
 
2.7.3  Conclusion 
I have demonstrated the capability of T1-weighted DCE-MRI to quantify important 
physiological information such as blood flow and fractional interstitial volume in the mouse 
pancreas, in which there was no precedence. Technical challenges in pancreas localization 
and rapid T1-weighted imaging to capture mouse hemodynamics were overcome. This 
technology enables future studies in pancreatic vascular development and perhaps serves as 





2.8 Limitations in Dual Compartment Model, Mouse Pancreas MRI and T1 Estimation 
In this work, I have made quite a few assumptions in order to quantify the contrast agent 
pharmacokinetics and characterize microvasculature in the mouse pancreas including 
representation of microenvironment with a two-compartment model, uniform tracer 
distribution in the blood plasma, negligible echo-time, perfectly spoiled gradient-echo signal, 
negligible motion and insignificant effect of anesthesia on perfusion. Actual experimental 
conditions deviate from ideality and reduce precision of quantified parameters. Challenges in 
DCE-MRI include selection of an appropriate kinetic model, optimal choice of imaging 
protocol for high accuracy in real-time T1 quantification, precision of measurements and 
relevance to physiology. In this section, I discuss the impact of aberrations and suggest 
methods to ameliorate their detrimental effects. 
 
2.8.1 Dual-Compartment Model 
The tissue voxel scenario adopted in the estimation of the pharmacokinetic parameters is an 
oversimplified two-compartment model (i.e., pancreatic interstitium and blood plasma only). 
In reality, contrast agent molecules are delivered throughout the body via the circulation 
system, resulting in tracer diffusion into the extracellular space of multiple organs. A more 
comprehensive model that could be used is displayed in Figure 2.10 below, which includes 
clearance from kidney and loss of tracer into non-pancreatic EES (96). In addition, contrast 
agent pharmacokinetic is complex in pathological tissues due to morphological changes and a 
more comprehensive multi-compartment model would be essential for improved 
physiological interpretation (125). For example, contrast agent molecules might permeate 
into necrotic -cells, be captured in the interstitial space due to protein binding or 
phagocytized by macrophages (126), resulting in an overestimation of ve. I adopted the 
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modified TK model in this work to account for the impact of tracer concentration in the blood 
plasma in T1 relaxation. However this model assumes that the tracer is well-mixed with 
uniform biodistribution in each of the compartments it occupies, which could result in 
consistent underestimation of vp and overestimation of K
trans
 (127). To overcome this fallacy, 
St Lawrence and Lee (127,128) adapted the tissue homogeneity model (TH) introduced by 
Johnson and Wilson (129), via an adiabatic approximation, and defined the plasma tracer 
concentration as a function that varies along the capillary length and time, i. e. Cp = Cp(x,t). 
This model allows the assessment of blood flow and extraction simultaneously. Although the 
TK, modified TK and TH models have been adopted for use in the clinical assessment of 
blood flow and characterization of microvasculature, it must be noted that they are still only 
simple models that attempt to correlate pharmacokinetic quantities to the complex physiology. 
Thus the interpretation is flawed to some extent. For example, flow heterogeneity is not 
considered in the models at all (130). Flow heterogeneity differs between regions and 
individuals and may not remain constant, as assumed in this study, but could change as a 
function of pathology (131). Additionally, the fitted kinetic parameters are estimates that 
depend on the fitting algorithm and imposed conditions (e.g., initial guesses in the fitting 
routine). It is important to address these uncertainties because it is only after the model 
parameters have been accurately estimated that the diagnostic or prognostic efficacy of 




Figure 2.10: Compartmental model of DTPA tracer distribution. The conventional 
compartments (plasma, whole-body extracellular space and kidneys) are represented with 
solid lines. The leakage into the pancreas extravascular extracellular space is drawn with 




 characterize tracer excretion in the 
kidneys and influx into the EES at rest of body respectively. 
 
2.8.2 Sensitivity to Contrast Agent Concentration and Precision in T1 measurements 
Sensitivity to contrast agent concentration in real-time is very dependent on the accuracy of 
the dynamic T1 quantification. A compromise between precision, spatial resolution and 
imaging speed is essential. In this thesis we have adopted the rapid Snapshot FLASH 
sequence for dynamic measurements in order to acquire the arterial input function with 
sufficient temporal resolution. However, this technique tends to underestimate T1 values at 
very short repetition times and its accuracy deteriorates with shorter TR. A calibration factor 
or full analysis of signal evolution would be necessary to rectify the discrepancies (133,134).  
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stresses the uniformity of the RF field. Imperfection in the transmitted B1 field causes flip 
angle inhomogeneity within the slice and leads to significant deviations in calculated T1 
values from the true values (135). Parker et al. proposed a methodology which explicitly 
corrected for the shape of the RF pulse and for spatial variations in transmitted RF field 
intensity. Including these factors in the derivation of T1 gives a substantial improvement in 
accuracy and precision of T1 measurements in the presence of RF non-uniformity and non-
ideal pulse profiles (136). The thin slices also increase the risk of motion artifacts, 
exacerbated by the respiratory motion at the abdomen, as well as elevate partial volume 
effects.  Respiratory-gated acquisition and motion correction could partially alleviate these 
artifacts (137-139). Alternatively, 3D acquisition could be utilized with an added advantage 
of augmented SNR (140).  
 
The requirements for high temporal resolution are related to the studied pathology and the 
adopted pharmacokinetics model. A high temporal resolution is required for DCE-MRI in 
many conditions, especially for bolus tracking in tissues with leaky vasculature. Simulations 
have suggested that the arterial input function would have to be sampled every second in 
order to limit errors in model parameters within 10% (141). Although Snapshot FLASH 
offers imaging speed, its signal-to-noise ratio is a fraction       of spin-echo techniques 
(142). The low SNR characteristic of ultrafast gradient-echo techniques poses a challenge in 
fitting the noisy data to the model and handicaps the accuracy of kinetic parameters. 
Alternatively, spin-echo approaches for rapid T1 measurements such as EPI–based sequences 
like Look-Locker (143,144) possess the advantage of acquiring entire T1 measurements at 
every time point within the series with high SNR. Thus the appropriate imaging sequence has 




Another factor that could corrupt T1 measurement is the application of user-defined regions-
of-interest (ROI) analysis. ROI methods yield enhancement curves with good SNR, but lack 
the spatial resolution and are prone to partial volume averaging errors. Furthermore, the 
placements of ROI vary between users and that could incur inconsistencies on the outcome of 
the analysis. ROI analysis could also be detrimental because heterogeneous regions of 
enhancement might actually be indicating changes in microvessel density, VEGF expression 
or highlighting pathological processes like necrosis (145,146). Selecting an ROI would then 
average these events and mask their significance. To minimize errors incurred with ROI 
analysis, Evelhoch et al. has recommended a DCE-MRI protocol for accurate T1 
measurements (99). Alternatively, pixel mapping of pharmacokinetic parameters could be 
adopted to depict quantitative enhancement information exactly co-registered with anatomic 
images on a pixel-by-pixel basis. In this manner, information pertaining to tissue 
heterogeneity is completely preserved and the need for ROI placement is eliminated (54,147). 
  
We have assumed that the echo-time is negligible compared to the T2
*
 attenuation effect on 
the MRI signal ( i.e. TE  << T2
*
(t) ). As illustrated in the previous chapter, all exogenous 
contrast agents exert both longitudinal and transverse relaxation effects. The ratio r1/r2 
usually decreases with magnetic field strength, and thus spin-spin relaxation influence is 
augmented and cannot be ignored, especially in the preclinical environment. This signifies a 
necessity to include the signal decay factor  
     
 
  
    
 
 
   
  
 into eqn. (2.15), where T2
*
(t) is 
the changing transverse relaxation time during the dynamic scans and T20
*
 is that at baseline. 
Thus there is a need for a pulse sequence that could measure the T2
*
 simultaneously with T1. 
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Heilmann et al. accomplished this feat by combining a saturation recovery turbo-FLASH 
technique with a multiple gradient-echo sequence and using it for AIF assessment (63,148).  
 
2.8.3  Physiological Relevance and Validation of DCE-MRI Parameters  
Semi-quantitative analysis of signal enhancement provides a convenient and easy method to 
compare between physiological states and hints at the pathogenesis. However, it is important 
to realize that semi-quantitative diagnostic criteria cannot be simply transferred across 
imaging centers. The extracted parameters are profoundly affected by experimental 
conditions such as dosage, pulse sequences used, scanner field strength, acquisition 
parameters etc. Quantification techniques aim to minimize such variability and allow 
comparison between patients and between different imaging centers. Besides, quantification 
derives kinetic parameters that are based on physiological processes and thus can provide 
insights into tissue biology (80). Validation is an important step in establishing the 
authenticity of derived pharmacokinetic parameters and confirming their relevance to the 
underlying physiology. Although our hypothesis of impaired vascular development in 
STAT3-deficient mice appeared to agree with the semi-quantitative results, no histological 
validation on the islet morphology was performed. Available methods to validate DCE-MRI 
measurements in blood flow and capillary permeability include fluorescent microsphere 
technique (149,150), autoradiography (151) and the use of radio-labeled probes (152).  
 
Besides validating kinetic parameters obtained with DCE-MRI, there is also a need to verify 
their relationship to glucose sensing in the pancreas. We could perhaps reference this by 
looking at blood flow in other tissue types. In healthy patients, insulin-mediated increases in 
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skeletal muscle blood flow leads to increased glucose uptake. But this mechanism is defective 
in insulin-resistant patients. It has been proposed that constitutive reductions in capillary 
density or insufficient blood flow alters insulin and glucose delivery into muscles, causing 
insulin resistance (153). Thus reduced perfusion might act as a biomarker of insulin-
resistance. There is also a need to distinguish the hemodynamics between species with 
respect to insulin secretion. In the perfused rat pancreas, insulin secretion upon glucose 
infusion appears to occur in two distinct phases - an early, or rapid, release of insulin which 
subsided within approximately 2 min, followed by a late or slow release phase which 
continually increased in rate until termination of the glucose infusion (154). Mice seem to 
have a different insulin release dynamics characterized by a constant 2
nd
 phase (155). Thus 
their hemodynamic responses to glucose might differ.  
 
2.9 Chapter Conclusion 
In this chapter, I have showcased the possibility of non-invasive in-vivo measurement of 
pancreatic blood flow with DCE-MRI. Semi-quantitative kinetic parameters facilitate a 
convenient means of comparison between contrast enhancements in wild-type and STAT3-
deficient mice. The derived quantities appear to corroborate with the impaired fenestration of 
capillaries in the latter phenotype, giving reduced uptake and slower clearance. Quantitative 
pharmacokinetic parameters were derived from a modified Toft-Kermode model that 
compartmentalized the plasma and extracellular spaces. With the AIF, which was estimated 
by a bi-exponential function, the dynamic contrast agent concentration in the extravascular 
extracellular and plasma spaces were fitted into the model to derive blood flow F. Although 
aberrations exist in the modeling and errors are incurred in the T1 measurements, this is the 
first quantitative perfusion study to be implemented in mouse pancreas as far as I know, and 
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IN VIVO TRACKING OF EXOGENOUS CELL 
















With the discovery of pluripotent stem cells in humans, an entire new research field in 
cellular therapy has emerged. It is anticipated that therapeutic stem cell repair could 
rejuvenate damaged tissues and organs that would otherwise deteriorate and malfunction. A 
key consideration in the success of any stem cell therapy is the precision of cell delivery to 
the targeted site. Stem cells labeled with exogenous MR sensitive contrast agents have been 
actively pursued in the past decade to provide in vivo information on cell delivery and 
migration. Labeled with either positive or negative contrast agents, proton relaxation is 
altered in these cells and that phenomenon facilitates its distinction from native cells. In-vitro 
cell labeling with super-paramagnetic iron-oxide nanoparticles (SPIOs) coupled with T2
*
-
weighted MRI is currently the most popular cell tracking methodology. The resultant 
hypointensities present in the MR image however are convoluted with other undesired effects 
such as susceptibility artifacts, partial volume and local magnetic field inhomogeneities, 
leading to confused interpretation of labeled cells. An elegant solution is to turn iron-induced 
hypointensities into hyperintensities. For this chapter, I primarily explored the potential to 
generate positive contrast in SPIO-labeled cells with a Multiple Ultra-short Echo Time 
(MUTE) pulse sequence. A summary of current positive contrast enhancement techniques is 
first discussed with their strengths and weaknesses highlighted. Then I considered MUTE and 
illustrated its superior positive contrast generating mechanism. With a clever combination of 
MUTE and the White-marker technique, the potential of Z-shimmed UTE (ZUTE) to boost 






3.2 Types of Contrast Agents for Cell Labeling  
Therapeutic regeneration and repair of pathological tissues and organs with exogenous stem 
cells have been actively investigated in the last decade. Transplantation of pluripotent cells 
such as embryonic and mesenchymal stem cells (1) promises rejuvenation in a myriad of 
degenerative diseases, including myocardial infarction and central nervous system disorders. 
Regardless of their ameliorative mechanisms, central to the success of such corrective cell 
therapy are the ability to track their migration from the site of implantation to relevant foci of 
disease, and survival for sufficient periods of time to exhibit their regenerative properties (2). 
MRI cell tracking provides a non-invasive method to observe the migration dynamics of 
transplanted cells and their residence time in the targeted tissue or organ, with high temporal 
and spatial resolution. However, because MRI cannot distinguish between exogenous and 
intrinsic native cells due to their almost similar T1 and T2 values, transplanted cells must be 
labeled with an MR-sensitive contrast agent. Key issues that must be answered in MRI 
tracking of labeled cells include: 1) the physical attachment between the contrast agent 
particles and the cells, i.e., are they attached on the surface receptors or incorporated into the 
cells; 2) the minimum amount of contrast agent required per cell for obvious MRI 
visualization; 3) biocompatibility and intracellular stability of the synthetic complexes in the 
cells; 4) possibility to link functionalized groups and ligands for molecular targeting; 5) 
quantification of in vivo detected cells; and 6) impact of contrast agent particles on cell 
function. The ideal label should exhibit high detection sensitivity at low concentration, 
homogenous incorporation in all cells, high stability without toxicity concerns, flexible 
ligand-binding on the coating for molecular sensing, distinct relationship between MR signal 
and concentration for quantification, as well as minimal detrimental impact on normal 




3.2.1 T1-weighted Cellular and Molecular Targeting 




 - based nanoparticles attenuate 
proton relaxation to provide positive contrast, i.e., labeled cells appear as hyperintense spots 
or regions. Gadopentetate dimeglumine (Gd-DTPA) has been demonstrated to be easily 
incorporated into mouse embryonic and neuronal stem cells via gene transfection agents such 
as lipofectamine or calcium phosphate, yielding a labeling efficiency of up to 83% and 
doubling of longitudinal relaxation rate (3). MR signal amplification is the essence of high 
detection sensitivity and that could be accomplished by manipulating the interaction between 
Gd-chelates and surrounding protons. Aime et al. introduced a Gd-loaded apoferritin complex 
in which several Gd-HPDO3A units are trapped within the large cavity in apoferritin (4). The 
interaction between the paramagnetic centers and the high number of protein hydration water 
molecules and mobile protons induces further exchange with the bulk solvent, amplifying the 
presence of the Gd
3+
 ions by 20 times compared to free Gd-HPDO3A in water.   
 
Another paramagnetic label that has been explored for cellular labeling is Manganese. Mn
2+
 
is an essential heavy metal ion that can enter cells through voltage-gated calcium channels, 
enabling active brain regions (5) and changes in inotropic status in the heart to be monitored 
by MRI (6). In vivo tract tracing of neuronal pathways facilitated by anterograde transport of 
Mn
2+
 has also been demonstrated (7,8). Success in physiological imaging with manganese 
enhanced MRI (MEMRI) prompted the investigation of MnCl2 as a positive contrast cellular 
biomarker. In-vitro cell labeling with MnCl2 for detection with MRI was first demonstrated 
by Aoki et al. in blood lymphocytes (9). Subsequently Yamada and co-workers proved its 









positive contrast and enables in-vivo cellular tracking, some major drawbacks exist and 
impede their clinical implementation. One concern is biotoxicity, and emerging evidence 
suggests that gadolinium induces a rare disorder known as ‘nephrogenic systemic fibrosis 
(NSF)’ in patients with renal failure (11-13). A number of studies have shown that Mn2+ 
uptake in the heart causes a delayed augmentation of contractility, induced by its inhibition of 
cell-surface Na-Ca exchange activity (14,15). In addition, it is well known that chronic 
exposure to manganese leads to a neurological disorder resembling Parkinson’s disease (16).  
 
3.2.2 T2 / T2
*
 -Weighted Cellular and Molecular Probes 
Due to their lower detection sensitivity and biotoxicity at high doses, gadolinium and 
manganese compounds are much less popular compared to their T2/T2
*
-weighted counterpart, 
superparamagnetic nanoparticles, also known as SPIOs. Iron oxide nanoparticles composed 
of maghemite and magnetite (Fe2O3, Fe3O4) stabilized by various coating agents (17) are 
characterized by a large magnetic moment in the presence of a static external magnetic field, 
which makes them suitable as MR contrast agents. This large magnetic moment is caused by 
a crystal ordering that induces cooperation between the individual paramagnetic domains (~ 
30 nm), which consequently do not show any magnetic remanence (i.e. restoration of the 
induced magnetization to zero upon removal of the external magnetic field), unlike 
ferromagnetic materials (18). SPIOs possess suitable properties that make them attractive for 
cell labeling; 1) they provide the most signal change per unit of metal, appearing as 
hypointensities that extend beyond their spatial dimensions (19). This feature is the most 
important characteristic of SPIOs and it effectively determines their detection sensitivity. 
Hence it will be discussed thoroughly in the next section. 2) SPIOs typically have dextran 
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coatings that are biodegradable, releasing the submicron iron crystal cores (~5-30 nm 
diameter) that can be absorbed into the body via the normal iron metabolic pathways (20,21). 
3) The dextran surface coating permits linkage to functional groups and ligands and enables 
specific molecular targeting (e.g. the cross-linked iron oxide (CLIO) nanoparticle platform 
that could conjugate to a wide range of hetero-bifunctional linkers such as transferrin, 
annexin V or twin-arginine-translocase (TAT) peptides (22,23). 4) Histological verification 
of cell incorporation is easily performed with optical staining such as  Prussian blue (24). 5) 
Iron content per cell can be easily quantified with inductively coupled plasma mass 
spectrometry (ICP-MS); and 6) their effect on proton relaxation can be manipulated 
according to size (25). 7) Labeling protocols such as transfection have been optimized for 
some mammalian cell lines (26-28). With such attractive physiochemical properties, it is 
natural that SPIO–based particles are currently the most popular contrast agent used for in-
vivo cellular tracking in preclinical models and in the clinic.  
 
3.2.3 Negative Contrast Generation Mechanism with SPIOs  
Both T1 and T2 (or T2
*
) relaxation times are shortened by iron-oxide particles. The magnetic 
susceptibility effect of SPIOs is generally dominant over longitudinal relaxation to give a 
much greater r2/r1 ratio (r1 and r2 are longitudinal and transverse relaxivities, respectively) 
than paramagnetic molecules such as Gd-DTPA, i.e. signal dephasing from reduced T2 or T2
*
 
is greater than signal enhancement due to shorter T1 (17). The observed effect on MR signal 
intensity depends on various factors, including particle composition, particle size, 
concentration of particles within an imaging voxel and data acquisition parameters (29). At 











 at 9.4 T) (30), thus signal voids are often interpreted as SPIO-
labeled cells (2).  
 
A collection of SPIO labeled cells will superimpose a field pattern onto the static magnetic 
field, resulting in a locally perturbed field. For a small paramagnetic particle, the field 
perturbation Bz,inh outside the particle can be described by a dipole and it depends on the 
magnetic susceptibility difference  between the SPIO and its surroundings, radius a of the 
SPIO (assumed spherical), radial distance r from the iron core and the angle  relative to the 
main magnetic field B0 as given by eqn. (3.1) below. It is also commonly expressed as eqn. 
(3.2), where V characterizes the local magnetic dose of the marker as the product of the 
difference of volume susceptibilities to the environment and the marker volume.  
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 (3.2)  
The localized field inhomogeneities induced by the superparamagnetic centers cause field 
variations within imaging voxels, resulting in spins within the voxels to precess at different 
frequencies according to the Larmor equation. For gradient-echo sequences without 
refocusing RF pulses, the voxel signal will decay because of irreversible intravoxel dephasing 
and gives rise to an average voxel signal given by: 
        
 
 
                
 
 (3.3)  
                         (3.4)  
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Where  is the additional phase resulting from an inhomogenous magnetic field distortion 
      in the z-direction, (r) is the spin density, V is the voxel volume (mm
3
), TE is the echo 
time (ms), and  is the proton gyromagnetic ratio. 
 
For a single slice, signal loss owing to dephasing in the slice direction will be dominant. 
Integration of eqn. (3.3) over the slice thickness d results in the normalized complex signal 
per voxel, as given by eqn. (3.5). The resultant signal amplitude varies spatially as shown in 
figure (3.1), effectively creating a ‘blooming’ artifact which acts as a negative contrast 
biomarker of labeled cells in a T2
*
-weighted image. This typical dipole susceptibility effect 
extends way beyond the SPIO size, and is the reason why SPIOs offer much higher 
sensitivity than Gd (III) or Mn
2+
 contrast agents. When a congregation of cells occurs, their 
dephasing effects can be summed together, which further enhances detection sensitivity (31). 






 (3.5)  
 
Figure 3.1: Simulation of susceptibility effect of a superparamagnetic biomarker at 9.4 T in a 
1 mm
3
 voxel. Assumed parameters are  = 1x1010, V = 1x10-7 mm3 and TE = 10 ms.  
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3.3 Review of Positive Contrast Techniques for Cellular Tracking 
In this section, I review positive contrast techniques that have been demonstrated recently for 
cell tracking in the clinic, namely off-resonance imaging (ORI), inversion recovery with on-
resonance water suppression (IRON) and white-marker (WM). The physical basis of these 
methods relies chiefly on the susceptibility effect of SPIOs, which are exploited in different 
schemes to generate positive contrast. I briefly explain the underlying principles of each 
technique and highlight their strengths and weaknesses, emphasizing on their suitability in 
the preclinical environment.    
 
3.3.1 Off-Resonance Imaging (ORI) 
Off-resonance imaging was proposed recently by Cunningham et al. (32) to generate positive 
contrast of intracellular superparamagnetic particles. It exploits the shift in resonance 
frequencies of protons surrounding the nanoparticle caused by its susceptibility effect 
according to eqn. (3.6). To illustrate this phenomenon, Figure 3.2A displays the simulated 
spatial variation in resonance frequency shift f (Hz) of spins surrounding a SPIO 
nanoparticle at 9.4 T. Its dipole behavior is obvious in that protons in the North and South 
poles (parallel to the static field B0) have positive chemical shifts while those at the East and 
West regions have negative chemical shifts. The largest magnitude chemical shift is observed 
to be at the immediate vicinity of the SPIO nanoparticle, and decreases radially.  
                   (3.6)  
The chemical shifts essentially broaden the on-resonance water peak and induces a spread of 
off-resonance protons. By selectively exciting a small spectral range of protons at off-
resonance (see Figure 3.2B), we can highlight specific regions either on the East-West or 
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North-South axes. Since only selected off-resonance spins are excited, while the rest do not 
give rise to any signal, the emanated MR signal without background signal provides positive 
contrast of the cells.  
 
Figure 3.2: (A) Spatial variation in proton resonance frequency surrounding a 
superparamagnetic nanoparticle. Chemical shift polarity is indicated by ‘+’ and ‘-‘. (B) Off-
resonance RF excitation at fs selects the protons within the spectral window bandwidth BW, 
while others including on-resonance spins are not excited. In this illustration, the spins in the 




In-vitro studies have demonstrated the potential of off-resonance imaging in cell 
quantification based on a nonlinear relationship between measured signal and cell number 
(32). ORI also offers high contrast-to-noise ratio (CNR) since the background signal (i.e. 
from on-resonant protons) is almost non-existent. Feasibility studies have been demonstrated 
in the positive contrast visualization of SPIO-labeled embryonic stem cells in mouse limbs 
(32,33), tracking infiltration of macrophages in the infarcted mouse heart (34) and in rabbit 
hind-limbs implanted with much larger micron-sized SPIOs (35). ORI has also been used to 
visualize MR-compatible passive devices such as intra-myocardial needles (36).  However, 
there are a few technical constraints regarding this positive contrast technique which retard 
their adoption in the preclinical environment. First, specially designed RF saturation pulses 
have to be calculated since only unique off-resonance frequencies with certain bandwidths 
are desired. For optimal excitation at a fixed frequency offset, the bandwidth has to be narrow 
and that in turn reduces signal amplitude.  Thus ORI requires spin-echo refocusing in order to 
obtain sufficient signal-to-noise ratio, which prolongs scan time. A recent study by Farrar and 
co-workers modeled and compared the sensitivity, specificity and linearity of ORI at two 
preclinical field strengths of 4.7 T and 14 T in the detection of different concentration of 
monocrystalline iron oxide nanoparticles (MION) solutions (34). Since different iron contents 
give rise to different off-resonance profiles, in addition to wider on-resonance linewidth at 
high magnetic field strength, the diagnostic ability of ORI relies on the capability to 
differentiate MION-shifted resonances from on-resonance water; this stresses the robustness 
of the designed RF pulse because on-resonance protons must be suppressed effectively 
without affecting off-resonance water. The situation becomes more complex at the air/tissue 
interface, where the field inhomogeneity is most pronounced and further distorts the chemical 
shift distribution, compromising specificity as a result. Since iron concentration linearly 
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correlates with the induced chemical shift, care must be taken in the choice of labeling 
concentration to prevent an overlap in off resonance frequencies between iron-induced and 
air/tissue susceptibility effects. Second major hurdle to ORI is the nonlinear relationship 
between signal intensity and iron concentration (34). Beyond a MION concentration of 
approximately 150 g ml-1, T2-induced decay dominates and signal intensity decreases. Thus 
an ultra-short echo time sequence might be necessary to ensure TE << T2. Third obstacle to 
preclinical translation is the degradation of specificity due to wider on-resonance linewidth 
(34). Therefore shimming is a very critical procedure that could determine the diagnostic 
accuracy of ORI at high magnetic field strength. Finally, ORI is not a signal efficient method 
because only the positive or negative frequencies (i.e., NS or EW regions) are excited. Hence 
detection sensitivity might be low. In summary, the optimal performance of ORI will likely 
be seen at low fields, with moderate MION concentrations and with sequences that could 
perform very short echo-times. Its performance in the small animal environment would 
require extremely uniform shims and high performance gradient systems for short TE.  
 
Demonstration of Off-Resonance Imaging Potential at 9.4 T 
As a demonstration of ORI’s potential at 9.4 T when the above conditions are partially met, 
i.e. reasonable shimming and short echo-time, I prepared a phantom consisting of water and 
2.56 mM of SPIO solution (SHU555C, Resovist®) and compared images acquired with T2
*
-
weighted and ORI. After extensive 3D-volume shimming, the on-resonance linewidth 
achieved was 0.1 ppm or 40 Hz. Parameters used in the acquisition were: TR = 50 ms, TE = 
2.3 ms, excitation flip angle = 60°, matrix = 128  128, field-of-view = 16  30 mm2, 
frequency offset = 500 Hz, spectral selective RF bandwidth = 100 Hz (sinc). The imaging 
results are displayed in Figure 3.3. We observe that off-resonance excitation enables positive 
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contrast of SPIO solution, but the image appeared noisy partially due to the narrow RF 
excitation bandwidth of 0.25 ppm and the acquisition of gradient echoes instead of spin-
echoes.  
 
Figure 3.3: Proof-of-principle that off-resonance imaging has the potential to provide positive 
contrast of SPIO at 9.4 T. Phantom consisted of water and a 2.56 mM solution of SHU-555C 
(Resovist®).  
 
3.3.2 Inversion Recovery with On-Resonant water suppression (IRON) 
Stuber and co-workers invented this inversion recovery technique that nulls both fat and on-
resonance water signals, while exciting the remaining off-resonance protons with a 
broadband RF excitation (37,38). Figure 3.4 illustrates this concept whereby on-resonance 
saturation destroys the longitudinal magnetization of protons distant from the SPIO 
nanoparticle. By choosing the appropriate delay times (Td1 and Td2), fat can be 
simultaneously nulled. The text in the figure explains the physical principles of IRON. This 
technique has been demonstrated to produce positive contrast visualization of SPIO-labeled 
mesenchymal stem cells implanted in rabbit hind-limbs (37),  MIONs injected into lymph 














































Figure 3.4: Physical principle of IRON. (A) The spectral distribution of fat, off- and on- 
resonance water. The on-resonance protons are saturated, effectively eliminating background 
signal. Broadband excitation encompasses a wide spectrum. (B) To suppress the fat signal, 
dual non-selective inversion pulses (180°) are applied. (C) The first 180° pulse inverts all 
proton pools, including fat. Since the T1 of fat is low, its longitudinal magnetization Mz,fat will 
recover faster than other tissue protons. The second inversion pulse will cause the 
magnetization to invert once more, while flipping that of off- and on- resonance protons 
(Mz,off and Mz,on respectively) to positive polarity. Subsequently an on-resonance saturation 
pulse destroys the longitudinal magnetization of background water, followed by the usual 
signal acquisition. The delays Td1 and Td2 have to consider the T1 relaxation times of fat and 
the different proton pools, and are timed accordingly for successful fat nulling. (D) The 
longitudinal magnetization evolution of on-resonance protons in the IRON sequence. We 
observe from the temporal evolution of longitudinal magnetization that the fat signal is 
suppressed while on-resonance protons contribute minimal signal compared to off-resonance 
water.  
 
Advantages and Disadvantages of IRON Imaging 
The application of broad–band excitation in IRON eliminates the need for a robust spectrally 
selective RF pulse as seen in ORI. In addition, there is no fat signal corrupting the image. The 
biggest gain in IRON is perhaps all off-resonance protons surrounding the SPIO are excited 
by the broadband RF, and that increases sensitivity compared to ORI. Thus it is a more 
signal-efficient technique. A minimum of 125,000 cells could be detected in-vivo and there 
appears to be a linear correlation between signal enhancement and cell concentration, thus 
quantification might be possible (37). Disadvantages of IRON are very similar to that in off-
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resonance imaging, including the stringent requirement for a homogenous magnetic field. 
Thus at high magnetic field strength in preclinical systems, implementation is expected to be 
challenging. Alternative sources of off-resonance signal inevitably lead to positive signal that 
might not necessarily be related to the presence of the susceptibility-generating SPIO-labeled 
cells, especially at tissue borders, air-tissue interfaces with local B0 inhomogeneities (37).  
 
3.3.3 Gradient Echo Acquisition for Superparamagnetic Particles with Positive 
Contrast (GRASP) or White-Marker Imaging 
The physical principle of White-Marker imaging is based on phase compensation with 
gradient application in the slice direction (41,42). A typical slice selection involves excitation 
of a slice of thickness d followed by a refocusing gradient to undo its accumulated phase. 
This results in on-resonance protons with null phases. In the presence of an SPIO 
nanoparticle however, its susceptibility effect causes surrounding protons to accrue additional 
phase according to eqn. (3.4). If that phase can somehow be nulled during slice refocusing, 
some off-resonance protons would be refocused completely while on-resonance protons 
remain dephased, thus the MR signal arising from the former proton pool will dominate. 
White-marker imaging achieves that goal by adding a fraction  of the slice refocusing 
gradient amplitude Gssr, which has duration ssr during the slice refocusing process. The 
effective phase at the echo-time is then given by eqn. (3.7) with resulting voxel signal 
according to eqn. (3.8).          being the spatial spin distribution surrounding the SPIO. 
Maximum signal will arise from protons that satisfy the condition                
                                         (3.7)  
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 (3.8)  
 
White-marker at 9.4 T 
To prove that this method is theoretically feasible at 9.4 T, we ran a simulation with the 
following parameters: a 1 mm
3
 voxel with thickness d = 1 mm,  = 1010, V = 10-7 mm3, B0 
= 9.4 T, TE = 10 ms, Gssr = 0.5 T/m and tssr = 0.15 ms. Results comparing T2
*
-weighted ( = 
0) and white-marker ( = 0.45) imaging are shown in Figure 3.5. In the latter, background 
signal is subdued because of incomplete phase compensation, whereas off-resonance protons 










Figure 3.5: Simulation to illustrate negative and positive contrast of a superparamagnetic 
marker at 9.4 T. White-marker suppresses background signal and compensates phase accrued 
by surrounding protons in the slice direction.  
 
To explore experimentally the potential of white-marker, we tested its ability to produce 
positive contrast on biological samples. An excised mouse brain injected with SPIOs 
nanoparticles was embedded in agarose and placed in a 9.4 T horizontal bore MRI scanner. 
Acquisition with typical T2
*
-weighted gradient echo is first carried out with 100 % slice 
refocusing gradient (i.e.  = 0), followed by White-marker imaging with 60% ( = 0.4) 
refocusing.  Relevant scan parameters were: TR = 120 ms, TE = 4 ms, excitation flip angle = 
30°, matrix = 128  128, field-of-view = 20  20 mm2.  
 
Figure 3.6: Negative and positive contrast of SPIOs in an excised mouse brain. Arrowheads 
depict non-SPIO regions that display positive contrast due to coincidental phase 
compensation. Although the phases of ventricles (dashed arrows) are not sufficiently 
compensated, they still exhibit substantial signal because of their high proton density. 
SPIO SPIO




The SPIOs are conspicuously visible in both gradient-echo and white-marker images. The 
signal in the unlabeled contralateral region is 112 units and 38 units for T2
*
-GRE and White-
marker, respectively. Thus we can see that background signal is suppressed in White-marker 
due to incomplete gradient refocusing in the slice axis. Contrast-to-noise ratio, which is 
defined in eqn. (3.9), is - 48 and + 36, respectively based on region-of-interest (ROI) analysis. 
The reason for the lower contrast magnitude in white-marker is the T2
*
-effect of SPIO. A 
method to overcome such signal decay is the use of very short echo-times, which can be 
achieved with an ultra-short echo time (UTE) pulse sequence. This is the topic in the next 
section.  
                             
           
      
 (3.9)  
Where Sspio is the signal intensity in SPIO region-of-interest, Sctrl is that in the contralateral 
region and noise is the standard deviation of noise. 
 
Advantages and disadvantages of White-Marker Imaging (WM) 
The White-marker technique possesses some practical qualities that are absent in ORI and 
IRON sequences, which are high sensitivity, ease of implementation and high imaging speed 
(since gradient-echo imaging can be used). A mere multiplication factor has to be added to 
the slice-refocusing gradient amplitude in WM to achieve robust positive contrast (41). A 
recent comparison between IRON and White-marker imaging demonstrated the latter’s 
higher sensitivity in detection of SPIO-labeled glioma cells in vivo (43). Its feasibility has 
been demonstrated in applications including the detection of ferritin deposition in in-vivo 
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thrombi (44) and cell tracking during stem cell therapy of the infarcted myocardium (45). 
There are a few limitations in the visualization of SPIO-labeled cells with White-marker 
though. First, dephasing appears to be relatively ineffective for voxels that are only partly 
occupied by observable spins. This partial volume effect could give rise to edge enhancement 
artifacts (46). Second, wherever the local field inhomogeneity is compensated, 
i.e.,             , hyperintensity will result. Thus accidental local compensation of 
susceptibility-induced field gradients, e.g. in air-tissue interface or tissue boundaries, could 
be confused with actual SPIO-labeled cells. In addition, even though on-resonance protons 
are insufficiently refocused, they could still display signal if their spin density is sufficiently 
large. An example can be seen in Figure 3.6, whereby the ventricles in the brain display 
positive contrast, even though there is no SPIO-induced susceptibility effect.  Therefore 
specificity is not optimal in White-Marker imaging. Third, since the SPIO-induced B0 field 
inhomogeneities are spatially varied in x, y and z directions, and only phases in the slice 
direction are compensated, not all surrounding spins would be refocused completely. This 
effect has already been predicted in the simulation (see Figure 3.5), whereby only specific 
protons exhibit positive contrast.        
 
3.4 Positive Contrast with Multiple-Echoes Ultrashort-echo Time (MUTE)  
In this section, we introduce a pulse sequence that would improve specificity and provide 
robust positive contrast of SPIO-labeled cells, which is the Multiple-Echoes Ultrashort Echo 
Time (MUTE).  To understand the positive contrast generating mechanism with MUTE, we 
shall first describe the signal evolution of SPIO-labeled cells and how they can be segregated 
from native tissue with positive contrast. Then the pulse sequence of MUTE is explained in 
detail including changes I adopted to cater for high field applications. As a demonstration of 
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MUTE’s superiority in specificity and contrast, a comparative study was carried out with 
white-marker imaging. The effect of iron content per cell on detection sensitivity is also 
discussed.  
 
3.4.1 Simulation Study of Positive Contrast Enhancement with MUTE  
An expression for the spoiled steady-state incoherent (SSI) signal (also known as Fast Low 
Angle Shot or FLASH) (47) is: 
   
          
   
  
      
      
   
  
     
    
   
  
   
(3.10)  
where M0 is the magnitude of longitudinal magnetization at thermal equilibrium, k is a 
constant dependent on scanner performance and  is the excitation flip angle. 
 
We adopt a simple relaxation mechanism whereby SPIO lowers the T1 and T2
*
 of surrounding 
protons according to eqn. (3.11) and (3.12). T1 and T2
*
 are the respective observed 
longitudinal and transverse relaxation times of SPIO-labeled cells. T10 and T20
*
 are that of 











   






   
           (3.12)  
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The cell of interest in the simulation is healthy rat myocardium, which has approximate 
relaxation times T10 = 950 ms and T20
*
 = 36 ms at 9.4 T. To input an experimentally relevant 
concentration [SPIO], we assume an iron content of 16 pg per cell (26) and an intra-
myocardial injection of 1 million cells in 20 l (48), resulting in a total concentration of 14.3 









) of SPIO solution at 9.4 T (49), we calculated the signal intensity of 
labeled (Sspio) and unlabeled myocardium (Smyo) within an echo-time range of 0 to 10 ms, in 
0.2 ms steps and at a TR of 150 ms. We also define contrast enhancement (CE) as the 
normalized signal intensity difference between Sspio and Smyo, according to eqn. (3.13). 
Assumed parameters in the simulation are M0 = 1, k = 1 and  = 60°. 
               (3.13)  
 
Figure 3.7A shows the simulation result, which illustrates the rapid signal decay of SPIO-
labeled cells compared to the unlabeled myocardium. For typical gradient-echo sequences 
with echo-times of a few milliseconds, SPIO-labeled cells would translate as signal voids due 
to transverse relaxation effect. The plot also suggests that positive contrast (CE > 0) can be 
achieved if echo-time is kept below 0.35 ms.  But in order to exploit the T1-shortening effect 
of SPIO and maximize positive contrast, echo-time should ideally be as close to zero as 
possible. However, this might not be feasible because of hardware limitations such as 
gradient slew rate and amplitude (50). A more attractive alternative is to enhance positive 
contrast with a subtraction between the absolute FID and subsequent ECHO signal intensities 
(51). The difference signal intensity Ssubtract is given by eqn. (3.14). Post-subtraction contrast 
(CEsubtract) between labeled (Ssubtract,spio) and unlabeled cells (Ssubtract,myo) is then calculated 
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according to eqn. (3.15). In this simulation, we assumed that FID is acquired at TE = 0 ms 
and the echo-time of the ECHO is varied from 0 to 10 ms. 
                      (3.14)  
                                        (3.15)  
 
Figure 3.7B plots the signal intensities and contrast after subtraction between FID (TE = 0 ms) 
and ECHO signals (TE = 0 – 10ms). Due to the dominant T2
*
 shortening effect of SPIO, 
labeled cells had a much greater signal difference than unlabeled myocardium. This is 
advantageous because it implies high positive contrast is possible in SPIO-labeled cells with 
a subtraction between FID and the ECHO. We also observe that the contrast peaks at TE = 
1.7 ms, beyond which no more detectable signal manifests from SPIO-labeled cells and 
contrast decreases gradually.  
 
The minimum echo-time available for FID signal acquisition depends on the width of the 
excitation RF, and k-space sampling strategy (centric, spiral or Cartesian). To obtain 
maximum positive contrast via subtraction between FID and ECHO signals, the T1 relaxation 
effect of SPIO must be exploited. In other words, the echo-time of FID has to be a minimum. 
Figure 3.7C illustrates the effect in contrast enhancement at different FID echo-times. The 
simulated results show that positive contrast increases to a maximum and decreases gradually 
for all the curves. The most significant observation is that maximum positive contrast 
decreases exponentially as FID echo-time increases (Figure 3.7D), owing to failure in 




This simulation highlights the potential of MUTE to generate and optimize positive contrast 
from SPIO-labeled cells. Three key conclusions are derived from this simulation study: 1) In 
order to maximize positive contrast with this technique, echo-time of FID has to be as low as 
possible. Thus RF excitation and refocusing gradients have to be very short, including 
utilization of centric k-space sampling, 2) subtraction between FID and ECHO signals could 
yield much higher positive contrast than mere reliance on FID, because it exploits the T2
*
 
dephasing effect of SPIO, and 3) ECHO acquisition must be carried out at optimal echo-time 
in order to obtain maximum positive contrast. This implies that meticulous timing 





Figure 3.7: (A) Signal intensity of SPIO-labeled cells and unlabeled myocardium with echo-
time. Positive contrast could be obtained if TE was shorter than 0.35 ms. (B) Subtracted 
signal intensity between FID and ECHO collected at different echo-times. Positive 
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Signal Intensity of SPIO-labeled Cells and Unlabeled Native 
Myocardium after Subtraction between FID (TE=0 ms) and 








Figure 3.7: (C) Contrast enhancement curves as echo-time of FID is increased. (D) 
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3.4.2 MUTE Pulse Sequence  
The multiple-echo ultrashort echo time (MUTE) pulse sequence was recently implemented in 
the clinic to visualize tissues with very short T2 relaxation times, such as ligaments, tendons 
and bone (52-57). Its key feature is the ability to acquire MR signal at very short echo-times, 
potentially as low as 70 s (58). Figure 3.8 displays the schematic diagram of a typical 
MUTE pulse sequence, comprising principle characteristics such as: 1) preparation pulses for 
fat saturation or inversion recovery to suppress long T2 tissue components (59,60); 2) 2D  or 
3D  excitation with dual polarity sinc pulses (61) or non-selective hard pulse (51,62); 3) slice 
or slab refocusing (for selective excitation only); 4) non-cartesian (spiral or radial) centric 
readout with high bandwidth for rapid acquisition of free induction decay signal (61,62); and 
5) gradient refocusing readout to acquire subsequent echoes (51).  
 
 Figure 3.8: Schematic diagram of a MUTE pulse sequence. The essence of the technique is 
to enable the minimum echo-time allowed by the hardware.  
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Minimum Phase Shinnar Le-Roux – VERSE RF Excitation 
The above pulse sequence characteristics work together to achieve the minimum allowable 
echo-time and enhance positive contrast of very short T2 tissue components. Most of these 
features can be adapted in preclinical scanners with the exception of half-sinc excitation. This 
slice-selection scheme is particularly sensitive to gradient imperfections and eddy currents 
(63), resulting in poor slice profile at high magnetic field strength. In addition, two 
acquisitions with opposing slice gradient polarity are required to attenuate out-of-slice signal 
(61), doubling imaging time. To overcome this obstacle, I implemented a minimum phase 
Shinnar Le-Roux (SLR) pulse in our 9.4 T preclinical scanner instead (64). This excitation 
pulse induces minimum phase within the slice, demanding a shorter slice refocusing gradient 
that in turn directly reduces echo-time. In addition, the minimum phase SLR pulse enables 
slice selection with a single gradient polarity, unlike its half-sinc counterpart, therefore 
achieving similar scan efficiency as a normal T2*-weighted sequence.  As we strive towards 
even lower echo-time, the minimum phase SLR pulse is combined with the Variable-Rate-
Selective Excitation (VERSE) algorithm to synchronize RF excitation pulse and slice 
selection gradient (60,65). This scheme is illustrated in Figure 3.9A, in which the time from 
RF peak amplitude to end of slice selection gradient (ta) is 0.188 ms, compared to 0.572 ms in 
a SINC pulse with similar 1 ms duration. In our 9.4 T MRI preclinical scanner, the echo-time 
for a typical T2
*
-weighted gradient-echo sequence is approximately 2.46 ms, assuming field-
of view of 30 mm, matrix size of 256  256, receiver bandwidth of 100 kHz and a symmetric 
SINC excitation pulse of 1 ms duration. In addition, the pulse induces a phase that is only 
about a third of that by the SINC pulse, as seen in Figure 3.9B. Thus the duration of the slice 
refocusing gradient can also be significantly trimmed. In summary, a minimum echo-time of 
0.292 ms is achievable with our setup. Figure 3.9C compared the profiles of a 1 mm slice 
between typical SINC and minimum phase SLR-VERSE excitations. We observe that the 
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latter attenuates out-of-slice signal more effectively with diminished in-slice rippling as well, 
while preserving slice profile integrity.  
 
Figure 3.9: (A) Synchronized minimum phase SLR-VERSE excitation and slice selection 
gradient. (B) Phase accrued across slice that is subsequently nulled with slice refocusing 
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3.4.3 Radial Sampling 
In order to minimize TE and T2
*
 decay, center-out k-space sampling strategies are employed 
in UTE sequences (i.e. 1
st
 data point is at k = 0). Popular sampling trajectories include radial 
(62,66,67), spiral (68-70) or their combination (61,71). In this thesis, we have employed a 
radial acquisition strategy because of its favorable intrinsic properties. First, it is robust 
against motion-induced artifacts (72-74). Second, the oversampling of k-space origin 
increases signal-to-noise ratio. Third, image reconstruction can be implemented using 
established filtered back-projection and regridding techniques.  For 2D-MUTE imaging, the 
gradients involved in radial readouts are calculated according to:  
          (3.16)  
          (3.17)  
   
          
 
 
       
 (3.18)  
Where G is the gradient amplitude applied during readout (in T m
-1
),  is the projection angle, 
BWreceiver is the receiver bandwidth (in Hz) and FOV is the isotropic field-of-view (in m). 
Figure 3.10A illustrates this sampling strategy in k-space. In order to prevent aliasing and 
satisfy Nyquist sampling criteria, the following condition must be met (75): 
              (3.19)  
Where nr is the number of radial readouts and kmax is the extent of occupied k-space. For 3D-
MUTE, we adopted the stack-of-radial trajectory, as shown in Figure 3.10B, instead of spiral 
trajectory that is favored in the clinic (62,76).  One of the reasons is the latter requires a large 
number of radial projections to meet the Nyquist sampling criteria. For example, a typical 
number of spiral projections for a spatial resolution of 8 mm
3
 (FOV = 200  200  200 mm3) 
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is ~ 31,000, leading to a total acquisition time of ~26 min (77), whereas only 15,700 radial 
projections are required with the stack of radials. In addition, we aim to implement MUTE 
for cell tracking in a rodent heart, which implies that very fast imaging and switching of 
gradients are necessary. Such scan conditions might induce eddy currents and cause mis-
trajectories in k-space, leading to image artifacts (69,78). Since stack-of-radials consists of 
radial trajectories only on a plane, mis-trajectories can be more easily corrected than that in a 
3D spiral.   
 
Figure 3.10: 2D-radial and 3D stack-of-radial sampling in MUTE. Crosses denote locations 
























Point Spread Function (PSF) 
A quantitative approach to describe image artifacts and to judge the effect of polar sampling 
is to calculate the point-spread-function (PSF). Ideally the PSF should consist of one delta 
function in the center of image space. However, real-world image artifacts induced by field 
inhomogeneities and gradient non-linearity occur and their cumulative effects can perhaps 
best be described by the broadening of the central peak (blurring), or side lobes (ghosts and 
aliasing). To understand the radial effects of polar sampling, the PSF can be broken up into 
two separate components, namely the PSF without decay Psa(r) and the blurring function 
induced by T2
*
 relaxation Pblur(r) (62). Psa(r) is essentially the behavior of the main lobe in the 
principal polar PSF profile (79) as given in eqn (3.20).  When normalized to the unit pixel 
size /kmax, its full-wdith half-maximum (FWHM) rsa is 1.41 times an equivalent Cartesian 
acquisition (62). The blurring function on the other hand considers the impact of the short T2
*
 
with respect to the readout acquisition time TAQ according to eqn. (3.21). Its normalized 
FWHM is then 0.49TAQ/T2
*
, therefore radial blurring becomes significant when readout time 
is much longer than T2
*
. Although very fast readout then becomes necessary to record the 
FID signal from SPIO-labeled cells, a caveat exists in that the required receiver bandwidth 
will be very large, resulting in lower signal-to-noise ratio, because SNR is proportional to  
 
           
  (80). Fortunately, the center of k-space is oversampled and that could 
compensate the SNR. Numerical treatment of the blurring function suggests an optimal TAQ = 
0.81·T2
*
 for maximum SNR (62). As an example, the mean T2
*
 of 16 million SPIO-labeled 
glioma cells is ~ 2 ms at 3 T (58), which would translate to an optimal TAQ at 1.62 ms. The 
effective point spread function PSF(r) is a convolution of these two components and is 
illustrated in Figure 3.11 together with Psa(r) and Pblur(r).  The resultant FWHM is 
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approximately 1 pixel unit. In summary, radial sampling results in imaging blurring which 
could be ameliorated at the expense of SNR.  
         
         
       




         
  
  
   
 
 
         
  




   
 (3.21)  







Figure 3.11: Point-spread-functions illustrate blurring of a single point in the center of image 
space as a result of radial sampling. Psa(r) is the PSF without decay, Pblur(r) is that with T2
* 
decay and PSF is the effective point-spread-function.  
 
Disadvantages of Polar Sampling and Possible Remedies 
There are a couple of disadvantages associated with radial sampling when compared to 
Cartesian acquisition. First, there is a 57 % increase in total scan time in accordance with 
Nyquist criteria. Under-sampling of k-space can be adopted though to improve scan 
efficiency without major artifacts (81). Streaking artifacts common in under-sampled radial 
data can also be reduced with iterative reconstruction (82). Second, gradient timing errors 
skew the k-space trajectory and introduce image artifacts (83), while magnetic field 
inhomogeneities distort image geometry (84). Measuring the actual k-space trajectory to 
correct for gradient non-linearity and eddy current effects can be applied (85). Third, image 
blurring in the point-spread-function is proportional to the TAQ/T2 ratio as illustrated above. 
Therefore ultrafast gradients are required to image SPIO-labeled cells with very short T2
*
 (e.g. 
high cellular iron content or aggregated cell cluster). Fourth, such non-Cartesian sampling 
does not permit direct 2D Fourier Transform image reconstruction but rather via a technique 
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known as regridding. Regridding is a critical aspect in MUTE because it directly impacts the 
image quality and will therefore be discussed in detail in the following section. 
 
3.4.4 Non-Cartesian Regridding 
When the entire MR data set is acquired along a uniformly sampled rectilinear k-space 
trajectory, the image can be reconstructed using FFT. It is more complex to reconstruct non-
Cartesian trajectories such as spiral and radial. Although non-rectilinear sampled k-space can 
be reconstructed with a straightforward extension of discrete fourier transform (DFT) (86), it 
is too slow for practical use. Alternatively, the data could be resampled into a regular 
Cartesian grid via convolution with a smoothing function, and then Fourier transformed to 
form an image. This technique is known as regridding (87,88) and is the most popular 
interpolation method employed because of its speed and adequate image quality.  
 
The basic idea of regridding (89) is to convolve each data point with an appropriate gridding 
kernel, which is chosen to be wide enough to extend to neighboring grid points while 
maintaining reasonable computation time (90). This algorithm accumulates the contribution 
of each data sample to the surrounding grid points on the Cartesian mesh.  After all samples 
have been processed, the regridded data are FFTed to produce a reconstructed image. 
Because convolution with the gridding kernel results in multiplication of the image by its FT, 
substantial shading will be present. This undesired artifact is eliminated by dividing the 
image by the FT of the kernel. Figure 3.12A illustrates the sampling procedure. In summary, 




Figure 3.12: (A) Scheme of a 2D gridding procedure. The data samples lie on an arbitrary 
trajectory through k-space (dashed line). The sampled data points are convolved with a 
gridding kernel and resampled onto a rectilinear Cartesian grid. (B) Flow chart illustrating the 
regridding process.  
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Mathematical Description of 2D Regridding 
The 2D version of regridding that has been implemented in this thesis can be described 
mathematically. The ideal continuous k-space data are M(kx,ky). During acquisition, these data 
are sampled in a non-Cartesian fashion by a sampling function SNC(kx,ky) given by:    
                                   
 
 (3.23)  
where  denotes the delta function. The resulting non-Cartesian data MNC(kx,ky) recorded are 
given in eqn. (3.24).  
                                (3.24)  
The regridding process begins by first defining a 2D Cartesian sampling function SC(kx,ky):    
                      
 
                 
 
 (3.25)  
Where the k-space sampling distances are given by: 
               (3.26)  
 is the k-space oversampling factor ( > 1) and FOV is the field-of-field, assumed to be the 
same in both x and y directions. Second, a gridding kernel C(kx,ky) is defined and is usually  
either a SINC (87) or Kaiser-Bessel function (90) (more about the kernel function in the next 
section). MNC(kx,ky) is then convolved with the gridding kernel and sampled onto the 
Cartesian grid to yield the Cartesian sampled data MC(kx,ky): 
                                           (3.27)  
After 2D Fourier transform of the resampled Cartesian data, the resultant image obtained 
mc(x,y) is given by: 
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  (3.28)  
 
Effects of regridding in image space 
The effects of the various operations in eqn. (3.28) on the ideal image m(x,y) can be 
interpreted as follows: First, convolution with the radial sampling function sNC(x,y) induces 
image blurring. In addition, sidelobes are usually created due to the pattern of the samples in 
k-space. Second, the image is apodized by the transform of the gridding kernel. While this 
has the undesirable effect of producing shading in the image, it also has the advantage of 
suppressing the sidelobes that were generated by the convolution with the sampling function. 
Third, the rectilinear sampling in k-space creates replication in image space. Sidelobes from 
the first replication might interfere with the desired image. A 1D illustration of these effects 
on an ideal image is given in Figure 3.13.     
 
Figure 3.13: Effects of various terms in image regridding process given by eqn. (3.28) 
117 
 
Apodization and C(kx,ky) 
The apodization function c(x,y) is the Fourier transform of the gridding kernel C(kx,ky), and it 
causes undesired shading of the image upon multiplication. This function could be 
determined numerically and can be used to correct the artifact. Deapodization occurs by 
dividing the image by the ideal apodization function. In practice, however, it is preferred to 
divide out only part of the apodization in order to preserve the sidelobes attenuation. Hence in 
this thesis, the deapodization function applied has an attenuation factor a included: 
        
 
        
 (3.29)  
The overall image reconstruction process then becomes: 
 
        
                                
 
    
 
 
    
  
        
 
(3.30)  
The selection of the gridding kernel has been addressed in the literature (87,88,90). The 
optimal gridding kernel is one whose Fourier transform is rectangular and band-limited like a 
sinc function, as given below.  
                              
  
   
      
  
   
  (3.31)  
                                  
 
    
      
 
    
  (3.32)  
However, the infinite extent of a sinc function would prohibit efficient computation and 
hence a windowed sinc function is normally utilized instead (87). But convolution with a 
truncated sinc function will contribute side lobes, which are aliased back into the image after 
sampling onto the Cartesian grid. Therefore a compromise has to be met between 
computation time and aliasing artifacts. Jackson et al. has optimized this tradeoff, by 
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designing a Kaiser-Bessel convolution function (90). This 2D Kaiser-Bessel function is based 
on J0, the zero-order modified Bessel function of the first kind. The separable gridding kernel 
used in this thesis, i.e.                          is thus: 
         
 
  





  (3.33)  
Where Wk denotes the kernel width and  is a free design parameter to achieve the best 
possible performance. The corresponding apodization function in the image domain is also 
separable such that                      and it is described by eqn. (3.34) . 
        
         
       
     
      
 (3.34)  
As illustrated in Figure 3.13, subsequent sampling onto the Cartesian grid creates aliasing 
artifacts, thus oversampling is routinely implemented to resolve that, albeit an increase in 
computation time. One of the difficulties in designing a gridding solution is that a different 
gridding kernel (or ) must be chosen for each choice of oversampling ratio  and kernel 
width Wk. Beatty and co-workers have devised a formula to optimize the regridding process 
without major aliasing artifacts or loss in computation efficiency (88). That is to calculate  
according to eqn. (3.35).  With an oversampling ratio of 2 and a kernel width of 4,  is equal 
to 8.9962. The corresponding gridding kernel and apodization functions are illustrated in 
Figure (3.14).  













  Figure 3.14: Kaiser-Bessel convolution function CKB(k) with kernel width Wk = 4, 
oversampling ratio  = 2 and free design parameter  = 8.9662. Next to it is the 
corresponding apodization function calculated according to eqn. (3.34). 
 
Density Compensation 
As shown in Figure 3.10, sampled data are placed along each radial spoke in k-space. Thus 
the sampling density is non-uniform, unlike a Cartesian acquisition, and must be corrected in 
order to minimize reconstruction error (92). An important first step in the gridding process is 
therefore weighting the data before interpolation to compensate for non-uniform sampling 
density.  A weighting function W(kx,ky) is multiplied with the radially sampled data before 
convolution with the gridding kernel, as described in eqn. (3.36).  
Kernel width, Wk = 4





                                                      (3.36)  
The appropriate weighting function is proportional to the k-space area that is associated with 
each data sample. The area could be numerically approximated by the spacing of samples 
along the trajectory multiplied by the spacing between trajectories. Rasche et al. described an 
efficient algorithm to solve this problem known as a Voronoi diagram (93). Figure 3.15 
displays the Voronoi diagram of the radial sampling pattern. A density estimate for each data 
point would be the area of each of the cells. This approach has the significant advantage that 
it only depends on the sampling pattern itself and not on the acquisition order. This allows the 
application to this technique even in cases where trajectories intersect (94).    
 
Figure 3.15: (A) Voronoi diagram divides the plane into regions that are closest to any 
individual point. The inverse area associated with each sample is its weighting. (B) 











An alternative method to obtain a weighting function is to assume an ideal isotropic 2D radial 
sampling pattern and calculate the area associated with each sample geometrically (89). This 
technique is straightforward and especially suitable for simple k-space trajectories such as 
radial projection.  Referring to Figure 3.15B, samples are located along radii at multiples of 
kx = ky = kr. The weighting to apply is the inverse of the sampling density (kx,ky), i.e.  
          
 
        
 (3.37)  
If there are N projections, then the central sample is acquired N times. For this sample the 
weighting is 1/N multiplied by the area of the central disk that is closest to the origin. 








 (3.38)  
The weighting for the first sample is given by the area in the next annular ring outside the 
disk divided by the number of samples. 
    
 
 
   












     
  (3.39)  
For samples that lie on subsequent annular rings, i.e., n > 1,  
    
   
 
     
  (3.40)  
In this thesis, both Voronoi diagram and projection density estimation techniques are 






3.5 A Multi-Echo Technique for In-Vivo Positive Contrast Detection of SPIO-
Labeled Cells in the Rat Heart at 9.4 T 
We present here a multi-echo ultrashort echo-time technique that exploits the T1-relaxation 
effect of iron-oxide to achieve positive contrast of SPIO-labeled cells with high sensitivity in 
a beating rat heart.  
 
3.5.1 Introduction 
Heart failure is the leading cause of death worldwide. The majority of such deaths are caused 
by ischaemic heart disease, which originates from obstruction of blood supply in the coronary 
arteries. Heart muscles then die giving rise to myocardial infarction and a loss of cardiac 
function. To compensate for the contractile loss in the infarct region, they are stressed harder, 
compounding the pathological condition. Although it has been suggested that endogenous 
regenerative mechanisms exist to repair the infarcted tissue, such as division of existing 
cardiomyocytes, bone-marrow stem cell mobilization into the injured myocardium and 
resident cardiac stem cells activation, it is found that the adult mammalian heart is severely 
limited in these aspects. Insufficient proliferation, inadequate mobilization, limited 
differentiation and restricted multi-potency are hurdles to myocardium self-renewal (95). To 
overcome this handicap, therapeutic cell treatment has been proposed. A myriad of stem cell 
phenotypes have been investigated for cardiac therapy such as embryonic stem cells, cardiac-
derived stem cells (96) and endothelial progenitor cells (97). The precise amelioration 
mechanisms of these variant cell phenotypes, their functional integration and long-term 
physiological impact are currently being aggressively pursued in both animal models and 
human clinical trials.  
123 
 
Cell delivery to the infarcted myocardium critically impacts the success rate of the therapy. 
Many methods exist, each with their own strengths and weaknesses. Intravenous injection is 
minimally-invasive and convenient, but it suffers from homing issues. Intra-myocardial 
delivery directly positions the cells into the injured myocardium, but it requires invasive open 
chest surgery. Since cell number is a key factor in the mitigation of myocardial damage, a 
reliable and non-invasive imaging modality is essential to study the migration of transplanted 
cells as well as assess functional improvement. 
 
A caveat to a negative contrast detection scheme is the misinterpretation of signal voids as 
transplanted cells. MR signal can be nulled by an array of factors including local magnetic 
field inhomogeneities, susceptibility artifacts and partial volume effects. The heart is 
especially vulnerable to such aberration because of its juxtaposition with lungs. Recently, we 
have demonstrated the use of ultra-short echo time imaging (UTE) to obtain positive contrast 
of SPIO-labeled mesenchymal stem cells injected into a mouse brain (98). By incorporating 
multiple-echoes and multiple-frame capabilities into the sequence, I was able to exploit both 
the T1 and T2 relaxation effects of iron-oxide to obtain high contrast-to-noise ratio of SPIO-
labeled cells in the beating rat heart.  
 
3.5.2 Materials & Methods 
Multiple-echo Ultra-short Echo Time Pulse Sequence (MUTE) 
An image was acquired at the shortest possible echo-time (hereby known as FID or UTE 
image). Subsequent refocused gradient echoes are collected by alternating gradient amplitude 
polarity and are referred to as ECHO. A cine-UTE sequence with multiple-frame acquisition 
124 
 
capability was also implemented whereby only the FID image was recorded for each frame in 
the cardiac cycle. The maximum number of frames possible in that setup was 20. Image 
reconstruction was carried out offline in Matlab with regridding. A Kaiser-Bessel 
interpolation scheme was employed with an oversampling factor of 2, free-design parameter 
 of 8.9962 and gridding kernel width of 4. The Voronoi scheme is used for density 
compensation in this study. 
 
Cell isolation and labeling 
Human mononuclear cells (MNCs) were collected by leukapheresis from peripheral blood of 
G-CSF-stimulated donors. They were washed twice with PBS, centrifugated for 10 min, 
plated in DMEM (Gibco, UK) and incubated at 37°C and 5% CO2. After 2 h, non-adhered 
cells were discarded with the media replaced with fresh DMEM and 10% fetal calf serum 
(Invitrogen, UK). Cells were subsequently labeled with SPIOs (Endorem, Guerbet 
Laboratories, UK) by incubation with 45 µl ml
-1
 media for 24h. They were then trypsinized, 
washed twice with PBS and re-suspended. 
 
Animal Preparation  
All animal procedures were approved by the University College London Ethics Committee 





1 male Wistar rat (Charles River Ltd, U.K.) aged 7 - 8 weeks was anaesthetized with intra-
peritoneal injection of Hypnovel-Hypnorm-water mixture (1:1:2, 2.5 ml kg
-1
, Roche U.K., 
VetaPharma U.K.). Each animal had its body temperature monitored and maintained at 37°C 
during the surgery. They were then artificially ventilated with pure oxygen (Respirator, 
Harvard Apparatus Ltd, U.K.) at 1 L min
-1
. A thoracotomy was performed in the 4th 
intercostal space following blunt dissection of the chest muscles to expose the heart. 5 x 10
5
 
and 2.5 x 10
5
 of MNCs, were directly injected into the left myocardium wall at the apex and 
mid-ventricle, respectively. The chest was closed and spontaneous breathing was re-
established. Animals were subsequently kept anaesthetized at 2% isoflurane for MRI.  
 
Each anaesthetized animal was rested on a heating blanket in the animal cradle adopting the 
supine position.  An electrocardiogram (ECG) was obtained via subcutaneous insertion of 
needle electrodes into the front limbs. Cardiac and respiratory monitoring and gating were 
performed using an MR-compatible system (SA Instruments, NY). Cardiac MRI was 
performed using a 9.4T (400 MHz) horizontal bore system (Varian Inc. Palo Alto, CA) with a 
shielded gradient system (strength = 400 mT m
-1




). A 72 mm 
quadrature volume coil was used for transmission and a cardiac phased array coil (Rapid 
Biomedical GmbH, Germany) was placed over its chest for reception. 
 
Ex-vivo Sample Preparation 
The rats were sacrificed after MRI. Their hearts were excised, perfused with PBS and 
followed by 24 h fixation in 4% PFA at 5°C. They were then placed in increasing sucrose 




In-vivo Tracking of SPIO-Labeled Cells with Cine-UTE 
An axial slice across the left ventricle where the SPIO-labeled cells were injected was 
acquired with cine-UTE. A corresponding gradient-echo image (GRE) was also acquired 
using the lowest possible echo-time and typical sequential Cartesian readout. Region-of-
interest analysis was implemented in ImageJ in which an area of 5.4 mm
2
 enclosing the 
SPIO-labeled cells was chosen in each image, and its mean amplitude recorded as Sspio. 
Similar ROI measurement was performed in the unlabeled myocardium to yield Smyo. The 
standard deviation of noise noise was obtained for the muscle. All three regions are indicated 
in Figure 3.16A. These values were then used to calculate the contrast-to-noise ratio (CNR) 
according to eqn. (3.9).  
 
Critical scan parameters were: TR = 7.5 ms, TE = 0.26 ms (cine-UTE) and 1.22 ms (GRE), 
regridded matrix size = 256 x 256, number of radial projections in cine-UTE = 403 
(satisfying Nyquist criteria), Field-of-view (FOV) = 55  55 mm, in-plane image resolution = 
215  215 m, receiver bandwidth = 50 kHz, flip angle = 12°, slice thickness = 1.5 mm, 
number of frames = 15, number of averages = 3, total scan time = 2 min.  
 
Ex-vivo MRI with MUTE 
A more powerful gradient insert (strength = 1000 mT/m, slew rate = 7700 mT/m/ms) was 
utilized in this experiment to reduce echo time.  Long axis left-ventricle views of the excised 
heart were acquired with a MUTE pulse sequence. ROI analysis was subsequently carried out 
on the two injected sites, namely LV and APEX. Each ROI was about 30 mm
2
 and standard 
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deviation of noise was measured in the agar embedding the sample. Contrast-to-noise ratio 
was calculated according to eqn. (3.9). Critical scan parameters were:  TE = 0.18 ms (FID), 
echo-interval = 2.79 ms, TR = 20 ms, number of echoes = 3, regridded matrix size = 256  
256, number of radial projections = 403, FOV = 40 x 40 mm, in-plane image resolution = 156 
 156 m, receiver bandwidth = 100 kHz, slice thickness = 1.0 mm, number of averages = 3, 
scan time = 24 s per slice. A 40 mm quadrature volume coil was used for transmit and receive. 
Images were cropped to 29 mm  18 mm for display. 
 
3.5.3 Results  
In-vivo Tracking of SPIO-Labeled Cells with Cine-UTE  
Figure 3.16A displays the FID image at the 7th frame of the cine-UTE MRI, i.e., during mid-
diastole, in which the SPIO-labeled cells at the apex were distinctly identified with positive 
contrast. UTE imaging exploited the attenuated-T1 relaxation time of SPIO-labeled cells to 
provide a superior contrast-to-noise ratio of + 21.1. For the Cartesian GRE image on the other 
hand, although the minimum allowed echo-time was chosen, it is still insufficiently short to 




Figure 3.16: The selected slice is near the apex of the heart where the cells were injected. (A) 
UTE, and (B) GRE images of the 7th frame in the cine-MRI. Regions-of-interest are chosen 
at the labeled cells, unlabeled myocardium and muscle. Contrast-to-noise ratios were 
calculated according to eqn. (3.9). Lung is visible in the UTE image as a direct consequence 
of the ultrashort echo-time. 
 
Ex-vivo MRI with MUTE 
Figure 3.17 illustrates the FID, ECHOs (acquired at TE = 2.56 ms and 5.12 ms, respectively) 
and their subtracted images in the excised heart. Table 3.1 presents the measured contrast-to-
noise ratio at the injected regions labeled as LV and APEX respectively. At the LV region, 
positive contrast in the FID image (TE = 0.18 ms) was +0.2, against the negative contrast 
ECHOs of -4.9/-8.9 at echo time of 2.56/5.12 ms respectively. When subtraction is performed 
between FID and the 1
st
 ECHO, positive contrast is significantly boosted to 2.5 and 4.5 at the 
mid-left ventricle and apex sites respectively. When the same subtraction procedure is 
performed with the 2
nd
 ECHO, enhancement is further boosted to 19.6 and 22.7, respectively. 












Figure 3.17: MUTE MRI of the excised rat heart depicting the FID, ECHO and their 
subtracted images. LV and APEX are regions in the left ventricle where the SPIO-labeled 
mononuclear cells were injected.  
Contrast-to-Noise Ratio LV APEX 
UTE (TE = 0.208ms) 0.2 0.1 
ECHO1 (TE = 2.56ms) -4.9 -9.3 
ECHO2 (TE = 5.12ms) -8.9 -10.6 
UTE-ECHO1 2.5 4.5 
UTE-ECHO2 19.6 22.7 
Table 3.1: Contrast-to-noise ratios of injected SPIO-labeled cells in the rat myocardium 
showcase the boost in positive contrast upon subtraction between a UTE image and that of a 
subsequent ECHO.  
 
 
FID (TE = 0.180ms) ECHO1 (TE = 2.56ms)














This is the first report of visualization of SPIO-labeled cells with positive contrast in a 
beating rat heart. The high contrast-to-noise ratio of 21.1 ± 7.4 illustrated the good sensitivity 
of UTE in the in-vivo detection of iron-labeled cells. We also observe that the image quality 
in UTE is higher than that in the Cartesian gradient-echo image, and this is attributed to its 
oversampling of k-space origin. An added advantage of our UTE sequence is that the built-in 
multiple-frame capability could facilitate cardiac function measurements (99), enabling 
simultaneous cell tracking and functional studies. At first glance, it would appear that ex-vivo 
UTE MRI of the excised heart displayed disappointing positive contrast enhancement in the 
FID image, especially at the injected site with 5 x 10
5
 cells. A couple of factors contributed to 
this dismal performance. First, the echo-time was not short enough leading to failure in 
exploiting T1-relaxivity effect of SPIOs. The importance of achieving very short echo-time 
has already been described in Figure 3.7A, especially in high iron content environment (49). 
Second, a higher cell concentration at the apex implied elevated iron–oxide content and hence 
a more severe T2
*
 decay is present, evident from its more negative contrast (-9.3 at APEX 
versus -4.9 at LV). At high field, r2/r1 ratio is large (100), and thus transverse relaxation 
outcompetes its longitudinal counterpart when echo-time is insufficiently short. This resulted 
in reduced signal and diminished positive contrast. At a longer echo time of 5.12 ms, the 
hypointensities escalated and increased negative contrast. Fortunately, one of the MUTE 
features is the exploitation of increased T2
*
 effect via a subtraction between the FID image, 
which is heavily T1-weighted and an ECHO image, which is heavily T2
*
-weighted. As evident 
in Table 3.1, this method propelled the achievable positive contrast by as much as 12 and 45 
times at the LV and APEX, respectively. Further exploitation of T2
*
 effect of SPIOs was 
achieved by subtracting FID and the later ECHO. That further boosted the positive contrast 
by 98 and 227 times, respectively. Thus higher cell concentration resulted in greater contrast 
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enhancement with MUTE. That could perhaps serve as a cell number quantification measure. 
Simulations in Figure 3.7D suggested that FID echo time should be as close to zero as 
possible to maximize positive contrast. To attain that goal, we could utilize 3D MUTE 
acquisition with a non-selective hard pulse (62), albeit at a cost to total scan time and image 
reconstruction computation time. Advancement in gradient hardware with higher slew rates 
and faster ramp times could ultimately lower echo-time too.  
 
Although cardiac infarction therapy with stem cells is usually detected with T2
*
-weighted 
MRI, it is difficult to discern between the infarcted region and delivered cells since they both 
appear as hypointensities (101,102). However, since only SPIO-labeled cells exhibit 
enhanced T1-relaxivity but not infarcted tissue, MUTE could possibly separate these two 
entities. Increasing intracellular SPIO concentration by employing nanoparticles of higher 
relaxivities, increasing SPIO incubation time or more efficient transfection would introduce 
larger changes in R1 and R2
*
, aiding delineation of labeled cells (26,103). Discovering cellular 
viability and function in-vivo is also a profound task that cell therapists covet (104). 
Unfortunately, current MRI cell tracking techniques do not provide such information. Passive 
cell labeling with SPIOs would have to be substituted with SPIO agents that target or report 
viable cells such as overexpression of endogenous ferritin (105,106). MUTE could then be 
employed to differentiate between viable and apoptotic cells, for example. 
 
3.5.5 Limitations of the Study 
Although cell number is key information in monitoring therapeutic cell treatment efficacy, no 





-weighted MRI usually relies on a inverse relationship between changes 
in transverse relaxation R2
*
 and cell number (107). But this is confounded when cell 
concentration is too high and T2
*
 becomes excessively low. Liu and co-workers have recently 
demonstrated the ability of UTE to measure very short T2
*
 of SPIO-labeled cells and 
displayed a qualitative relationship between T2
*
 and cell concentration at 3T (58). Thus 
MUTE possesses the potential for in-vivo cell quantification. Even though positive contrast 
detection of SPIOs was successful in this study, their biological microenvironment was 
unknown. MUTE only sensed the presence of SPIOs but could not differentiate between 
intracellular SPIOs, extracellular nanoparticles that were not washed out during cell labeling 
processes or cells that die upon injection into the myocardium and are subsequently taken up 
by macrophages (108). In addition, free iron could also be found at injected sites where 
hemorrhage is often present, and that would confuse detection of labeled cells (109). It has 
been suggested that the compartment (intra- or extracellular) that SPIOs reside in affects their 
R2 relaxation rates and this physical parameter could perhaps be utilized to distinguish 
between free iron and intracellular SPIOs (110). Another limitation is that the rats were 
sacrificed immediately after MRI and longitudinal scans were not performed. As cells divide 
and proliferate, the iron content would become diluted and reduced detection sensitivity. 
Thus the minimal iron content for in-vivo positive contrast detection with MUTE would have 
to be investigated to facilitate prolonged studies. 
 
3.5.6  Conclusion 
This is the first study that enabled in-vivo positive contrast visualization of infused SPIO-
labeled cells in a beating rat heart with a multiple-echo UTE technique. Subtraction between 
images acquired at ultrashort and long echo-times could boost contrast by as much as 227-
133 
 
fold. Higher cell number increased transverse relaxation rate and stressed the importance of 
very short echo time to exploit the T1-effect of SPIOs.   
 
3.6 In-Vivo Positive Contrast Tracking of Bone Marrow Stem Cells with 
Superparamagnetic Iron Oxide Particles: Is Bigger also Better?  
Bone marrow-derived mesenchymal stem cells (BMSCs) possess tremendous therapeutic 
potential because of their capacity to differentiate into multiple functional lineages including 
chondrocytes, osteocytes, adipocytes and myocytes (1). To assess the efficacy of BMSCs cell 
therapy, MRI methods are being developed to monitor their bio-distribution in longitudinal 
therapeutic studies. Superparamagnetic particles are currently the most popular magnetic 
sensors incorporated into exogenous cells. They could also be supplemented with fluorescent 
dyes for optical detection. One of the pivotal design parameters of such particles is the 
amount of iron content, which would determine their detection sensitivity. In this work, we 
compared the in-vivo positive contrast that could be achieved between BMSCs labeled with 
ultra-small IODEX-TAT-FITC nanoparticles (20 nm in diameter) and micron-sized iron-




Adult bone marrow stem cells are multipotent biological entities that have the potential to 
differentiate into a myriad of phenotypes. Two populations of bone marrow cells exist, 
namely hematopoietic stem cells (HSCs) which give rise to mature lineages of blood, and 
mesenchymal stem cells (MSCs). Studies have investigated the plasticity of BMSCs and 
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found that they possess the ability to differentiate into cardiac muscle, endocrine cells as well 
as central nervous system phenotypes such as neurons and glial cells (111). Their therapeutic 
potential has been demonstrated in many repair and regeneration studies including 
myocardial infarction (112,113) and neurodegenerative diseases (114). Their ability to 
migrate extensively across the brain has also led to suggestions of a vehicular role in cell and 
gene therapy (115).  
 
In order to develop effective cell therapies, the location, distribution and long-term viability 
of the implanted cells must be determined in a non-invasive manner. Superparamagnetic iron 
oxide particles are non-toxic and biocompatible intracellular labels that act as beacons in 
MRI. They could be easily incorporated into BMSCs via incubation (116) or transfection 
(117). There are many different types of SPIO particles that are distinguished by their 
physicochemical properties such as size, coating, proton relaxivities, biocompatibility, 
stability and biotoxicity (18). As far as MR sensitivity is concerned, the iron content per cell 
determines its ease of detection (118). Successful infiltration with a transfection agent could 
yield an iron content as high as 30 pg per cell (26). Ultra-small SPIOs (USPIOs) have very 
small iron cores of ~ 15-30 nm and are easily incorporated into the cells via endocytosis. In 
fact, their accumulation in cells gives rise to such a high iron concentration that as low as 3 - 
50 cells detection is possible in-vivo (119,120).  A particular attractive USPIO particle is that 
of an iron-oxide core with a dextran coating that is conjugated to HIV-derived transactivator 
of transcription (TAT) peptide (121). TAT-peptide has been demonstrated to promote cellular 
uptake of a myriad of biomolecules and its use as a transfection system enables high labeling 
efficiency with minimal incubation time (22). The peptide also includes fluorescein 
isothiocyanate or FITC, which serves as a fluoroprobe for in-vitro detection. Such dual-
labeled contrast agent permits identification of the cell population in-vivo as well as at the 
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microscopic cellular level. A major drawback of USPIOs is that each nanoparticle has very 
low iron content and millions of particles would have to be present within a voxel for 
detectability. Thus cells must either be heavily loaded with USPIOs, which might undermine 
their migration and viability, or an aggregation of cells must be present within the voxel, 
which decreases sensitivity. In addition, cellular division might dilute the label below the 
detection limit. An alternative compound is the much larger micron-sized iron oxide particles 
(MPIOs). They have a range of diameters from 0.96 to 5.8 m and are able to achieve an 
intracellular iron content of approximately 100 pg, which is three-fold higher than USPIOs 
(25). This has created a new frontier in single cell detection with high resolution MRI (122). 
BMSCs are highly proliferative cells and it has been demonstrated that they are equally 
distributed between two daughter cells during division (123) and thus could be tracked for 
prolonged periods of time. For example, bone marrow stem cells labeled with MPIOs and 
injected into infarcted myocardium have been shown to be detectable with MRI beyond 16 
weeks (124).  
 
This study aimed to compare the in-vivo positive contrast generation between the two types 
of SPIOs injected into a rat brain, USPIO – bifunctional contrast agent dextran-coated iron-
oxide nanoparticles (IODEX-TAT-FITC) of diameter 15 nm (121) and MPIO - an aggregate 
of iron oxide magnetite mixed with a fluorophore and encased within an inert polymer shell 






3.6.2 Materials and Methods 
BMSC Culture  
Bone marrow-derived BMSCs were harvested from femurs and tibias of adult male Wistar 
rats. The cells were seeded in high-glucose Dulbecco’s modified Eagle’s medium with L-
glutamine supplemented with 10% foetal bovine serum and 25 μg mL-1 gentamicin on poly-
L-lysine coated flasks. Culture media was replaced every 2 days. Haematopoietic and other 
non-adherent cells were removed during medium changes. After 10 to 14 days of primary 
cultivation, the adherent cells were nearly 80% confluent and were dissociated with 0.25% 
trypsin and 1 mM EDTA and re-plated to expand the cells through successive passages.  
 
In-Vitro Labeling with IODEX-TAT-FITC 
TAT-peptide derivatized ultra-small superparamagnetic iron oxide (USPIO) nanoparticles 
coated with dextran (IODEX-TATFITC; 15–20 nm) were prepared in our laboratory by Dr. 
Bhakoo Kishore using the method described by Josephson et al. (125). Briefly, the dextran 
coated USPIO nanoparticles were synthesized and subsequently conjugated with TAT-
fluorescein isothiocyanate (FITC) peptide. TAT-FITC was synthesized by the using FMOC-
protected amino acid (2-(1-H-Benzotriazol-2-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate; HBTU) activation chemistry. The final iron concentration was 2.5 mg 
mL
-1
 and the solution was sterilized by -irradiation prior to use. A group of BMSCs were 
labeled at passages 4–6 with IODEX-TAT-FITC by incubation for a minimum of 4–6 h with 
10 g/105 cells of the iron-oxide nanoparticles per ml of culture medium (121). The final iron 
concentration was 21 pg /10
5
 cells (Olympus Diagnostic Iron Kit, UK). The BMSCs were 
137 
 
dissociated from the cell culture dishes with 0.25% trypsin in 1 mM EDTA and re-suspended 
in PBS.  
 
In-Vitro Labeling with MPIO 
Superparamagnetic divinyl benzene inert polymer microspheres were obtained from Bangs 
Laboratories (Fishers, IN). The average size of each micro-particle is 0.96 m. The particles 
contain a magnetite iron oxide component (63.4%) as well as a fluorescein-5-isothiocyanate 
analogue (Dragon Green) component trapped within the polymer matrix (480-nm excitation, 
520-nm emission). BMSCs were incubated with 150 L of iron particles (2 L mL-1) for 18 h. 
Each particle contained 0.125 pg of iron. The labeled BMSCs were removed from culture 





 in phosphate buffered saline (PBS) at 4°C ready for 
transplantation. 
 
Proliferation Assay of MPIO-labeled BMSCs 
Labeled BMSC viability was assessed by in-vitro proliferation using a modified MTT assay 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) (Roche Diagnostics, 
Indianopolis, IN). Briefly, 1000 BMSCs per well of a 24-well plate were seeded at early 
passage (P3-P5) and growth curves established after overnight labeling with a range of 
particle concentrations (0.5-2.5 L mL-1). Particles were either removed by repeated washing 




Transplantation of BMSCs 
Healthy adult (250–300 g) male Wistar rats were maintained under anesthesia using 
isoflurane (2%) and oxygen (2 L min
-1
). Stereotactic surgery took place on a Kopf small 
animal stereotactic frame. Thermoregulation was monitored with a rectal probe and the 
temperature kept constant at 37°C. Prior to surgery, a single-cell suspension was prepared in 
DMEM supplemented with 0.04 mg mL
-1
 Bovine Pancreas DNase to prevent ‘clumping’ of 
the cells. 50,000 cells in a volume of 5 L were injected at a rate of 1 L min-1. The 
stereotactic co-ordinates for injection were based on Rat Brain Atlas (126) with reference to 
the bregma; anterior–posterior = 0.0 mm, lateral–medial = −2.0 mm, dorsal–ventral = −6.3 
mm. The needle (26G, outer diameter = 0.46 mm) was kept in situ 2 min before and 5 min 
after cell-injection to allow for intra-cranial pressure equalization. Subcutaneous 
buprenorphine (0.1 mg kg
-1
) was given as analgesia, with intra-peritoneal saline injection and 
post-op warming to aid recovery. 
 
In-Vivo Positive Contrast Detection with Multiple-Echo Ultrashort Echo Time (MUTE) 
Injected rats were maintained in an anaesthetized state with 1.5% isoflurane during MRI 
measurement. Positive contrast detection of BMSCs was carried out with MUTE at 9.4 T, 
with a single loop surface receiver coil for reception. Image reconstruction was carried out 
offline in Matlab with regridding. A Kaiser-Bessel interpolation scheme was employed with 
an oversampling factor of 2, free-design parameter  of 8.9962 and gridding kernel width of 
4. Scan parameters were: TR = 100 ms, TE = 0.3 ms (FID), Echo-interval = 2.56 ms, number 
of echoes = 8, flip angle = 45°, FOV = 30  30 mm, regridded matrix = 256  256. Regions-
of-interest were drawn at the labeled cells and at the unlabeled contralateral position. Using 
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the measured signal intensities, contrast-to-noise ratio was calculated according to eqn. (3.9) 
and compared between FID, ECHO and subtracted (FID-ECHO) images.  
 
3.6.3 Results 
Figure 3.18A displays a fluorescent microscopic image of IODEX-TAT-FITC labeled 
BMSCs with DAPI (nuclei) staining. Green fluorescence indicates the presence of particles, 
which have been efficiently transfected. Figure 3.18B-D displays the FID, ECHO and their 
subtracted MUTE images respectively. Figure 3.19A is an overlay between fluorescent and 
bright-field optical images indicating the successful incorporation of MPIOs into BMSCs 
after 18 h incubation. B-D displays the corresponding reconstructed images of MPIO-labeled 
cells in the rat brain. Table 3.2 compares the contrast-to-noise ratio between IODEX-TAT-
FITC and MPIOs labeled MSCs, based on ROI analysis. Positive contrast of 50,000 labeled-
cells was prominent in the FID images for both particles with contrast enhancement of + 27.9 
and + 49.0 respectively. At an echo-time of 18.2 ms, the T2
*
 relaxation effect of iron-oxide 
dominates over T1-attenuation effect, resulting in signal voids and negative contrast of -12.6 
and -48.3 for IODEX-TAT-FITC and  MPIO –labeled cells respectively. MUTE exploits the 
transverse relaxation of both iron-oxide particles and boosts the positive contrast of the cells 
upon subtraction between FID and ECHO images. IODEX-TAT-FITC-labeled MSCs saw an 
increase of 30 % in positive contrast to 35.6, while the larger MPIOs yielded an additional 
78 % in contrast to 87.0. Another significant difference is that the area of enhancement in the 
cells labeled with the large 0.96 m MPIOs is 10.1 mm2, whereas it is 4.05 mm2 for that 




Figure 3.18: (A) Fluorescent microscopic image of the FITC label showed the successful 
transfection of IODEX-TAT-FITC nanoparticles into the bone marrow cells. MUTE images 
acquired at TE = 0.3 ms (B) and 18.2 ms (C). (D) Subtraction between FID and ECHO 
images resulted in higher positive contrast. 
ECHO (TE = 18.2 ms) FID - ECHO
IODEX-TAT-FITC 
labeled BMSCs





Figure 3.19: (A) Overlay between green fluorescence and bright-field optical images 
depicting successful endocytosis of MPIOs into BMSCs. (B-C) illustrated the regridded 
MUTE images at various echo-times (TE = 0.3 ms and 18.2 ms) while D displays their 




ECHO (TE = 18.2 ms) FID - ECHO
MPIO-
labeled BMSCs




 Contrast - to Noise Ratio (CNR) 
 IODEX-TAT-FITC MPIO 
FID (TE = 0.3 ms) 27.4 ± 17.9 49.0 ± 36.8 
ECHO ( TE = 18.2 ms) -12.6 ± 32.2 -48.3 ± 17.2 
FID - ECHO 35.6 ± 31.8 87.0 ± 38.1 
% increase in positive contrast after 
subtraction 
30 % 78 % 
Area of positive enhancement (mm
2
) 4.05 10.10 
Table 3.2: Contrast-to-noise ratio comparison between IODEX-TAT-FITC and MPIO – 
labeled MSCs in the rat brain. 
 
Figure 3.20 illustrates the results of the MTT proliferation assay, in which an inverse 
relationship exists between cell division capability and labeling concentration. At the current 
labeling concentration of 2 L mL-1, there was 40% impairment in cell division. 
 
Figure 3.20: MTT proliferation assay depicting the effect of higher MPIO labeling 
































This is the first demonstration of positive contrast detection of IODEX-TAT-FITC –labeled 
BMSCs in the preclinical arena. By utilizing a multiple-echo UTE sequence, we were able to 
achieve high positive contrast in the FID image. When we loaded the cells with much larger 
MPIOs, it was further elevated (from + 27.4 to + 49.0). This is attributed to the augmented 
T1-relaxivity of MPIOs-labeled cells. It is to be clarified that MPIOs do not necessarily have 
larger longitudinal relaxivity (127); rather it was the total iron content per cell that 
contributed to the heightened T1-relaxation, as evident from eqn. (3.11). The difference in 
R2
*
-relaxation, on the other hand, is much more pronounced between USPIOs and MPIOs 
because the latter have at least 50% higher iron content (123). An obvious manifestation of 
this discrepancy is the negative contrast in ECHO images, in which MPIO-labeled cells are 
four times more hypointensed than the IODEX-TAT-FITC ones.  This discrimination is the 
reason why single cell detection is possible with MPIOs (122,128). And when that was 
exploited with MUTE, subtraction between FID and ECHO propelled positive contrast of 
MPIO-labeled cells to new heights, achieving 78% increment compared to 30% for USPIOs. 
Another conspicuous characteristic is that MPIOs created a larger area of positive 
enhancement, which was more than twice that in IODEX-TAT-FITC cells. This phenomenon 
effectively boosted detection sensitivity by 250%. That feature could very well determine the 
detection success of labeled-cells in situations such as low resolution images or sparse cell 
clusters (25). The amount of MPIOs incorporated in each cell was not quantified though, and 
its more pronounced transverse relaxation could be due to higher intracellular concentration 
as well as r2
*
 relaxivity (see eqn. (3.12). The adverse effect of MPIO labeling on cell 
proliferation was a concern that had to be addressed. Even though a previous study claimed 
that MPIO labeling of up to 10 L mL-1 for 18h had no impact on cell proliferation (25), 
those were porcine mesenchymal stem cells and not murine, thus the biological influence of 
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iron-oxide on cell activity might differ. A recent study comparing various MPIO labeling 
strategies into endogenous mouse neural progenitor cells also found a significant reduction in 
BrdU
+
 (proliferating) cells after injection with MPIOs, albeit a larger particle (1.63 m) was 
utilized (129). Nonetheless a cardiac repair study which utilized higher MPIO labeling 
concentration (2.7 L mL-1 versus 2 L mL-1 used in this study) and longer incubation (24 h 
against 18 h) on rat BMSCs claimed that there was no significant reduction in cell viability 
and proliferation (124). The main difference between the studies was BMSC culture 
conditions and that requires further investigation. 
 
3.6.5 Limitations of Study 
Although the positive contrast obtained is phenomenal in both USPIO and MPIO – labeled 
BMSCs, there were several weaknesses in this study that should be addressed. First, we did 
not quantify the iron content per cell for both particles. Nonetheless a previous study that 
labeled similar rat bone marrow cells with IODEX-TAT-FITC achieved an iron content of 
~9.5 pg per cell (121), and we did not expect ours to deviate significantly from that since we 
adopted similar culture and label procedures. Iron content in MPIO-labeled cells however 
would have to be quantified in order to determine the minimal iron load required to achieve 
optimal sensitivity, without inhibiting cellular function.  Second, functional assessment such 
as cell viability, toxicity and differentiation capability were not carried out. Since dextran-
coated particles can be degraded by the microenvironment of the lysosome, there is a danger 
that excessive loading of cells with dextran–coated particles may induce cell death due to 
iron-load or at least incapacitate normal cell activity (130). In addition, a well-labeled cell 
comprising of ~15 pg of iron presents an extremely high cellular concentration of 250 mM. 
Most studies to date have not detected significant toxicity, but this remains a major concern. 
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Particles coated with an inert matrix, such as the MPIOs described here, potentially can 
prevent this (25). Third, no longitudinal scan was implemented, thus the loss in sensitivity 
due to cell division could not be verified. It is expected that the MPIOs outperform the 
USPIOs in this aspect, purely based on its richer iron content. Larger MPIOs could also be 
utilized to further enhance the sensitivity (25).   
 
3.6.6 Conclusion 
In this study, I demonstrated that both IODEX-TAT-FITC and MPIO-labeled bone marrow 
stem cells could be detected with high sensitivity and visualized as hyperintensities in vivo. 
The multiple-echo ultrashort echo time technique employed here exploited the proton 
relaxation of USPIOs and MPIOs to raise positive contrast by 30 % and 78 %, respectively, 
upon subtraction between FID and ECHO images. MPIOs were twice more sensitive to 
detection than USPIOs, on the basis of their larger enhancement area. Cell proliferation 
appeared to be impaired with MPIOs and further characterization of its biological impact on 
cellular activity is necessary.  
 
3.7 Z-Shimmed Ultrashort Echo Time - A New Positive Contrast Detection Scheme 
We have shown that UTE could visualize SPIO-labeled cells with high sensitivity which 
could be further augmented with multiple echo acquisition and subtraction. To fully realize 
the potential of MUTE however, T2
*
 decay must be exploited to yield maximum positive 
contrast. That imply either a long echo-time or heavily iron-loaded cells are essential. The 
former is sensitive to motion and susceptibility effects, whereas the latter faces the risk of 





generate positive contrast, I introduced a technique that takes advantage of the T1-relaxation 
effect of SPIOs as well as the off-resonance that they induce, i.e., a hybrid of UTE and 
White-Marker imaging. In this section, the strengths posed by this technique are presented, 
notwithstanding the challenges involved, which are also discussed.   
 
3.7.1 Z-shimmed Ultrashort Echo Time Pulse Sequence (ZUTE) 
Z-shimmed UTE is a single image acquisition technique that records only the FID signal at 
very short echo-times. Its pulse sequence is very similar to MUTE, with modification made to 
the slice-refocusing gradient amplitude and disabling of the multiple-echo functionality.  
Displayed in Figure 3.21 is the ZUTE pulse sequence which basically incorporates minimum 
phase SLR-VERSE RF excitation, variable slice refocusing gradient amplitude and radial 
sampling for minimal echo-time.  
 
Figure 3.21: Pulse sequence of Z-shimmed Ultrashort Echo Time (ZUTE), a hybrid between 




(selective half-sinc or 
















3.7.2 Positive Contrast Enhancement Simulation with ZUTE 
The theoretical principles behind ZUTE are similar to that presented in Section 3.2.3. The 
main difference is that the echo-time is very short (TE < 0.3 ms), which results in a smaller 
accrued phase for protons surrounding the SPIO. That implies less compensation is required 
to null that phase. We refer to eqn. (3.8) with the following parameters: a 1 mm
3
 voxel with 
thickness d = 1 mm;  = 1; V = 10-6 mm3; B0 = 9.4 T, TE = 0.192 ms; Gssr = 0.5 T/m and 
tssr = 0.15 ms. Simulation results comparing T2
*
-weighted ( = 0) and ZUTE ( = 0.45) 
imaging are displayed in Figure 3.22.  
 
Figure 3.22: Simulated positive contrast achievable with Z-shimmed UTE technique. Echo-
time was 0.192 ms. Reducing the slice refocusing gradient amplitude by 45% enables phase 
compensation along the slice direction, giving rise to positive contrast. Equation (3.8) was 









3.7.3 Positive Contrast Comparison between MUTE and ZUTE  
 In order to demonstrate the capability of ZUTE, I first put theory into practice and quantified 
the positive contrast that it offered. An excised rat heart transplanted with SPIO-labeled cells 
was chosen for the first trial, and then its positive contrast superiority was confirmed in vivo.  
 
Ex vivo Sample Preparation 
All animal procedures were approved by the University College London Ethics Committee 
and the Home Office (London, UK), and conducted under the Animal (Scientific Procedures) 
Act 1986. 
1 male Wistar rat (Charles River Ltd, U.K.) aged 7 - 8 weeks was anaesthetised with an intra-
peritoneal injection of Hypnovel-Hypnorm-water mixture (1:1:2, 2.5ml/kg, Roche U.K., 
VetaPharma U.K.). The animal had its body temperature monitored and maintained at 37°C 
during the surgery. They were then artificially ventilated with pure oxygen (Respirator, 
Harvard Apparatus Ltd, U.K.) at 1 L min
-1
. A thoracotomy procedure was performed in the 
4th intercostal space following blunt dissection of the chest muscles to expose the heart. 5  
10
5
 of MNCs were directly injected into the left myocardium wall at the mid-ventricle. The 
chest was closed and spontaneous breathing was re-established. The rat was sacrificed after 2 
hours and its heart was subsequently excised, perfused with PBS and followed by 24 h 
fixation in 4% PFA at 5°C. It was then placed in increasing sucrose gradients (10, 20, and 





Ex vivo MRI with ZUTE 
A powerful gradient insert (strength = 1000 mT m
-1




) was used 
for ex vivo MRI to reduce echo time.  Sagittal slices of the excised heart were acquired with a 
MUTE pulse sequence. ROI analyses were subsequently carried out with selected areas 
displayed in the ECHO image. Each ROI was about 30 mm
2
 and standard deviation of noise 
was measured in the agar embedding the sample. The slice-refocusing gradient amplitude 
was multiplied with a factor , decreasing from 1 to 0, in steps of 0.1. This indicated a shift 
in k-space from 0 to 41.8 cm
-1
 in the slice direction. Corresponding T2
*
-weighted gradient-
echo and White-Marker images were acquired for comparison. Region-of-interest analysis 
with an area of 10.7 mm
2
 was executed on the labeled cells and unlabeled myocardium, with 
contrast-to-noise ratio calculated according to eqn. (3.9). Other scan parameters were:  TR = 
150 ms; TE = 0.192 ms (FID); 3.4 ms (GRE/WM); number of echoes = 1; regridded matrix = 
256  256; number of radial projections = 403 (UTE/ZUTE); FOV = 40 x 40 mm; in-plane 
image resolution = 156  156 m; receiver bandwidth = 100 kHz; slice thickness = 1.0 mm; 
number of averages = 3; scan time = 120 sec per slice; flip angle = 45°; Gssr = 49.3 G cm
-1
 
(ZUTE) /  35.0 G/cm (WM) and ssr = 0.156 ms (ZUTE) / 0.28 ms (WM). A 40 mm 
quadrature volume coil was used for transmit and receive.  
 
In vivo Sample Preparation and MRI with ZUTE 
A rat that has been stereotactically injected with 50,000 bone marrow stem cells, which were 
labeled with 0.96 m MPIOs as described previously in section 3.5.2, was inducted with 2-3% 
isoflurane and maintained at 1.5% with 1L min
-1
 air mixture. Positive contrast detection of 
BMSCs was carried out with ZUTE at 9.4 T, with a single loop surface receiver coil for 
reception. Image reconstruction was carried out offline in Matlab with regridding. A Kaiser-
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Bessel interpolation scheme was employed with an oversampling factor of 2, free-design 
parameter  of 8.9962 and gridding kernel width of 4. Scan parameters were: TR = 100 ms; 
TE = 0.192 ms (FID); number of echoes = 1; flip angle = 45°; FOV = 30  30 mm; regridded 
matrix = 256  256; Gssr = 19.7 G cm
-1
 (ZUTE) and ssr = 0.28 ms (ZUTE);  ranges from 0 
to 1. Regions-of-interest were drawn at the labeled cells and at the unlabeled contralateral 
position. Using the measured signal intensities, the contrast-to-noise ratio was calculated 
according to eqn. (3.9) and compared between FID images acquired at different values of .  
For each value of , the compensated slice gradient amplitude was converted into units of 
mT s
-1
 using eqn. (3.41) below, where Gssr was the slice refocusing gradient amplitude and 
ssr was its duration.  
                (3.41)  
 
3.7.4 Results 
Ex vivo MRI with ZUTE 
After ROI measurements at the injected site and unlabeled myocardium region, as indicted in 
Figure 3.24, CNR was calculated and compared between white-marker and ZUTE. The CNR 
plots are displayed in Figure 3.23A and B, respectively. white-marker imaging induced 
rephasing of protons surrounding SPIO-labeled cells to give a maximum positive 
enhancement of + 7.1. Without slice refocusing compensation, i.e., at  = 0 or Gz = 0 mT s
-1
, 
SPIOs created a hypointensity with CNR of -9.5. ZUTE on the other hand increased the 
hyperintensity from +11.7 ( = 0) to a peak of + 21.6 ( = 0.5). Figure 3.24 compares the 
MR images obtained with gradient-echo ( = 0), White-Marker ( = 0.2), UTE ( = 0) and 
ZUTE ( = 0.5). The positive contrast enabled with UTE already surpassed that of WM 
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(+11.7 versus + 7.1). Suppressing the background signal with ZUTE further enhanced 
contrast to +21.6.  
 
Figure 3.23: CNR comparison between (A) White-Marker and (B) ZUTE as accrued phase 






Figure 3.24: MR images comparing negative and positive contrast derived from T2
*
-weighted 
gradient echo, White-Marker, UTE and ZUTE imaging. Only images with maximum 





GRE: TE = 3.4 ms






In-Vivo MRI with ZUTE 
Figure 3.25A illustrates the increase in in-vivo positive contrast of 50,000 MPIO-labeled cells 
with ZUTE imaging. The routine UTE image in (B) gave rise to a CNR of + 40.2, whereas 
the maximum available with ZUTE (C) is + 57.9, an improvement of 44 %. As the phase 
became over-compensated, contrast began to decrease.  
 
Figure 3.25: (A) CNR depicting the gradual increase in positive contrast as phase within the 
excited slice was compensated with ZUTE. (B) UTE image at  = 0; and (C) ZUTE image at 
 = 0.2. 
A
B C
UTE: TE = 0.3 ms
Gz = 0 T.s
CNR = + 40.2
ZUTE: TE = 0.3 ms
Gz = 0.01 T.s






I demonstrated the phenomenal boost in positive contrast that could be achieved with ZUTE. 
In both ex-vivo excised hearts and in-vivo rat brain, the hyperintensity increased in 
magnitude with respect to its surroundings as the phase induced by SPIO-labeled cells 
became compensated.  A maximum value was reached when nulling of that phase occurred, 
as evident from eqn. (3.7) and (3.8). This is consistent with the White-Marker technique (42), 
which is essentially ZUTE but with much longer echo-time. Obviously UTE already 
outperformed White-Marker imaging in the excised heart (+11.7 versus +7.1, respectively) 
because it exploited T1-relaxation of SPIOs as well as minimized T2
*
 decay due to its very 
short echo-time (as discussed in section 3.5). With phase compensation, the positive contrast 
was nearly doubled. It is again emphasized here that the principle of ZUTE relies on 
rephasing specific protons surrounding SPIO, while dephasing distant ones. Therefore a 
‘blooming’ marker was observed in Figure 3.25 B and C, which appeared very similar to the 
simulated SPIO biomarker in Figure 3.22. The much larger MPIOs (in rat brain) had a more 
pronounced T1-relaxation effect and thus generated a more augmented positive contrast than 
the SPIOs (in excised heart). Close scrutiny reveals a difference between maximum positive 
contrasts enabled by ZUTE and MUTE (+57.9 and +87.0 respectively, see Table 3.2). There 
is a reason for this discrepancy. The MPIOs used here had large transverse relaxivity which 
facilitated large contrast enhancement in the subtraction of FID and ECHO images. ZUTE 
does not rely on T2
*
-decay because it is heavily T1-weighted. In fact, T2
* 
decay would reduce 
the signal because of a finite readout time. The almost equivalent CNR when USPIOs are 
used in the excised hearts, +21.6 (ZUTE) against +22.7 (MUTE, see Table 3.1), corroborates 
this hypothesis. Since ZUTE rephases protons in the excited slice, its weaknesses are akin to 
White-Marker’s, including partial volume effects and sensitivity to local magnetic 




I demonstrated an alternative method to generate positive contrast from SPIO-labeled cells 
that could be used in vivo as well as ex-vivo. Although ZUTE performance was slightly 
deficient compared to MUTE, in terms of maximum contrast enhancement, it offers some 
advantages such as single image acquisition and regridding, as well as ease of 
implementation without major concern of skewed k-space trajectories in the echoes. In 
addition, it is superior to White-Marker imaging and I demonstrated its capability in the 
preclinical environment.  
 
3.8 Chapter Conclusion 
For this chapter, I explored the feasibility of multiple-echoes UTE in in-vivo tracking of 
SPIO-labeled cells in the preclinical environment. Its superior positive contrast characteristics 
compared to current clinical techniques placed it at the forefront of cellular tracking in animal 
disease models. I also proposed a hybrid method that incorporated the high sensitivity of 
UTE and robust contrast offered by White-Marker imaging to meet demanding requirements 
in sensitivity, specificity and imaging speed. I am optimistic that these two positive contrast 
techniques will contribute significantly in understanding migration dynamics in future 
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REAL-TIME DETECTION OF CARDIAC 
GLUCOSE METABOLISM WITH DYNAMIC 









Dynamic nuclear polarization is a novel technique that has the capability to multiply the 
magnetic resonance signal of a 
13
C-labeled compound by at least 10,000 times (1). This 
opened up the path for real-time in-vivo characterization of glucose metabolism in the heart 
(2,3). In this chapter, we first present the utilization of DNP [1-
13
C] pyruvate in the 
measurement of intracellular pH in the heart, followed by an investigation into the function of 
acetyl-carnitine as a transient fuel store in myocardial carbohydrate metabolism. The 
possibility to study necrosis upon onset of ischaemia, via infusion of [1, 4-
13
C] labeled 
fumarate, is then discussed. Finally, we venture beyond MR spectroscopy into metabolic 
imaging, as a prelude into visualizing the biological processes that are critical in the energy 
production in the heart. All the work in this chapter was accomplished in the Cardiac 
Metabolism Research Group at the University of Oxford.     
    
4.2 Probing Cardiac Metabolic Activity with Steady-State 
13
C NMR/MRS 
Probing of biological processes in physiology with magnetic resonance has been an ongoing 
activity for decades. Dynamic 
13
C nuclear magnetic resonance spectroscopy (MRS) allows 
absolute metabolic flux along a particular metabolic pathway to be determined. As 
13
C-
enriched substrate is metabolized, the 
13
C label is transferred to its metabolic intermediates. 
The labeling pattern is dependent on the chemistry of the enzyme reactions, and the rate of 
labeling is determined by flux through the pathway and the pool sizes of the intermediates (4). 
From the 
13
C MRS spectra, resonances attributable to the specific carbon atoms of particular 
intermediates are identified by their chemical shifts. The area of the resonance peak is 
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proportional to the 
13
C content of the particular carbon site, and the fractional enrichment can 
be calculated if the intermediate pool size is known. The 
13
C NMR technique permits data to 
be acquired continuously and non-destructively while metabolism is in progress. Hence 
integrated biochemical and physiological responses of the tissue to external stimuli may be 
explored.  
 
An important application of 
13
C NMR is the evaluation of oxidative metabolic activity within 
a tissue, as a measure of functional activity that cannot be readily obtained under normal 
circumstances (e.g. brain). For a fundamental understanding of how 
13
C studies can be 
applied to monitor metabolic flux in such systems, the data from studies in the heart have 
provided particular insight. Infusion of [
13
C]–enriched substrates allow the metabolic activity 
of the tricarboxylic acid cycle (TCA) to be monitored in the intact heart. Using 
13
C NMR, 
Malloy et al measured the fractional enrichment of [2-
13
C] acetyl-CoA entering the cycle and 
the relative activities of the oxidative versus the anaplerotic pathways in the perfused rat heart 
(5).  Neurohr and co-workers demonstrated the feasibility of detecting 
13
C-enriched glutamate 





C NMR thus provides a useful methodology to investigate in-vivo metabolic 
activity in a non-invasive manner. 
 
4.2.1 Low Detection Sensitivity in 
13
C NMR  
The biggest obstacle in the use of steady-state 
13
C NMR for metabolic probing is its 
extremely low detection sensitivity. To understand the reasons for this limitation and 
elucidate the need for hyperpolarization, it is worth discussing the MR signal intensity S, 
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C],  and spin polarization P as given 
in eqn. (4.1).  The intrinsic low sensitivity of 
13
C detection can be partially attributed to its 
low ratio that is only a quarter of that in proton (10.71 MHz T
-1
). Coupled with a low natural 
abundance of 1.1%, it appears that detecting 
13
C with NMR becomes extremely difficult to 
perform under normal conditions. Spin polarization reflects the inequality between parallel 
(N
+
) and anti-parallel (N
-
) spins, parallel being aligned in the same direction as the main 
magnetic field         , and is given by eqn. (4.2) and (4.3) for a spin ½ nucleus. At normal body 
temperature of 310 K and clinical field strength of 3 T, polarization at thermal equilibrium is 
merely 2.5  10-6 for 13C while it is 9.9  10-6 for 1H. The quadrupled discrepancy is due to 
the gyromagnetic ratio difference. The low natural abundance of 
13
C could be alleviated in 
part by using 
13
C-labeled compounds. Even with such unique atomic composition however, 
the low physiological concentration of metabolites (usually less than 1 mM) severely limits 
its detection with 
13
C NMR, not to mention 
13
C MRI.  
                        
    (4.1)  
                        
     
     
  (4.2)  
        
    
    









C Compounds for Signal Enhancement 
Despite the low signal of 
13
C compounds, its large range of chemical shifts in various 
microenvironments has made it an important nucleus in analytical NMR, particularly for 
molecules of biological origin. For successful implementation, it is imperative that the 
demand for much higher SNR must be met. Referring to eqn (4.1), the only factor that can be 
adjusted with technology is the polarization. Advancing to higher field strength while 
maintaining an extremely low temperature appears to be the easiest solution for polarization 
enhancement. A straightforward ‘brute’ force approach does exactly that by cooling the 13C 
sample to liquid helium temperature (4 K) at a very high magnetic field (20 T) which 
increases the polarization by 1000 times (7). Unfortunately, 1000 times signal increase is still 
insufficient for clinical application, notwithstanding the impractical low temperatures that are 
required.    
 
Unity polarization indicates the occupation of a single energy state by all nuclei (i.e. 100% 
polarization). Therefore theoretically it should be possible to achieve an enhancement of 
400,000 times in 
13
C polarization at 3 T. At thermal equilibrium, the Zeeman energy gap 
between the two discrete energy levels in a spin-½ system is very small,       , and thus 
there is no energy advantage for nuclei to occupy either energy state. The Boltzmann’s 
distribution of spins is then almost equal between the two energy levels and polarization is 
low, as implied by eqn. (4.2). Hyperpolarization is the method employed to upset this balance 
by reordering the nuclei to occupy one energy level, as shown in figure 4.1. This allows 
transient non-equilibrium whereby one energy state contains many more nuclei than the other, 




Figure 4.1: The imbalance of spin-occupied energy states upon hyperpolarization. 
 
Many technological advances in the past two decades have occurred to make 
hyperpolarization feasible for applications in physiological examination, primarily  optical 
pumping (8,9), parahydrogen induced polarization (PHIP) (10,11) and dynamic nuclear 
polarization (1,12). Optical pumping involves the passing of circularly polarized light from 
lasers at suitable resonant frequencies along an outer magnetic field through cells containing 




He) together with either an alkali-metal vapor or metastable atoms. 
The angular momentum of the laser is absorbed and causes polarization of the total spin of 
the vapor or metastable gas. Thus, a ‘pumping’ of atoms having an anti-parallel spin state 
into more parallel-oriented spins takes place. The polarization is then transferred from the 
vapor or metastable atoms to the noble-gas atoms (13). This polarization enhancement 
technique has been particularly beneficial in the investigation of pulmonary (14,15).  The 
PHIP technique on the other hand involves the use of parahydrogen, which are isomers of 
hydrogen molecules with an anti-symmetric nuclear state. They have a total nuclear spin of 0 
and thus do not exhibit an NMR signal. In the late 1980s, Bowers and Weitekamp discovered 
that the catalytic hydrogenation of small organic molecules with parahydrogen led to a high 

















for the corresponding protons (16,17). The non-equilibrium proton spin order can be 
converted to longitudinal polarization of a nearby 
13
C molecule either by means of diabatic-
adiabatic field-cycling method (11) or by a sequence of rf pulses (18). The resultant highly 
polarized 
13
C compound, with polarization elevated by at least 100,000 times, is an effective 
contrast medium that combines the long T1 of 
13
C with a high concentration of the NMR 
active nucleus, thus enabling a considerable degree of signal enhancement (19). The 
hyperpolarized state is transient though as the polarization will strive to return to the thermal 
equilibrium level at a rate governed by the T1 relaxation time. The loss of polarization due to 
T1-relaxation leads to signal decay with time and is non-recoverable. T1 strongly depends on 
the chemical structure and environment of the hyperpolarized compound, and for 
13
C it can 
typically range from a few seconds to several minutes. 
 
4.3  Dynamic Nuclear Polarization (DNP) 
A nascent hyperpolarization method is the use of dynamic nuclear polarization, which is 
based on polarizing the nuclear spins in the solid-state. The rationale behind DNP is obvious 
from eqn. (4.3). The thermal equilibrium polarization for 
13
C is very low at 0.1 % under 
moderate conditions (1 K and 3 T) compared to the electrons, which are polarized to >90% 
owing to their much larger (6.73  107 versus 1.76  1011 rad s-1 T-1 respectively). The DNP 
technique effectively transfers the high polarization of electron spins to coupled nuclear spins 
(20). Although pioneering work by Jeffries, Abraham and Goldman in the 1950s opened up 
insights on nuclear polarization (21,22), the method’s requirement for nuclei to occupy the 
solid-state, at extremely low temperatures, prevented its application in biology. Fortunately, 
in 2003, iconic work by Ardenkjaer-Larsen and his coworkers solved this problem with a 
method to dissolve DNP-polarized samples and yet retain virtually all of the solid-state 
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polarization. By combining solid-state DNP and dissolution techniques, they enabled nuclear 
polarization of 40%, thus enhancing sensitivity by 45,000 times together with  in-vivo 
stability of approximately 1 min (1). In the following subsections, I briefly describe the 
physical mechanism behind DNP and outline the experimental procedures involved in a 
typical DNP-
13
C NMR experiment. 
 
4.3.1 Dynamic Nuclear Polarization Mechanism 
Consider a sample of MR-active nuclei that is doped with a source of fixed paramagnetic 
impurities. When microwave irradiation of frequency  is applied at or near the electronic 
Larmor frequency of the impurities e, electron-nuclear coupling occurs and leads to 
electron-nuclear transitions, which enhance the absolute nuclear polarization (22). The 
magnitude of enhancement, mechanism of polarization and the conditions which result in 
maximum enhancement depend on the nature of the electron-nuclear interactions.  
 
An Overhauser effect occurs when electron-nuclear interactions are time-dependent on a 
scale comparable to 1/e, and the enhancement maximizes when the irradiation frequency  
is equal to e. It has been observed in alkali metals, semiconductors, and in organic radicals 
such as coal (23). A solid-state effect (also known as solid effect) occurs in solids containing 
fixed paramagnetic centers, where the electron nuclear interactions are time-independent. 
Consider an assembly of nuclear spins I = ½ of Larmor frequency n embedded in a 
diamagnetic solid that contains a few paramagnetic impurities with electronic spins S = ½ of 
Larmor frequency e, coupled to neighboring nuclear spins by dipolar interactions. 
Since     , therefore      . In an environment with a strong magnetic field and 
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extremely low temperature (T ~ 1.2 K), virtually all electrons occupy the lower energy state, 
in accordance with the Boltzmann distribution, but it is not the case with the 
13
C nuclei due to 
their much lower . When external microwave radiation is applied at a frequency     
  , electrons will possess sufficient energy to flip up to the next higher energy level, 
accompanied by either a simultaneous flip up of a nucleus to its higher energy-level (a ‘flip-
flip’, which occurs at the frequency     ) or flop down of a nucleus to the lower energy 
level (a ‘flip-flop’,  at the frequency     ). Flip-flip and flip-flop transitions are depicted 
in figure 4.2 (22). These transitions are so-called ‘forbidden transitions’ because their 
probability of occurrence is minimal without microwave excitation. Because the electronic 
relaxation rate is several orders of magnitudes faster than the corresponding nuclear 
relaxation rate, each electron can undergo transitions with many nuclei. With continued 
irradiation, nuclear polarization builds towards an enhanced value. Polarization enhancement 
is negative and becomes optimal at       , whereas it is positive at        (23). 
The other mechanism that enhances polarization is the thermal-mixing effect, which occurs in 
solids with fixed paramagnetic centers. When the broadening of the electron paramagnetic 
resonance (EPR) line becomes comparable to the nuclear Larmor frequency n, the nuclear 
Zeeman system is coupled to the electron broadening system, The polarization corresponding 
to this broadening system can thus be enhanced by irradiating at the electronic Larmor 
frequency e. Then because of electron-nuclear coupling, the nuclear Zeeman polarization 
also becomes enhanced. The overall polarization enhancement is a sum of solid-state and 
thermal mixing effects and it has been demonstrated that 100% polarization is possible with 






Figure 4.2: A schematic of the electron-nuclear transitions of the solid effect in a magnetic 
field. Sz and Iz denotes the spin of electron and nuclei respectively. ‘+’ indicates parallel while 
‘-‘ denotes anti-parallel orientation. At a low temperature T ~ 1.2 K, all electrons are at the 
lower energy level (Sz = -1/2). Microwave irradiation at          excites electrons to 
the higher energy-state and leads to a ‘flip-flop’ transition in which the nuclei are transferred 
from the high to the low energy states, resulting in a positive signal enhancement. On the 
other hand, microwave irradiation at          leads to a ‘flip-flip’ transition in which 
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4.3.2 Liquid-State DNP 
A hyperpolarized solid-state organic molecule cannot be delivered efficiently into the 
circulation and it must be converted into a liquid state, with minimal loss in polarization. To 
create a highly polarized liquid-state 
13
C biological sample, the compound is first doped with 
a source of single-electron substance and then subjected to microwave irradiation within a 
super-cooled (~1.4 K) 3T magnet. For this thesis, the compound used to study the metabolic 
fate of exogenously infused pyruvate consists of [1-
13
C] pyruvic acid was mixed with a small 
concentration of paramagnetic centers known as triarylmethyl (trityl) radical OXO63 (25). 
An optimal dose of the radical is important because an excess of paramagnetic centers 
hastens nuclear relaxation (preventing polarization build-up) (1) whereas a deficiency results 
in slow polarization (26). The helium-cooled environment is meant to force all electrons to 
occupy the lower energy-state, which increases the total ‘flipping’ transitions. It has been 
suggested that a minute addition of gadoterate meglumine (Gd-DOTA) could be further 
added in order to boost polarization enhancement. It is hypothesized that the Gd
3+
 chelated 
ions shorten the electronic T1 in the sample and allow each electron to polarize more nuclei 
(26), though it is yet to be confirmed. A microwave sweep to identify the appropriate 
frequency for positive polarization enhancement is displayed in Figure 4.3a, which occurs at 





 sample at 94.139GHz with microwave power of 100mW. 
Dynamic nuclear polarization is carried out in a commercial hyperpolarizer system 
(‘Hypersense’) from Oxford Instruments and is normally completed within an hour. A picture 
of the instruments is shown in figure 4.3c. Main components of the hyperpolarizer consist of 
a 3.35T magnet with a sample insert that is cooled to 1.1K during DNP, a microwave 
generator  for irradiation and a pressurized dissolution system (1). During dissolution, the 
hyperpolarized sample is dissolved in an alkaline buffer (NaOH) and heated to body 
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temperature. An 80 mM solution of sodium pyruvate with a net polarization of ~30% and pH 
between 7.0 – 7.8 is then obtained. Figure 4.3d illustrates a schematic diagram of the process 
in a routine experiment with the hyperpolarized biological probe. 
 
Figure 4.3: (A) Microwave frequency sweep to identify the optimal frequency for positive 




 sample. (B) The 
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Figure 4.3c: DNP polarizer at the Cardiac Metabolism Research Group in the University of 
Oxford. To maximize the limited lifetime of the hyperpolarized sample, the hyperpolarizer is 
placed juxtaposition to the 11.7T vertical bore MRI system. (d) A typical process flow 




4.4 Energy Generation in the Heart 
Heart muscle is both consumer and provider of energy. It consumes energy locked in the 
chemical bonds of fuels through their controlled combustion and converts chemical energy 
into mechanical energy. The heart also provides energy in the form of substrates and oxygen 
both for itself and to the rest of the body.  It is a center of immense metabolic activity because 
adenosine 5’-triphosphate (ATP), the chemical energy available, has to be continually re-
synthesized from its breakdown products, adenosine 5’-diphosphate (ADP) and inorganic 
phosphate (Pi). The greater the cardiac output, the higher the ATP turnover rate. Since the 
heart’s contractile activity essentially controls nutrition delivery to the rest of the body, it is 
unsurprising that the heart produces and uses 35 kg of ATP daily, more than 100 times its 
own weight and more than 10,000 times the amount of ATP stored in the heart for impromptu 
hydrolysis (27). Additionally, it consumes 10% of O2 in the body, despite accounting for only 
0.5% of body weight. Impairment in energy transfer in the heart is thus detrimental to proper 
physiological functioning of the human body.   
 
In the heart, the direction of most enzyme-catalyzed reactions is catabolic, which is the 
breaking down of large macromolecular fuel complexes into smaller molecules, liberating the 
energy stored in the chemical bonds in the process. Biochemists have found it convenient to 
group the breakdown of substrates into three stages, as illustrated in Figure 4.4 (28). The first 
stage involves the breakdown of substrates into acetyl-CoA via fatty acid -oxidation, 
glucose or amino-acids metabolism. In the second stage, acetyl-CoA units are oxidized in the 
Krebs or TCA cycle to CO2. Four pairs of electrons are transferred (three to NAD+ and one 
to FAD) for each acetyl group that is oxidized. Then ATP is generated as electrons flow from 
the reduced forms of these carriers to O2 in a process known as oxidative phosphorylation. 
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More than 90% of the ATP generated by the degradation of foodstuffs is formed in this third 
stage.  For this thesis, we delivered hyperpolarized 
13
C-labeled pyruvate into the heart and 
track its metabolic fate. Thus we are more interested on the oxidative decarboxylation of 
pyruvate into acetyl-CoA, as well as its subsequent downstream biochemical processes in the 
TCA cycle.  We shall follow the catabolism of pyruvate into the Krebs cycle, with particular 
attention paid on metabolic regulation via control of (1) amount of enzymes, (2) their 
catalytic activities and (3) substrate accessibility. The investigation of acetyl-carnitine as a 
temporary storage compartment of acetyl-units at the end of Stage 1, before incorporation 
into the TCA cycle, is also explored. 
 
Figure 4.4: The three stages of energy transfer in heart muscle consist of intermediary 
metabolism, Krebs citric acid cycle and the respiratory chain. The aim of intermediary 






















4.4.1 Metabolic Fate of Pyruvate   
Pyruvate is the downstream metabolic product of glucose via the glycolytic pathway and is a 
central metabolic intermediate that can either be further oxidized or used as a building block. 
Its metabolic fate is summarized in figure 4.5, where its downstream metabolites and the 
enzymes that are involved in the biochemical processes are displayed. This three-carbon -
keto acid is a major metabolic junction governing the flow of molecules in metabolism. It can 
be reduced into lactate, catalyzed by the enzyme lactate dehydrogenase (LDH). This pathway 
generates NAD
+
 and enables continual operation of glycolysis under anaerobic conditions. 
Another readily reversible reaction in the cytosol is the transamination of pyruvate to alanine, 
an amino acid. Transamination is a major link between amino acid and carbohydrate 
metabolism. The third fate of pyruvate is its anaplerotic role, whereby it undergoes 
carboxylation to become oxaloacetate inside the mitochondria. This pathway serves as a 
source of replenishment of intermediates in the citric cycle. When a paucity of oxaloacetate 
occurs and the citric acid cycle is slowed, acetyl-CoA activates pyruvate carboxylase to 
accelerate the synthesis of oxaloacetate.  A fourth, perhaps most important fate of pyruvate is 
its oxidative decarboxylation to acetyl-CoA. This irreversible reaction inside mitochondria is 
a decisive reaction in metabolism because it commits the carbon atoms of carbohydrates and 
amino acids to oxidation in the citric acid cycle or synthesis into lipids. The pyruvate 
dehydrogenase complex (PDH), which catalyzes this irreversible funneling, is stringently 
regulated by multiple allosteric interactions and covalent modifications. Pyruvate is rapidly 
converted into acetyl-CoA only if ATP is needed or if two-carbon fragments are required for 




Figure 4.5: Principle biochemical pathways depicting the metabolic fate of pyruvate. 
Metabolite substrates are in blue boxes whereas catalytic enzymes are in red boxes. The 
metabolic processes that are investigated in this thesis are in dashed boxes together with the 
respective sections which the reader is referred to. Abbreviations for the various enzymes, 


















































Section 4.6: Acetyl-carnitine 
as an energy store
S4.5: Measuring intracellular pH










C] – Labeled Pyruvate   
The heightened sensitivity enabled by hyperpolarized 
13
C nuclei offers the possibility of 
using non-invasive NMR spectroscopy to measure fluxes through individual enzyme 
catalyzed reactions (29,30). [1-
13
C] pyruvate has been used successfully to probe pyruvate 
dehydrogenase activity and lactate production. Aberrations in these biochemical processes 
appear to reflect pathophysiology and thus they have been proposed as potential biomarkers 
of diseases. Schroeder et al demonstrated the feasibility of real-time in-vivo assessment of 





) as an indicator of PDH flux, they were able to detect a 65% reduction 
in the conversion of pyruvate to acetyl-CoA in STZ-induced rats, and established a negative 
correlation between bicarbonate production and disease severity.  Lactate accumulation in the 
heart has also been shown to be a metabolic indicator of cardiac ischaemia (2). Albers and 
co-workers observed increasing hyperpolarized lactate production in prostate cancer 
development and proposed its utilization as a biomarker of tumor progression (31). Day et al 
hypothesized that the reduction in lactate production in tumors is due to tumor cell death and 
proposed using lactate dehydrogenase flux to assess the effectiveness of chemotherapy (32).  
 
Normal cardiac function is dependent on a constant rate of ATP resynthesis by mitochondrial 
oxidative phosphorylation and, to a much lesser extent, glycolysis. Oxidation of fatty acids is 
responsible for about 60–90% of the resynthesized ATP, with the balance coming from the 
oxidation of pyruvate that is derived from glycolysis and lactate uptake (33).  Cardiac ATP 
production is controlled largely by the rate at which the Krebs cycle operates (28). The chief 
fuel input to the Krebs cycle is the 2-carbon acetyl-CoA molecule, which is produced from 
oxidation of fatty acids, ketone bodies or glucose via glycolysis and oxidative 
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decarboxylation of pyruvate. Some mechanisms that lead to energetic imbalances in heart 
disease could thus be studied by simultaneously monitoring the source and the fate of 
glucose-derived acetyl-CoA in the heart. DNP hyperpolarized [2-
13
C] pyruvate fulfils this 
role by offering real-time assessment of Krebs cycle metabolism using 
13
C MRS. Metabolic 
responses to physiological perturbation such as ischaemia has been demonstrated to be 
directly measurable with 1 second temporal resolution (2).   
 
To probe the downstream metabolic processes of DNP hyperpolarized pyruvate, 
13
C label is 




 carbon position, dependent on the biochemical pathway of interest. In 
Section 4.5, we utilized [1-
13
C] pyruvate to study the inter-conversion between bicarbonate 
and carbon dioxide in order to examine the role of carbonic anhydrase (CA) mediation in 
regulating intracellular pH. Real-time metabolic imaging to visualize PDH and CA activities, 
upon infusion of [1-
13
C] pyruvate, are discussed in Section 4.8. [2-
13
C] pyruvate on the other 
hand is used in the investigation of acetyl-carnitine role in myocardial carbohydrate 
metabolism, and that is discussed in Section 4.6. Although it appears that dual-labeling could 
improve experimental efficiency by measuring metabolic fluxes of the above processes in one 
attempt, it is technically very challenging because the chemical shifts of metabolites range 
widely and a wide receiver bandwidth is necessary, which reduces the spectral resolution. In 
addition, some metabolites such as lactate and glutamate have very similar chemical shifts 
(183.2 and 183.7 ppm respectively), and their overlapping spectra could convolute the 
analysis. An exception is the hydration of dual-labeled [1,4-
13
C2]fumarate, which produces 
[1,4-
13
C2]malate with two distinct resonances. We investigate the potential application of 
[1,4-
13




4.5 Measuring Intracellular pH in the Heart using Hyperpolarized Carbon Dioxide 




P Magnetic Resonance Spectroscopy Study 
The aim of this study was to evaluate the potential of hyperpolarized [1-
13
C]pyruvate to 
measure intracellular pH (pHi) in healthy and diseased heart with 
13
C magnetic resonance 
spectroscopy. PDH flux was measured before and after ischaemia and with CA activity 







CO2 ratio can be used reliably for pHi quantification in the rat heart.  
 
This work has recently been published in Cardiovascular Research (34) and is a collaborative 
effort between Cardiac Metabolism Research Group and the Proton Transport Group at the 
Department of Physiology, Anatomy and Genetics in the University of Oxford, and the 
Cancer Research UK Cambridge Research Institute. The manuscript was prepared by Dr. 
Marie A. Schroeder.  
 
4.5.1 Introduction  
In myocardial ischaemia, anaerobic glycolysis increases in the heart, producing intracellular 
protons and lactic acid that accumulate in the intra- and extracellular spaces (35). Some of the 
acid reacts with HCO3
-
 to form CO2, which adds to any CO2 generated by residual oxidative 
metabolism. Accumulation of protons, lactic acid and CO2 in the ischaemic heart decrease 
intracellular pH from normal physiological levels of around 7.1-7.2 (36). Transient acidosis 
during ischaemia may be beneficial though and it exerts temporary cardio-protection by 
conserving ATP for ion transport (37). However, prolonged ischaemia reduces ATP 

















 exchanger, thus raising 
myocardial Ca
2+
 and damaging the myocardium. A measure of intracellular pH would thus 
open up insights into the state of acidosis in the ischaemic heart and allow assessment of 
therapeutic interventions on ATP production.  
 
The gold standard of measuring intracellular pH in the isolated perfused heart is 
31
P magnetic 
resonance spectroscopy (38), based on the chemical shift in inorganic phosphate (Pi) peak 
(39,40). However, 
31
P MRS cannot measure cardiac pHi in-vivo because the presence of 2,3-
diphosphoglycerate (2,3-DPG) in the ventricular blood contaminates the myocardial Pi peak 
(38,41). It has been demonstrated recently that detection of hyperpolarized 
13
CO2 is possible 




 and their ratio has been used to map the extracellular 
pH in tumors (42) according to the Henderson-Hasselbach equation, where pKa is the acid-
dissociation constant of CO2, which is 6.15 in the Krebs-Henseleit buffer (43).  
            
     
    
       
  (4.4)  






CO2 are detectable with 
13
C MRS when [1-
13
C] 
pyruvate is broken down via PDH (29,44), we could perhaps measure intracellular pH with 
this probe, provided the following conditions are met:  




 catalyzed by carbonic anhydrase 
must be slow and 








pH can be reliably measured in tumors because of the high CA activity on the surface cells 
(45) and within erythrocytes (46), and the slow, transporter-mediated cellular uptake of 
infused bicarbonate (47). These conditions though may not apply in cardiac myocytes 
because the metabolically generated CO2 diffuses rapidly from the mitochondria into the 
cytosol, and subsequently into the extracellular space (48).  HCO
3-
 may also be removed from 








 exchanger (43).  Intracellular CA 
activity in cardiac myocytes is normally low (49) and could be further depressed in ischaemia 







CO2 prior to decay of the hyperpolarized 
13
C MR signal. 
 
4.5.2  Materials and Methods 
Isolated Perfused Rat Heart 
All investigations conformed to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996), 
the Home Office Guidance on the Operation of the Animals (Scientific Procedures) Act, 1986 
(HMSO), and to institutional guidelines. Male Wistar rats (~300 g) were anaesthetized using 
a 0.7 mL i.p. injection of pentobarbital sodium (200mg/mL Euthatal). The beating hearts 
were quickly removed and arrested in the ice-cold Krebs–Henseleit perfusion buffer, and the 
aorta was cannulated for perfusion in re-circulating retrograde Langendorff mode at a 
constant 85 mmHg pressure and 37°C temperature. The Krebs–Henseleit bicarbonate 
perfusion buffer contained 1.2 mM inorganic phosphate (KH2PO4), 11 mM glucose, and 2.5 
mM pyruvate and was aerated with a mixture of 95% oxygen (O2) and 5% carbon dioxide 
(CO2) to give a final pH of 7.4 at 37°C. The broad-spectrum CA inhibitor, 6-ethoxyzolamide 
(ETZ), was dissolved in dimethyl-sulfoxide (DMSO) and added to the perfusate to achieve a 
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final concentration of 100 mM (with DMSO < 0.01% of total buffer volume). ETZ was 
expected to evenly distribute throughout the intra- and extracellular spaces to inhibit all 
cardiac CA isoforms.  
 
Control Protocol 
Isolated hearts (n = 6) were perfused for 30 min at 85 mmHg. For the initial 20 min, 
31
P MRS 
was used to measure pHi. After that, hyperpolarized [1-
13
C]pyruvate was infused and the 
progress of 
13




Inhibition of Carbonic Anhydrase with ETZ 
Hearts (n = 5) were perfused for 10 min in normal buffer, after that they were switched to 
buffer containing 100mM ETZ. 
31
P MRS was performed for 20 min (10 min before and 10 
min after switch over to ETZ-containing buffer). 10 min after the start of ETZ perfusion, 
hyperpolarized [1-
13






Reperfusion following ischaemia 
Hearts (n = 12) were perfused for 30 min, followed by 10 min of global ischaemia, and 15 
min reperfusion. 
31
P MRS spectra were acquired for 20 min immediately before and 9 min 
during ischaemia. Hyperpolarized [1-
13
C]pyruvate was infused immediately after ischaemia. 
In some hearts (n = 6), 
31
P MRS was performed throughout the reperfusion period. In other 
hearts (n = 6), 
13
C MRS was performed for 2 min during initial reperfusion with 
hyperpolarized [1-
13
C]pyruvate, followed by 10 min of 
31
P MR spectral acquisition.  
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Magnetic Resonance Spectroscopy 
31
P MR spectra were acquired at 202.5 MHz using a 30° RF pulse and a repetition delay of 
0.25s. The phosphocreatine (PCr) resonance was set the reference at 0 ppm. Each spectrum 
consisted of 120 transients, giving a total acquisition time of 30 s. As these partially saturated 
spectra had shorter repetition times than the longitudinal relaxation time of 
31
P nuclei, an 
unsaturated spectrum was initially acquired from the hearts using a 90° pulse with repetition 
time of 15 s and 40 transients, and an acquisition time of 10 min. The unsaturated spectra 
were used to correct metabolite concentrations for the effects of saturation. Acquisition of 
13
C 




C]pyruvate infusion continued throughout acquisition. Spectra were acquired with 1 s 
temporal resolution over 2 min (excitation flip angle = 30°, 120 acquisitions). Spectra were 
centered at 150 ppm and referenced to the [1-
13
C] pyruvate resonance at 171 ppm, and 4096 






C MR spectra were analyzed using the AMARES algorithm, as implemented in the 
jMRUI software package (52). Spectra were DC offset corrected based on the last half of 
acquired points and peaks corresponding with [1-
13
C]pyruvate and its metabolic derivatives 
were fitted assuming a Lorentzian line shape, initial peak frequencies, relative phases, and 
linewidths. For spectra acquired from perfused rat hearts, the maximum peak area of each 
metabolite over the 2 min of acquisition was determined for each series of spectra and 
expressed as a percentage of the maximum [1-
13
C]pyruvate resonance. The rate of signal 
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production for each metabolite, in percent per second (%.s
-1
), was measured as the slope of 
the mean metabolite increase over the first 5 s following its appearance, over which time the 
metabolite signal increased linearly. Additionally, a first-order exponential signal decay term 
was fitted to each metabolite peak from the point of maximum signal over the course of 
signal decay. Decay of the hyperpolarized signal depends on the intrinsic spin–lattice 
relaxation of the nucleus, production and consumption rates of the metabolite, and metabolite 
washout, and may therefore provide information about metabolite accumulation in the states 






CO2, and their 







to the maximum pyruvate peak area to allow for any differences in polarization, was used as 






CO2 time courses were 
inserted into an applied form of the Henderson–Hasselbalch equation:  
             
     
    
       
  (4.5)  
The output of Eq. (4.5) is a variable pR which should, under the two conditions outlined in 
Section 4.5.1, measures pHi. Upon the initial arrival of [1-
13







 (and thus pR) equilibrated over several seconds to reach a 
steady-state value. The calculated pR was fit to a first-order exponential equation to 





P MR spectra were analyzed using the AMARES algorithm in the jMRUI software 
package. Spectra were corrected for DC offset using the last half of acquired points. The PCr, 
Pi, -, -, and -ATP resonances were fitted assuming a Lorentzian line shape, peak 
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frequencies, relative phases, line widths, and J-coupling parameters. pHi was calculated from 
the Pi chemical shift (40). Absolute 
31
P metabolite concentrations were calculated using an 
ATP concentration of 10.6 mM from the first -ATP peak area (53) and expressing all other 
ATP and PCr peak areas relative to this area (54). 
 
Statistical methods 
Data are given as mean ± standard error. Statistical significances between pre- and post-
ischaemic groups, and pre-ischaemic and ETZ-perfused groups, were assessed using a paired 
Student’s t-test. Statistical significance was considered at P < 0.05. 
 
4.5.3 Results 
Myocardial Energetics in Isolated Perfused Heart 
Cardiac function and 
31
P MR spectra were characteristic of the isolated rat heart during pre- 
ischaemia, ischaemia, and reperfusion (36). Pre-ischaemia, the average [ATP] was 10.60.7 
mM and [PCr] was 19.7±0.9 mM (Figure 4.6). Two minutes after stopping coronary flow, 
[PCr] decreased to 3.2 mM, and remained at 1.1–2.1 mM for the remainder of ischaemia. The 
rate of [ATP] hydrolysis during ischaemia was 0.14±0.10 mM/min. Five minutes after 
reperfusion; PCr had recovered to 17.6±1.9 mM, whereas ATP remained at 8.2±2.5 mM. 
Perfusion with ETZ had no effect on [ATP] or [PCr] throughout the perfusion protocol. Prior 
to ETZ perfusion, hearts had an average PCr of 17.8±1.9 mM and ATP of 10.6±0.5 mM. 




Figure 4.6: Changes in ATP, PCr, Pi and pHi, before, during and after ischaemia. ATP levels 
gradually decreased during ischaemia and after reperfusion, partially recovered to pre-
ischaemia levels. PCr levels rapidly decreased at the onset of ischaemia and rapidly recovered 
to pre-ischaemic levels after reperfusion. Pi rapidly increased at the onset of ischaemia and 
rapidly decreased to pre-ischaemic levels after reperfusion. pHi gradually deceased from 7.07 





PDH flux in Isolated Perfused Heart 
A representative spectrum of [1-
13
C]pyruvate in the perfused heart, and the typical kinetic 
progression of [1-
13
C]pyruvate metabolites, is shown in Figure 4.7. Following infusion of [1-
13
C]pyruvate into control hearts, [1-
13








C]alanine (176.5 ppm) were clearly detectable with high
 
signal compared with the baseline. 
A resonance corresponding to
 13
CO2 was also visible, with 1 s temporal resolution, at a 
chemical
 
shift of 124.5 ppm. The initial rates of production and the maximum
 
peak areas for 
the [1-
13
C]pyruvate-derived metabolites, in pre-ischaemic,
 
ETZ, and reperfused hearts, are 
given in Table 4.1.
 






CO2, and their sum were
 
not 




infused into the myocardium 








CO2 production was 54% slower 
upon reperfusion,
 
compared with the pre-ischaemic myocardium, as indicated by the
 
slope of 
the reperfusion peaks shown in Figure 4.8. Additionally, the decay
 
rate of hyperpolarized 
13
CO2 signal was 30% faster in reperfused hearts
 
than in pre-ischaemic hearts (P < 0.001), 
indicating enhanced CO2
 
washout upon re-flow after ischaemia.
 
ETZ had no significant effect 














CO2, compared with pre-ischaemic hearts (Figure 4.8). However, ETZ 
increased the maximum 
13





 peak area by two-fold (Table 4.1, P < 0.001). Additionally, the decay rate of 
hyperpolarized 
13
CO2 signal was 19% faster in reperfused hearts than in pre-ischaemic hearts 






Figure 4.7: (A) Representative spectrum acquired during hyperpolarized [1-
13
C] pyruvate 
infusion into the isolated perfused heart. Five single 1 s spectra were summed to yield this 
spectrum, acquired using a 30° rf pulse. (B) Changes in the metabolic products of [1-
13
C] 





















6 ± 1 31 ± 3† 7 ± 2 4.2 ± 0.3 3.5 ± 0.2 5.7 ± 0.4 
Initial production rate 
(% / s) 
0.7 ± 0.1 4.4 ± 0.4† 0.7 ± 0.2 0.43±0.09 0.28 ± 0.03 0.7 ± 0.01 
Decay, (s) 35 ± 4 22.3 ± 0.2* 41 ± 5 39 ± 2 41 ± 1 43 ± 7 


















4.7 ± 0.6 3.8 ± 0.4 2.1± 0.2* 0.60±0.06 0.70 ± 0.06 2.6±0.2† 
Initial production rate 
(% / s) 
0.49±0.06 0.21 ± 0.04* 0.14±0.02* 0.06±0.02 0.053±0.007 0.31±0.03† 
Decay, (s) 43 ± 4 35 ± 2 44 ± 4 48 ± 2 33 ± 2† 39 ± 3* 
 
Table 4.1: Metabolite levels and kinetic parameters from 
13
C MR spectra in pre-ischaemia, 
reperfused and ETZ-perfused isolated hearts. Data are expressed means ± SEM. All 
metabolite levels and initial production rates are expressed as a percentage of maximum [1-
13
C] pyruvate signal. Significant difference from pre-ischaemic hearts: *P < 0.05, †P < 0.001. 
 
Figure 4.8: Comparison of the time courses for the sum of the bicarbonate and carbon dioxide 
peaks, normalized to the maximum value of pyruvate area. The maximum peak area did not 
change following either intervention, compared with control. Following ischaemia, the initial 
slope of the curve was significantly reduced. 
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Measurement of pHi in the isolated perfused heart 






CO2, which were used for the calculation of 







CO2 were out of equilibrium for 5 s before pR reached a steady-state value of 
7.12±0.10 (Figure 4.9B). Fully relaxed 
31
P measurements, acquired in the pre-ischaemic heart, 
gave a pHi of 7.07±0.02. The pHi measured using 
31
P MRS and the 95% confidence interval 
are overlaid on the 
13
C results in Figure 4.9B. 
31
P MRS confirmed that CA inhibition with 
ETZ had no effect on steady-state myocardial pHi (pHi of 7.02±0.03 before ETZ treatment 
and 7.00±0.04 after ETZ treatment). Perfusion with [1-
13












CO2. The pR, 






CO2 ratio, stabilized within 20 s to a steady-state pR of 
6.21±0.13 (Figure 4.9D). Thus, inhibition of CA activity slowed CO2–HCO3
-
 conversion, as 
shown by the lengthening of the out-of-equilibrium period, but also by the steady-state pR 
which was 0.79 pH units below the pHi measured using 
31





Figure 4.9: (A) The bicarbonate and carbon dioxide, both normalized to maximum pyruvate 
peak area, vs. time in control hearts (n = 6). The point-by-point ratio of these species was 






CO2 in control hearts 
compared with measurement of pHi using 
31
P MRS in the same group of hearts. (C) The 
bicarbonate and carbon dioxide, both normalized to maximum pyruvate peak area, in hearts 







in ETZ-perfused hearts compared with measurement of pHi using 
31
P MRS in the same group 
of hearts. The steady-state pR approached 6.21, a value which underestimated the true pHi of 





In reperfused hearts, 
31
P MRS revealed that pHi recovered from a value of 6.49±0.04 at the 
end of ischaemia to 7.04±0.13, at a rate of 0.73 pH units/min during the 45 s immediately 
after reflow (Figure 4.10). In hearts reperfused with hyperpolarized [1-
13







CO2 ratio was the same as pHi from 
31
P MRS after 15 s of reperfusion. 




P measurements gave almost identical pHi measurements 
(
13
C: 7.01±0.01 at 45 s and 6.98±0.02 at 75 s; 
31
P: 7.04±0.13 at 45 s and 7.00±0.04 at 75 s). 
 
 







CO2 ratio and the pHi measurements made using 
31
P MRS. The x-axis shows the 
time after reperfusion with hyperpolarized [1-
13
C] pyruvate. The 
31
P measurement at t = 0 
equals the pHi following 10 min of simulated ischaemia. Each pR measurement was 
calculated as the average of 30 s of spectra, acquired 15 s before and after the equivalent 
31
P 







PDH Flux before and after ischaemia 
To study the CO2/HCO3
-
 equilibrium, PDH flux must be sufficient to generate MR-detectable 
levels of 
13
CO2. Therefore, our first aim was to determine the effect of ischaemia on pyruvate 
oxidation. In the isolated rat heart perfused with pyruvate alone or pyruvate and fatty acids, 
ischaemia has been found to decrease PDH activity and glucose oxidation for several minutes 







CO2 from 0.57±0.06 to 0.26±0.05%.s
-1
, indicating a decrease in 
the initial rate of pyruvate oxidation, and thus inhibition of PDH activity in reperfusion. 






CO2 produced was not observed, 
suggesting that PDH flux recovered to control levels within 30 s. Most importantly, sufficient 
13






CO2 ratio to be 








CO2 equilibrium as a measure of cardiac pHi 






CO2 ratio in the isolated perfused rat heart into a variable, pR, 
using the Henderson–Hasselbalch equation. At steady-state, pR in the isolated perfused rat 
heart was 7.12±0.1, to the pHi of 7.07±0.02 measured using 
31
P MRS. These values are 
similar to those of Merritt et al. (44), and with pHi measured by others using 
31
P MRS 
(40,41,48,53,57). Thus, hyperpolarized [1-
13
C]pyruvate can be used to obtain an accurate, 
non-invasive measurement of cardiac pHi. As a first test of the suitability of pR to measure 
pHi, we inhibited cardiac CA activity in perfused rat hearts, without altering pHi. We found a 





P MRS. Low pHi, such as that observed during myocardial ischaemia, inhibits CA 






CO2 ratio would not be a good measure of pHi in the 
ischaemic/reperfused heart without correction for low CA activity. 
 
4.5.5 Limitations of the study 
To measure pHi using [1-
13







CO2 resonances can be accurately quantified above the baseline noise. At a 




 resonance is 10-fold larger than the 
13
CO2 resonance, so 
13
CO2 quantification requires efficient hyperpolarization, high PDH flux, and careful data 
acquisition. An increase in achievable polarization, from the 30% observed here to 60%, has 
recently been reported and will aid 
13
CO2 quantification (58). Also, strategic data acquisition 
after the 
13
C equilibration period, over a shorter duration and with a higher excitation flip 
angle may further increase the 
13
CO2 signal.  
 
A second limitation of this study is the fact that the hyperpolarized label cannot directly 
distinguish between metabolites located in the intra- and extracellular spaces. We can be 






CO2 signal was produced within the 
myocardium. However, it is possible that trace amounts of 
13
CO2 may have diffused out of 




 spontaneously by 







CO2 signal to our pHi measurement was small because: (i) in vivo 
spectroscopic 
13




 is confined to 
the myocardium, a region dominated by the intracellular space; (ii) in the perfused heart, high 
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coronary flow rates (20 mL/ min) would have rapidly removed hyperpolarized metabolites, 
and (iii) the close agreement between pR measured with 
13
C and pHi measured with 
31
P in the 







these species would have equilibrated according the pHo of 7.4. 
 
4.5.6 Conclusion 
Currently, the non-invasive measurement of cardiac pHi in humans is not direct, because 
blood 2, 3-DPG signal overlies the myocardial Pi signal. Here, we have shown that in the 






CO2 ratio accurately measured pHi in the 






CO2 may offer an alternative technique for the non-invasive measurement of pHi in normal 
hearts, and in diseased hearts with normal or elevated CA activity (53). Future work will 






CO2 ratio with pHi 
measurements made using invasive, blood-removed or open-chest techniques. 
 
Since acidosis is a characteristic feature of ischaemia, assessment of ischaemic heart disease 







CO2 ratio. We observed excellent agreement between pHi measured using 
31
P 
MRS and pR measured using 
13
C MRS in the reperfused myocardium when pHi was > 6.74 
(Figure 4.10). However, multiple factors shift pR relative to pHi, including inhibition of CA 
activity at low pHi and stimulation of membrane transport during reperfusion following 
ischaemia (60,61). Pharmaceutical agents, such as cariporide, inhibit membrane ion transport 
and have been used clinically to reduce ischaemia–reperfusion injury (62), but also block CA. 
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CO2 ratio to measure pHi may not be valid in ischaemic, 
acidic hearts, and in patients with ischaemic heart disease who use drugs that inhibit 
membrane ion transport. Additionally, it is reasonable to expect that intracellular CA 
expression and activity may be either reduced or increased in other forms of cardiomyopathy 
(63). Correction of pR to pHi will require full characterization of CA activity in each 
pathophysiological state. 
 
4.6 The Dynamic Roles of Acetylcarnitine in Myocardial Carbohydrate Metabolism: 
An In Vivo Study 
Previous studies have indicated that mitochondrial acetylcarnitine, produced from acetyl-CoA 
via carnitine acetyltransferase (CAT), may be involved in balancing the glucose-fatty acid 
cycle in the heart. We used hyperpolarized [2-
13
C]pyruvate, in concert with magnetic 
resonance spectroscopy (MRS), to monitor the incorporation of pyruvate dehydrogenase 
(PDH)-derived acetyl-CoA into the acetylcarnitine pool and the Krebs cycle, in real-time and 
in vivo. Our results demonstrated that CAT out-competes citrate synthase for pyruvate-
derived acetyl-CoA in the healthy heart, with only a fraction directly oxidized via the Krebs 
cycle. While the critical role of PDH in balancing the glucose-fatty acid cycle is undisputed, 
CAT and acetylcarnitine also regulate the contribution of carbohydrates to cardiac ATP 
production. 
 
The manuscript has been prepared by Dr. Marie A. Schroeder and is in the midst of 




4.6.1 Introduction  
Adenosine triphosphate (ATP) is the only immediate source of energy for the heart, and 
cardiac ATP production is controlled largely by the rate at which the Krebs cycle operates. In 
normal hearts, Krebs cycle flux is maintained by continual citrate synthase-mediated 
condensation of acetyl CoA with oxaloacetate to form citrate. Acetyl CoA is produced from 
the oxidation of fatty acids, ketone bodies, or glucose via glycolysis and the enzyme pyruvate 
dehydrogenase (PDH) (64). The marked variability in the roles of glucose and fatty acids as 
cardiac fuels has been described as t he glucose-fatty acid cycle (65). 
 
PDH catalyses the irreversible oxidation of pyruvate to form acetyl CoA, NADH and CO2, 
and is fundamental in balancing the relative contributions of glucose and fatty acid oxidation 
to cardiac ATP production. Normally, 60-90% of cardiac ATP is derived from fatty acids, 
and accordingly several PDH-mediated mechanisms exist to preserve fatty acid oxidation at 
the expense of glucose oxidation. In hearts chronically exposed to elevated free fatty acids, 
both protein expression and activity of pyruvate dehydrogenase kinase (PDK) are increased 
(66), phosphorylating and thus inactivating PDH (67). Acutely, PDK inhibits PDH activity in 
the presence of fatty acid oxidation end-products (acetyl CoA and NADH) (68), and PDH 
flux can be reduced directly by high acetyl CoA/CoA and NADH/NAD+ ratios (69). 
 
Despite the central role of fatty acid oxidation in cardiac energy production, metabolic 
flexibility remains the key characteristic enabling the heart to meet its high ATP demand (70). 
For example, during aerobic exercise and after eating, glucose and other carbohydrates 
become important cardiac fuels (71,72). The PDH enzyme complex responds to increases in 
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cardiac workload and carbohydrate supply via the associated enzyme pyruvate 
dehydrogenase phosphatase (PDP), which dephosphorylates and thus activates PDH in 




 and insulin (73,74). High levels of 
mitochondrial pyruvate also activate PDH by inhibiting PDK (75). Increased pyruvate 
oxidation without a concomitant decrease in fatty acid oxidation, however, could 
theoretically inhibit further PDH flux via accumulation of acetyl CoA and subsequent end-
product inhibition. Intuitively, to enable increases in carbohydrate oxidation, there must be a 
regulatory pathway ensuring that pyruvate-derived acetyl CoA is either buffered, or oxidized 
preferentially to fatty acids. 
 
In a recent study (2), we used hyperpolarized [2-
13
C] pyruvate as a metabolic tracer in the 
isolated heart to observe the relationship between PDH flux and Krebs cycle metabolism in 
real time, using 
13
C magnetic resonance spectroscopy (MRS). As anticipated we observed 
conversion of pyruvate into the Krebs cycle intermediates citrate and glutamate. However, we 
also observed that a substantial fraction of pyruvate oxidized by PDH was converted to 
acetylcarnitine. Acetylcarnitine is produced by carnitine acetyltransferase (CAT), which is 
stimulated by mitochondrial acetyl CoA and carnitine (76). Our observation in the intact heart 
was consistent with the previous work of Lysiak et al., who reported that in heart 
mitochondria, acetyl CoA derived from pyruvate is particularly accessible to CAT, and that a 
greater proportion of acetylcarnitine is produced from pyruvate-derived acetyl CoA than from 
fatty acid-derived acetyl CoA (77). More recent studies have contributed evidence suggesting 
that acetylcarnitine may be an integral component of cardiac carbohydrate oxidation. It has 
been suggested that the acetylcarnitine pool may store acetyl units exceeding Krebs cycle 
requirements, to buffer rapid increases in substrate demand, and to release free CoA for 
maintenance of PDH flux (78,79). Further, Saddik et al. have proposed that myocardial 
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acetylcarnitine may serve as a precursor of cytosolic malonyl CoA, an inhibitor of fatty acid 
uptake (80). This pathway would provide pyruvate oxidation with a direct route to inhibit 
fatty acid oxidation. 
 
These results point to clear involvement of CAT and the acetylcarnitine pool in regulating the 
glucose-fatty acid cycle alongside PDH. However, the nature of the dynamic relationship that 
exists in vivo between acetylcarnitine, pyruvate oxidation, fatty acid oxidation, and Krebs 
cycle flux has yet to be determined. The aim of this study was to use hyperpolarized [2-
13
C] 
pyruvate as a metabolic tracer to examine the role of CAT in facilitating oxidative 
carbohydrate metabolism in the heart. We determined the metabolic fate of pyruvate-derived 
acetyl CoA by following its production and subsequent relative conversion into either 
acetylcarnitine or citrate in the isolated perfused heart. 
 
Our results have demonstrated that more than half of all the pyruvate-derived acetyl CoA that 
enters the Krebs cycle does not immediately condense with oxaloacetate, but rather, is first 
incorporated into the acetylcarnitine pool. The unique metabolic position of CAT enables its 
role in buffering the supply of acetyl units to the instantaneous cardiac demand. Further, this 
study has contributed to evidence that the acetylcarnitine pool may be fundamental in 
maintaining PDH flux, by both increasing PDH activity and facilitating feedback inhibition 






 4.6.2  Materials and Methods 
Trityl radical was obtained from GE-Healthcare (Amersham, UK). [2-
13
C] pyruvic acid and 
all other compounds were obtained from Sigma (Gillingham, UK). Investigations conformed 
to Home Office Guidance on the Operation of the Animals (Scientific Procedures) Act, 1986 




C] Pyruvate preparation 
 [2-
13
C]pyruvic acid (40 mg), mixed with a 15 mM concentration of trityl radical and a trace 
amount of Dotarem, was polarized with 45 min of microwave irradiation. The sample was 
subsequently dissolved in a heated, pressurized alkaline solution to yield sodium [2-
13C]pyruvate with a polarization of ~20% and physiological temperature and pH.  
 
Saturation transfer experiments 
Five male Wistar rat hearts (heart weight ~1 g) were perfused in the Langendorff mode, in a 
protocol identical to that previously described in the previous section. Three experiments 
were then performed in each perfused heart: 1) control, 2) acetylcarnitine saturation, and 3) 
control-saturation (Figure 3). 
1) Hyperpolarized [2-
13
C]pyruvate was diluted to 2.5 mM and delivered to the heart, and 
13
C 
metabolites were detected as normal, with a 1-s temporal resolution over the course of 2-min 
(TR = 1 s, excitation flip angle = 30°, 120 acquisitions,  sweep width, 180 ppm; acquired 
points, 4096; frequency centered at 125 ppm). The precise frequency of the [1-
13
C]acetyl-
carnitine resonance was noted.  
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2) After a second dose of 
13
C was polarized (45 min), 2.5 mM [2-
13
C]pyruvate was  again 
delivered to the heart, and 
13
C spectra were acquired as before while saturation was 
continually applied (described below) exactly to the [1-
13
C]acetyl-carnitine resonance as 
determined in the previous experiment (~175 ppm).   
3) A third dose of 2.5 mM [2-
13
C]pyruvate was delivered to the heart, and a control-
saturation experiment was performed: 
13
C spectra were acquired while saturation was applied 





C]acetyl-carnitine peaks, and ensured that the saturation 
pulse bandwidth was narrow enough to prevent any confounding saturation of the [1-
13
C]citrate resonance.  
To achieve continuous saturation, a cascade of eight SNEEZE pulses (81) was applied 
exactly at the acetylcarnitine frequency. Each SNEEZE pulse had a time-bandwidth product 
of 5.82 and 100 ms duration, with 100 µs interval between pulses. The effective full-width 
half-maximum bandwidth was ~160 Hz when tested on a sample of acetone. 
 
MR data analysis 
All cardiac 
13
C spectra were analyzed using the AMARES algorithm as implemented in the 
jMRUI software package. Quantified peak areas were normalized to peak [2-
13
C]pyruvate 
signal, plotted against time, and the maximum peak area of each metabolite was determined 
for each set of spectra. 
In acetylcarnitine saturation experiments, spectra were summed over the 50 s following 










C]pyruvate. These single spectra 
were then quantified as described above, and used for subsequent analyses. 
 
Statistical methods 
Values are reported ± SEM, and all analyses were performed in GraphPad Prism (GraphPad, 
La Jolla, California). All statistical differences within groups were assessed using one-way 
ANOVA with a post-hoc Tukey’s Multiple Comparison Test. Statistical significance was 
considered at the p < 0.05 level. 
 
4.6.3 Results 
Acetylcarnitine saturation experiments  
The acetylcarnitine resonance was selectively saturated to crush the MR signal in all nuclei 
incorporated into the acetylcarnitine pool, without affecting biochemistry. By analyzing the 
effect of acetylcarnitine saturation on the magnitude of the citrate resonance, we could 
qualitatively distinguish the fractions of [2-
13
C]pyruvate-derived acetyl CoA that were 1) 
converted immediately into citrate, 2) converted into acetylcarnitine and stored, and 3) 
converted into acetylcarnitine prior to rapid re-conversion to acetyl-CoA and incorporation 
into the Krebs cycle. 
 
To ensure that the low-SNR citrate and glutamate peaks were quantified accurately, 50 
spectra acquired with 1 s temporal resolution were summed, starting with the spectrum at 
which infused [2-
13
C] pyruvate first arrived at the heart. Therefore, the magnitudes of the 
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acetylcarnitine, citrate, and glutamate peaks reflected the amount of 
13
C accumulated in each 
metabolite pool over 50 s. To ensure that the saturation pulse had no independent effects on 
the citrate peak, a control saturation experiment was performed in each heart, as detailed in 
Figure 4.11.  
 
The acetylcarnitine saturation pulse was completely effective, reducing the magnitude of the 
acetylcarnitine peak by 99.5% compared with control experiments. Further, the control 
saturation experiments confirmed that the saturation pulse had a sufficiently low bandwidth 
to avoid RF effects on the citrate peak. Selective saturation of the acetylcarnitine peak 
reduced the magnitude of the citrate peak by 63%. This result indicated that of all the [2-
13
C]pyruvate-derived acetyl CoA that was incorporated into the Krebs cycle over a 50 s time 
period, 63% was initially converted into acetylcarnitine, prior to release from the 
acetylcarnitine pool as acetyl CoA and incorporation into the Krebs cycle. The remaining 37% 
of [1-
13
C]citrate unaffected by saturation was produced from [2-
13
C]pyruvate-derived acetyl 
CoA that immediately condensed with citrate synthase. This effect was also observed as a 51% 
reduction in the magnitude of the glutamate resonance compared with controls. 
 
In a further set of experiments the citrate resonance was selectively saturated. No reduction in 
the acetylcarnitine resonance was seen, indicating that there was no reverse pathway for [1-
13




Figure 4.11: Design and results of the acetylcarnitine saturation experiments. A) Control data 
were acquired to identify the exact frequency of the acetylcarnitine peak. An example control 
spectrum is shown. Next, a saturation pulse (gray box: 160 Hz bandwidth) was applied 
continuously to the acetylcarnitine resonance, which was 730 Hz downstream of citrate. 
Finally, the same pulse was applied 730 Hz upstream of citrate as a control to ensure that 
citrate was not affected by RF saturation. B) Acetylcarnitine saturation crushed the 
13
C signal 
from the acetylcarnitine pool, and significantly reduced the citrate and glutamate peaks. The 
control-saturation experiment confirmed that acetylcarnitine saturation had no effect on 
citrate. Glutamate, which was 330 Hz nearer to the saturation pulse than citrate, was 




In healthy hearts, the careful regulation of the glucose-fatty acid cycle is considered to 
encourage rapid incorporation of all acetyl CoA produced into the Krebs cycle. Further, the 
relative fractions of acetyl CoA derived from either β-oxidation or PDH are thought to reflect 
the contribution of each substrate to cardiac ATP production. However, in this study, we 
observed that 63% of the pyruvate-derived acetyl CoA incorporated into the Krebs cycle was 
first reversibly converted to acetylcarnitine by CAT. An even greater proportion of the 
pyruvate-derived acetyl groups were stored as acetylcarnitine for a time exceeding the 
duration of our experiment, as evidenced by the large [1-
13
C]acetylcarnitine peak area 






It has been suggested that acetylcarnitine may serve as a precursor of cytosolic malonyl CoA, 
thus enabling feedback inhibition of fatty acid uptake by high levels of pyruvate oxidation 
(80). This hypothesis remains difficult to prove, due to technological limitations that prevent 
specific measurement of the cytosolic and mitochondrial fractions of acetyl CoA and malonyl 
CoA (82). However, tentative support has been provided by this study and others, which 
when considered together, suggest that supply of pyruvate-derived mitochondrial acetyl CoA, 
production of [1-
13
C]acetylcarnitine, and whole-myocyte levels of malonyl CoA correlate in 
the heart (64,80,82,83). These data advance the possibility that acetylcarnitine exported out of 
the mitochondria may offer an important source of cytosolic acetyl CoA in the heart, 
providing a link between mitochondrial acetylcarnitine and cytosolic malonyl CoA 




Figure  4.12:  Proposed mechanism describing the dynamics of acetylcarnitine involvement 
in the glucose-fatty acid cycle. Acetyl CoA produced by fatty acid β-oxidation and PDH are 
compartmentalized into distinct pools with divergent metabolic fates. Acetyl CoA from β-
oxidation is closely coupled to citrate synthase, while acetyl CoA from PDH has 2 parallel 
metabolic fates: incorporation into the Krebs cycle, or conversion to acetylcarnitine. 
Depending on oxidative demand, acetylcarnitine may rapidly re-convert into acetyl CoA 
(within several seconds), provide acetyl group storage in the long term, or leave the 




The link revealed between pyruvate-derived acetyl CoA and CAT indicates that acetyl CoA 
produced by PDH and β-oxidation exist as functionally compartmentalized pools with 
divergent metabolic fates. The critical role of PDH in balancing contributions of pyruvate and 
fatty acids to acetyl CoA production is undisputed; however, this study has demonstrated that 
CAT and acetylcarnitine also have key roles in regulating the contribution of carbohydrates 
to cardiac ATP production. Therefore, CAT activation via carnitine supplement may offer a 
useful metabolic therapy in cardiac diseases which are characterized by mismatched 
glycolysis and glucose oxidation, such as pressure-overload hypertrophy (79).  
 
  
4.7 Investigation of Metabolically Generated Hyperpolarized [1, 4 - 
13
C] Malate 
from [1, 4 - 
13
C] Fumarate as a Biomarker of Necrosis in the Ischemic Heart 
 
Cardiac ischaemia induces necrosis and apoptosis of myocytes, which are distinct 
mechanisms of cell death (84). Ischaemic necrosis is characterized by ATP depletion, cell 
swelling and loss of membrane integrity, whereas apoptosis usually requires energy, and is 
associated with cell shrinkage and phagocytosis without loss of membrane integrity. 
Prolonged or acute ischaemia destroy myocytes via necrosis. Recently, Gallagher and co-
workers have demonstrated the detection of hyperpolarized [1,4-
13
C2]malate, the downstream 




C magnetic resonance 
spectroscopy  in a murine lymphoma tumor.  After etoposide treatment, they observed a 2.4 
fold increase in hyperpolarized [1,4-
13
C2]malate and attributed it to tumor cell necrosis 
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causing a breakdown in membrane integrity. Thus the increase in the hydration of 
hyperpolarized fumarate to malate appears to be a potential biomarker of necrosis. The 
purpose of this study was thus to investigate whether hyperpolarized fumarate could be used 
as a biomarker of necrosis in the ischaemic rat heart. Hyperpolarized [1,4-
13
C2]fumarate is 
delivered into the isolated perfused heart before ischaemia, immediately upon reperfusion and 
30 min post-reperfusion. Results showed obvious enhancement in maximum peak of [1,4-
13
C2]malate in the time-courses and significant changes in the initial rate of malate production 
after reperfusion.   
 
4.7.1 Introduction 
Myocardial ischaemia is a pathological process that results in extensive necrosis. The 
deprivation of oxygen and nutrition triggers cellular and sub-cellular alterations, which 
accompany a progressive reduction in ATP production (85,86). The characteristic pattern of 











 (acidosis), and Ca
2+
; cytoplasmic, organellar, and cellular 
swelling with plasma membrane blebbing; and margination and clumping of nuclear 
chromatin. These cellular changes are due to progressive impairment of membrane 
composition, structure, and function (85,87). The compromised membrane permeability then 
allows the unregulated influx of divalent and trivalent cations, including calcium. 
Subsequently, the swollen cells develop physical defects (holes) in their cell membranes and 
rupture. These features of cell injury with cell swelling have been shown to involve cardiac 
myocytes subjected to hypoxia in vitro and cardiac muscle during the evolution of 
myocardial infarction in vivo (85,88). The underlying cellular membrane damage to 
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ischaemic myocytes is the basis for the diagnosis of myocardial infarction by pathology 
laboratory and nuclear cardiology methods (87). 
   
Fumarate is a metabolite derived from the oxidation of succinate in the Krebs cycle. It is then 
reversibly hydrated to become malate in the reaction catalyzed by fumarase. In in-vitro 
necrotic cells, Gallagher et al have established a correlation between rate of malate 
production and percentage of cells that lost plasma membrane integrity, using hyperpolarized 
[1,4-
13
C2]fumarate as the probe (89). They modeled the 
13
C label flux transfer between 
fumarate and malate, and noticed a 19 times increase in the forward rate constant in 
etoposide-treated lymphoma cells. In-vivo, 2.4 and 2.5 times increases were observed in the 
epotoside-treated mice in the forward and reverse fluxes respectively, together with a 59% 
increase in maximum malate signal. The enhanced fluxes and malate production indicated an 
increase in the concentration of fumarase available to its substrates, as a result of degradation 
in membrane integrity. The aim of this work is to investigate the possibility for detection of 




4.7.2 Material & Methods 
Polarization of [1,4-
13
C]Fumaric Acid (89) 
All chemicals were obtained from Sigma/Aldrich unless stated otherwise. [1,4-
13
C2]fumaric 
acid (3.23 mmol; Cambridge Isotope Laboratories) was dissolved in 8.74 mmol of DMSO 
containing 11.48 mol of a trityl radical (AH111501; GE Healthcare) and 0.48 mol of a 
gadolinium chelate [Gd-3; GE Healthcare]. The solution was sonicated and centrifuged, and a 
40 mg aliquot was hyperpolarized by using a method similar to that described (1,3). Briefly, 
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the sample was cooled to ~1.2K while irradiated with microwaves at 93.139 GHz and 
100mW for 1 h and then dissolved in 6mL of buffer containing 40 mM phosphate, 50 mM 
sodium chloride, and 40 mM sodium hydroxide, pH 7.4 at 10 bar and 180 °C. The resulting 
solution contained 20 mM [1,4-
13
C2]fumarate, which was then cooled to ~37 °C and diluted 
to 2.5 mM before perfusion into the isolated rat heart.  
 
Control Protocol 
Isolated hearts (n = 6) were perfused for 30 min at 85 mmHg. After this, hyperpolarized [1,4-
13
C2]fumarate was infused and the progress of 
13




Reperfusion following ischaemia 
Hearts (n = 5) were perfused for 30 min, followed by 10 min of global ischaemia, and 30 min 
reperfusion. Hyperpolarized [1,4-
13
C2]fumarate was infused immediately after ischaemia. 
13
C 
MRS was performed for 2 min with hyperpolarized [1,4-
13
C2]fumarate in two stages, initial 
reperfusion and 30mins after continuous reperfusion. 
 
Magnetic Resonance Spectroscopy 
Acquisition of 
13
C MR spectra commenced immediately after infusion of hyperpolarized 
[1,4-
13
C2]fumarate and the infusion continued throughout acquisition. Spectra were acquired 
with 1 s temporal resolution over 2 min (excitation flip angle = 30°, 120 acquisitions). 
Spectra were centered at 175 ppm and referenced to the [1,4-
13
C2]fumarate resonance at 175 
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ppm, and 4096 points were acquired over a bandwidth of 100 ppm. The area under each peak 
was used to calculate the concentrations of labeled metabolites. [1,4-
13
C2]fumarate produces 
a single peak, whereas [1,4-
13
C2] malate gives two resonances (181.2 and 182 ppm) and these 






C MR spectra were analyzed using the AMARES algorithm, as implemented in the 
jMRUI software package (52). Spectra were DC offset corrected based on the last half of 
acquired points and peaks corresponding with [1,4-
13
C2]fumarate and its metabolic 
derivatives were fitted assuming a Lorentzian line shape, initial peak frequencies, relative 
phases, and line-widths. For spectra acquired from perfused rat hearts, the maximum peak 
area of each metabolite over the 2 min of acquisition was determined for each series of 
spectra and expressed as a percentage of the maximum [1,4-
13
C2] fumarate resonance. The 
rate of signal production for each metabolite, in percent per second (%.s
-1
), was measured as 
the slope of the mean metabolite increase over the first 5 s following its appearance, over 
which time the metabolite signal increased linearly. Additionally, a first-order exponential 
signal decay term was fit to each metabolite peak from the point of maximum signal over the 
course of signal decay. Decay of the hyperpolarized signal depends on the intrinsic spin–
lattice relaxation of the nucleus, production and consumption rates of the metabolite, and 
metabolite washout, and may therefore provide information about metabolite accumulation in 





Data are given as mean ± standard error. Statistical significances between pre-ischaemic and 
immediate reperfused groups, and pre-ischaemic and 30 min continuous reperfused groups, 






C2]Malate Spectra and Time-Course 
A representative spectrum of hyperpolarized [1,4-
13
C2]fumarate in the isolated perfused heart 
and the kinetic progression of [1,4-
13
C2]malate is shown in Figure 4.13a. Following infusion 
of [1,4-
13
C2]fumarate into control hearts, [1-
13
C]malate (181.2 ppm) and  [4-
13
C]malate (180 
ppm) were clearly detectable with high signal compared with the baseline. The maximum 
peak area, initial rate of production and the decay time constant for the [1,4-
13
C2]malate in 
pre-ischaemic, initial reperfused and 30mins continuous reperfused hearts are shown in Table 
4.2. The corresponding graphs with means ± SEM are illustrated in Figure 4.14.  
 
Although there is an uptrend of maximum malate peak area after ischaemia, their differences 
are not significant. The initial production rate of [1,4-
13
C2]malate significantly increases by 
143% immediately after ischaemia (from 0.07 ± 0.01% to 0.17 ± 0.04%) and 157% after 30 
min reperfusion (from 0.07 ± 0.01% to 0.18 ± 0.07%) (p < 0.05). There are no significant 




Figure 4.13: (A) Representative spectrum acquired during hyperpolarized [1,4-
13
C2] fumarate 
infusion into the isolated perfused heart. (B) Representative time-course of [1,4-
13
C2] malate 




















30 min after 
reperfusion  
Max. malate / fumarate (%) 2.9 ± 0.7 3.9 ± 0.6 5.1 ± 1.1 
Initial production rate (% / s) 0.07 ± 0.01 0.17 ± 0.04 * 0.18 ± 0.07* 
Decay, (s) 41.1 ± 0.2 38.9 ± 1.9 51 ± 4.5 
    
Table 4.2: Metabolic levels and kinetic parameters from 
13
C MR spectrum in pre-ischaemia, 
initial reperfused and 30 min post-reperfused isolated hearts (n = 5). * indicates p < 0.05. 
Figure 4.14: Changes in maximum malate peak area and initial malate production rate, before 
ischaemia, upon reperfusion and 30mins post-reperfusion.  
 
4.7.4 Discussion 
To study the onset of cell death with ischaemia, we have introduced 10 min of global 
ischaemia to the isolated rat heart. Immediately after ischaemia, we reperfused the heart with 
hyperpolarized fumarate, and demonstrated that the production of [1,4-
13
C2]malate can be 
detected in real-time. 
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malate production rate, probably due to a higher fumarate-malate flux. The underlying 
mechanism could be increased substrate uptake by the cardiomyocytes or escape of fumarase 
into the extracellular matrix (89), either of which indicates compromised cellular membrane 
permeability. After 30 min reperfusion, the initial rate of malate production stabilized, which 
indicated an arrest in necrosis, preventing further myocardium damage. Thus cell death did 
not appear to proliferate. Nonetheless, ischaemia triggers the activation of a series of 
signaling molecules such as caspases and tumor-necrosis factor- that inevitably lead to cell 
death of injured myocytes (90). Besides, growing evidence has surfaced suggesting that 
apoptosis is induced upon onset of ischaemia and is accelerated when the ischaemic heart is 
reperfused, further triggering a cascade of apoptotic signaling pathways (91-93). An example 
of such an apoptogenic protein is cytochrome c, which is released by the mitochondria during 
ischaemia. Cytochrome c has been known to activate caspases, inhibit mitochondrial 
respiratory chain activity and produce free radical in the mitochondria (92). If the heart is 
kept under prolonged ischaemia, ATP depletion will limit caspase activation and cause 
widespread necrosis (94). But if the heart is reperfused, cytochrome c release and caspase 
activation that occurred during the previous ischaemic period will trigger further caspase 
activation at reperfusion, potentially causing widespread apoptosis (95,96). Myocyte 
apoptosis in the reperfused heart has been demonstrated in both animal models (96,97) and 
humans (98,99). Despite the intense interest on the role of apoptosis in pathology of 
cardiovascular disease such as ischaemic heart disease, majority of cell death occurred via 
necrosis (85,86,100). The decay time constant did not differ significantly between pre-
ischaemic and reperfused hearts even though malate production increased. This could be due 
to the activation of malate dehydrogenase by the high malate concentration, resulting in an 




In this study, we did not perform histology to confirm the onset of necrosis. The fractionation 
of cell death attributable to necrosis and apoptosis was also not verified. Establishing a 
quantitative correlation between metabolism of hyperpolarized fumarate and necrosis severity 
would improve interpretation and add diagnostic value. There appeared to be no change in 
maximum peak area of hyperpolarized malate, contrary to the 59% increase seen in treated 
tumor (89). This warrants further investigation.  
 
4.7.5 Conclusion 
We have demonstrated the utilization of hyperpolarized [1,4-
13
C2]fumarate as a potential 
positive contrast agent of necrosis in the isolated perfused heart. Further quantification such 
as fumarase and malate dehydrogenase kinetics, in addition to histological verification of cell 












4.8 Real-Time Metabolic Imaging with Chemical Shift MRI 
The emergence of hyperpolarized 
13
C techniques shifts the paradigm in the study of 
metabolism from steady-state to real-time, offering us unprecedented insight into the 
bioenergetics and cellular dynamics in pathology. 
13
C MRS is currently the main workhorse 
that provides this information. It enables high detection sensitivity (provided 
13
C label is 
sufficiently polarized) and ease of operation (normally single-pulse acquisitions would 
suffice). With the exception of isolated perfused organs such as the heart and liver, in-vivo 
detected signal with 
13
C MRS origins from the tissue of interest as well as its surrounding 
environment. The derived metabolic time-course is thus somewhat corrupted and there is a 
risk of drawing the wrong conclusions. In addition, pathology rarely progresses 
homogenously throughout the organ but rather via regional deterioration. As we advance into 
the domain of personalized medicine, therapeutic drugs would have to be target–specific and 
precise in locating targets. A mapping of metabolic activity throughout the diseased organ is 
thus essential for accurate localization of abnormal metabolism and tissue degeneration. In 
addition, metabolic imaging could also provide new information on disease progression such 
as proliferation, and aid in pathodiagnosis and disease staging.  
 
The advent of hyperpolarized MRI began with the use of optically pumped noble gases such 
as 
3
He (102-104) and 
129
Xe (105,106)  in the 1990s, primarily in lung perfusion studies where 
1
H MRI is inferior in signal-to-noise ratio (107). In addition, since the resonance frequency of 
129
Xe depends on its physical phase (gaseous or liquid) (108) and the local microenvironment 
(109), it has been exploited to reveal regional pO2 in the blood (110) as well as monitor the 
dynamics of 
129
Xe when transported from alveoli to the pulmonary blood (111), from which 




C is the choice of label since carbon is present in all organic molecules and the 
13
C label 
chemical shift is directly related to its molecular structure. An injectable hyperpolarized 
solution could be used to visualize part of the vascular system (11), to map physiological 
parameters (112,113)  or probe metabolic pathways (114). The DNP method is a general 






N etc.) Real-time metabolic imaging 
with DNP [1-
13
C]pyruvate has been demonstrated in murine muscles (115) and swine 
myocardium (114) in-vivo. The resulting lactate and alanine biodistribution maps allow the 
distinction of regions with different lactate dehyodrogenase (LDH) and alanine transaminase 
(ALT) fluxes. Since lactate production is effectively a biomarker of tumor viability (31,116) 
and cardiac ischaemia (2), metabolic CSI could provide assessment in both function and 
spatial proliferation of the diseases.  
 
Oxidative decarboxylation of DNP hyperpolarized [1-
13
C]pyruvate, mediated by the pyruvate 
dehydrogenase (PDH) complex, is a critical reaction that produces acetyl-CoA for ATP 






CO2 is in a 









production has been shown to be an effective biomarker of real-time, in vivo PDH flux (3). 
Thus, the capability to visualize these metabolites in vivo allows us to probe metabolic 
processes that are critical to energy production and the physiological condition of the heart. 
However, to fully understand the changes observed in vivo it is useful to be able to study a 
model system where the exact parameters of the system can be carefully controlled. The 
perfused rat heart has been used as such a model system for many years, but the limitations of 
a small heart size and the resulting requirement for high spatial resolution have so far 
prevented metabolic imaging of the perfused heart with hyperpolarized [1-
13
C]pyruvate. In 
this study, we aimed to demonstrate the feasibility of mapping the spatial distribution of 
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hyperpolarized pyruvate, lactate, alanine and bicarbonate in the perfused rat heart via the 
implementation of a rapid, high spatial resolution, chemical shift imaging approach. 
Technical considerations including the limited polarization lifetime of 
13
C label as well as 
optimization of pulse sequence for optimal SNR will be discussed. 
 
4.8.1 Limited T1 Lifetime of the Hyperpolarized Pyruvic Acid (CSI) 
Although hyperpolarized 
13
C biomolecules allow unprecedented access into the dynamics of 
metabolic activity, their short T1 effectively limit signal acquisition and provide only a small 
window of opportunity to probe their metabolic fate. Dependent on the biochemical pathway 
of interest, that window might be restrictively short. Thus the longitudinal relaxation time is 
an extremely critical factor in real-time metabolic investigation. In addition, each RF pulse 
applied during MR spectroscopy removes some polarization, and thus a compromise has to 
be met between getting sufficient SNR and following the temporal evolution of metabolites. 
A RF power calibration of hyperpolarized [1-
13
C]pyruvate would provide both the T1 and the 





C MRS was carried out. A total of 60 acquisitions were done, first 30 readings had a RF 
attenuation factor of 30 dB and the next 30 had 24 dB. Repetition time was 1 s. We fitted the 
acquired signal S into eqn. (4.6), where A is a constant and assuming an exponential decay in 
polarization. The acquired and fitted results are displayed in Figure 4.15. The estimated T1 
value is ~50 seconds and flip angle is ~5°. Thus CSI imaging has to be completed within 50-
60 s.  
          
  





Figure 4.15: T1 measurement and flip angle calibration of sinc pulse for chemical shift 
imaging of metabolites, upon dissolution of hyperpolarized [1-
13
C] pyruvate.  
 
 
4.8.2 Materials and Methods  
Isolated Heart Perfusion  
Rat hearts (n=3) were rapidly excised from male Wistar rats (~350 g) and perfused in the 
recirculating retrograde Langendorff mode and then placed in the centre of an 11.7 T, vertical 




























T1 Measurement and Flip-Angle Calibration
fitted
measured
RF attenuation = 30dB RF attenuation = 24dB
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Chemical Shift Imaging  
A 2D gradient-echo CSI pulse sequence was implemented with acquisition begun 18 s after 
the start of infusion following identification of an optimal imaging window in the 1D 
spectroscopy time course. A single CSI image with centric phase encoding was acquired 
axially through the middle of the heart over a time-course of 64 s with TR = 250 ms, TE = 
0.85 ms, FA = 25°, SW = 40 ppm, SP = 512, FOV = 24 x 24 mm, matrix = 16 x 16, slice 
thickness = 5 mm. Post-processing with Matlab included zero-filling the data to 128 x 128, 
2D Fourier Transformation and automatic detection of the resonance of each metabolite to 
generate metabolic maps of pyruvate, lactate, alanine and bicarbonate. A reference proton 
image was acquired with a FLASH imaging sequence (matrix = 128 x 128, TR = 100 ms, TE 




C MR Spectroscopy 
The time course in Figure 4.16 illustrates the temporal evolution of hyperpolarized lactate, 
alanine and bicarbonate following infusion of pyruvate. All metabolites reached their peak 
amplitude at approximately 20 s after the start of infusion. Therefore subsequent CSI imaging 
was chosen to begin at t = 18 s so that the centre of k-space coincided with the peak 










CO3-. The imaging window is overlaid on the plot. 
 
Gradient-echo Chemical Shift Imaging 
Figure 4.17 shows the axial proton image along with the metabolite maps for pyruvate, 
lactate, alanine and bicarbonate. The left and right ventricles are highlighted on the 
metabolite maps by the dotted lines. The peak pyruvate signal is seen just outside the heart at 
the location of perfusion buffer drainage. All other metabolites are localized within the 















in the perfused heart along with a reference proton image. The dotted lines indicate the 
borders of the left and right ventricles. 
 
4.8.4 Discussion 
We have demonstrated the capability of metabolic imaging with DNP [1-
13
C]pyruvate as 
substrate in the isolated perfused heart. Even though the oxidative carboxylation of 5 mM 




 signal that was only 3% of maximum pyruvate peak, it was still 





correlates with the severity of diabetes (3) and thus the ability to map bicarbonate 
distribution in the perfused heart would further enlighten the pathophysiology of the diabetic 
heart. Unfortunately, the 
13
CO2 signal was insufficient for imaging (~0.6% of [1-
13
C]pyruvate); otherwise an intracellular pH map could be obtained according to our study in 





 instead, which has been shown to produce substantial 
13
CO2 (42). Thus it appears 
that 
13
CO2 signal has to increase by at least 5 times in the isolated perfused heart to permit 
detection with CSI. According to eqn. (4.1), the most direct way to achieve that, partially at 
least, would be to increase polarization. Johannesson and co-workers have demonstrated the 
almost 3 times enhancement in [1-
13
C]pyruvate polarization by increasing polarizing 
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magnetic field from 3.35 T to 4.64 T (58). The biggest hurdle though is that polarization time 
is tripled as well.    
 
Metabolic activity of lactate dehydrogenase in the reduction of pyruvate into lactate is clearly 
mapped with CSI. This facility would be beneficial in mapping the extent of myocardial 
damage in ischaemic hearts, in which lactate metabolism increases by 5-fold upon 
reperfusion (see Table 4.1). In addition, Golman et al has demonstrated that lactate 
production from pyruvate in pigs is compromised in regions of myocardial cell death after 15 
min occlusion, and that could also be mapped with CSI (59). It has also been proposed that 
the pyruvate map could be used for qualitative perfusion assessment in the diseased heart 
(114). The visualization of alanine in the isolated perfused myocardium has been shown to be 
feasible.  It has been demonstrated that regions in the heart that are still viable after induction 
of ischaemia continue to exhibit transamination of pyruvate into alanine (59). Therefore the 
presence of alanine acts as a biomarker of cell viability.  
 
Limited by the finite polarization of hyperpolarized metabolites as well as the smaller 
gyromagnetic ratio of 
13
C, resolution was restricted to 1.5 x 1.5 x 5 mm
3
 to achieve sufficient 
SNR. In addition, each metabolite map obtained in this work was an average signal in 50 sec 
of its time-course and did not portray the dynamics of metabolism. Thus for metabolic maps 
to accurately interpret the physiological response of the heart to hyperpolarized pyruvate, 
rapid real-time CSI is necessary. In order to increase precision in metabolic mapping and 
achieve higher spatial resolution, customized pulse sequences that consider the T1 and T2 
relaxation times in different regions and compartments of the myocardium should be adopted. 
For example, Mansson and coworkers demonstrated a potential multiple-echo steady-state 
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free-precession (SSFP) sequence that could perform doubly as well in terms of spatial 
resolution and reduce scan time by four-fold, compared to a gradient-echo CSI pulse 
sequence (117). Optimizing the acquisition time window, adopting variable flip angles 
scheme, 3D spatial acquisition and using an appropriate sampling strategy (e.g. EPI) are some 





C chemical shift imaging allows 2D visualization of pyruvate metabolism 
in the isolated perfused heart. Localized metabolic maps, such as the bicarbonate map, 
provide real-time spatial information on energy production in the myocardium. A spatial 
resolution, before zero-filling, of approximately 11 µl permits localized detection of 
metabolism throughout the left ventricle. Future work will include reducing the TR and 











4.9 Chapter Conclusion 
In this chapter, we have demonstrated the versatility and competency of hyperpolarized 
13
C 
biomolecules to study the dynamic metabolism of the heart. Tracking intracellular pHi 
changes during ischaemia offers a real-time insight into the pH homeostasis mechanism 
within cardiac myocytes. We have also explored the potential of hyperpolarized fumarate as a 
biomarker of cellular necrosis as well as enabled spatial metabolic mapping in perfused 
hearts. Advancement of dynamic nuclear polarization technique to increase polarization will 
facilitate more precise measurements and quantification, corroborating the results that were 
achieved. Increased availability of 
13
C-labeled compounds will permit investigation of a 
wider range of metabolic pathways and allow real-time monitoring of therapeutic 
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In this thesis, we have demonstrated the versatility of magnetic resonance imaging to cross 
boundaries from physiological to cellular and down to molecular dimensions. Qualitative and 
quantitative perfusion imaging in the mouse pancreas allows differentiation of microvascular 
environment between pathology and normal tissue, and could perhaps serve as biomarkers of 
abnormal angiogenesis or impaired glucose response. Cellular tracking with high positive 
contrast facilitates in-vivo visualization of transplanted cells and could boost success rate of 
cellular therapy. Metabolic processes and fluxes in the heart could be detected in real-time 
using the hyperpolarized 
13
C- labeled biomolecules, and serve as robust biomarkers of 
ischemia and necrosis. From molecular to functional imaging, the diversity of information 
provided by MRI is unparalleled by other imaging modality and it would indeed become the 
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Abbreviations for enzymes and other biochemical compounds 
Enzymes 
 
LDH Lactate dehydrogenase 
ALT Alanine transaminase 
PC Pyruvate decarboxylase 
CA Carbonic anhydrase 
PDH Pyruvate dehyrogenase 
CAT Carnitine acetyltransferase 
CS Citrase synthase 
A Aconitase 
IDH Isocitrate dehydrogenase 
a-KDH  -Ketoglutarate dehydrogenase complex 
GDH Glutamate dehydrogenase 
SCS       Succinyl CoA Synthase  
SDH       Succinate dehydrogenase  
F        Fumarase  




ATP Adenosine triphosphate 
ADP Adenosine diphosphate 
GTP Guanosine triphosphate 






 Nicotinamide adenine dinucelotide 
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